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Abstract
Complement receptor type 2 (CR2; CD21) is a type 1 membrane-bound glycoprotein in 
the regulators o f complement activity (RCA) family. One of its ligands is C3d, a 
physiological cleavage fragment of the central complement protein C3. The extracellular 
portion is comprised of 15 or 16 short complement repeat (SCR) domains. Six of the 14 
linkers between these SCR domains are atypically long and the implications o f this on 
the solution structure and function o f CR2 was unknown. Two previous crystal 
structures of CR2 SCR 1-2 showed the two SCR domains formed contacts with each 
other in a closed V-shape. In this thesis, three different recombinant constructs of CR2 
were studied in solution using X-ray and neutron scattering, analytical 
ultracentrifugation, and constrained modelling. The combination of these techniques 
resulted in medium resolution structures for each of CR2 SCR 1-2, CR2 SCR 1-2 in 
complex with C3d, a CR2-Ig chimaera, and CR2 SCR 1-15. It was determined that the 
longest linkers within CR2 are highly flexible. CR2 SCR 1-2 was shown to exist in an 
open-V shape conformation, both free and in its complex with C3d. Studies on free C3d 
in solution showed that this forms concentration dependent dimers, although this 
dimerisation does not occur in the CR2 complex. The modelled complex between C3d 
and CR2 SCR 1-2 showed that SCR1 as well as SCR 2 is capable o f interacting with the 
ligand. The chimaera of fully glycosylated human CR2 SCR 1-2 with the mouse IgGl 
Fc domain confirmed the results for the solution structure of free CR2 SCR 1-2 and 
gives an insight into the therapeutic possibilities of such a molecule. Modelling of 
glycosylated full length CR2 revealed a flexible semi-extended arrangement of the 15 
SCR domains. These results provide an explanation of the molecular basis for the 
interaction of CR2 SCR 15 with C3d and three other ligands, CD23, gp350 and IFN-a, 
in terms of proximity relationships between neighbouring SCR domains. Insight was 
also obtained into the possible mechanisms by which CR2 SCR 1-15 may activate B 
cells.
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Chapter One
Complement in immunology
1
(1.1) Introduction to complement
Complement is the name for a group o f interdependent proteins found in 
plasma and other body fluids and forms an important part o f the innate immune 
system. These proteins were first seen to ‘complement’ the activity o f antibodies in 
the destruction o f antigens, although it is now known that the system can be 
activated in the absence o f antibodies.
The complement system was first documented in the late nineteenth century. 
It was observed that a heat-labile component o f fresh, cell-free serum was able to 
lyse bacteria (Buchner, 1889). This activity o f serum was termed ‘alexin’. Shortly 
afterwards Bordet described the loss o f the lytic activity o f serum from immune 
animals following heating, and the subsequent restoration o f activity with the 
addition o f non-immune serum. He concluded that two factors were involved, one 
heat-labile, the other stable, and named these as alexin and the ‘sensitizer’ (Bordet, 
1909). The name ‘complement’ was first used by Ehrlich and Morgenroth to 
describe the heat-labile substance because it appeared to complement the activity o f 
the stable component. Bordet, however, is recognized as having discovered the 
complement system as he showed with his complement fixation test that it was not 
merely an auxiliary factor.
During the first half of the 20th century, work on complement continued and 
it was established that the system comprised a series o f at least four proteins 
(Pillemer et al, 1941). In the 1960s Nelson and Miiller-Eberhard characterized an 
immunologically activated pathway, the classical pathway (Nelson et al, 1966; 
Miiller-Eberhard, 1968). It was thought that the system acted merely as a pro- 
inflammatory innate immunity system, effecting certain antibody functions on behalf 
o f the acquired immune system, and was termed an antibody-independent activation 
pathway o f immunity. In 1953 Pillemer had described the depletion o f C3 from 
serum by zymosan without the activation o f C l, C2, or C4. He called this the 
properdin pathway (Pillemer et al, 1954). This hypothesis was not verified until 
1971 (Gotze & Miiller-Eberhard, 1971), and the pathway was finally recognised as 
an alternative pathway o f complement activation. In 1972 Pepys (Pepys, 1972) 
recorded the observation that C3-depleted mice have an impaired acquired immune 
response. This finding indicated that the innate immune system is able to instruct the
2
acquired immune response and showed that the complement system plays a more 
interesting role than had previously been thought.
(1.2) The activation pathways and cascades
The complement system is now known to comprise over 30 proteins, several of
which are zymogens. Plasma complement proteins circulate in the blood in inactive
forms. These proteins are activated through enzyme cascades when the complement
system is triggered by the presence o f pathogens or antigen-antibody (Ag:Ab)
complexes. There are three distinct pathways o f activation -  the classical pathway,
the alternative pathway, and the mannan-binding lectin pathway -  all o f which
converge at the point o f C5 activation (Law & Reid, 1995; Janeway et ah 2001). 
(Carroll, 2004) (Miiller-Eberhard, 1988)
(1.2.1) The classical pathway
The classical pathway o f activation is triggered primarily by the interaction 
o f the C lq  fragment o f the C l complex with the Fc region o f IgG and IgM 
antibodies, which themselves are bound to repetitive epitopes found frequently on 
bacterial and viral surfaces. It can also be activated by C lq  binding directly to a 
pathogenic surface in the absence o f antibodies (Figure 1.1).
C l is a complex of one molecule o f C lq  together with two
molecules o f each o f the zymogens C lr  and C l s. C lq  has six globular heads linked 
to a collagen-like tail which surrounds C lr  and C l s. The interaction o f the globular 
heads o f C lq  with Ag:Ab complexes or pathogen surfaces induces a conformational 
change in (C lr.C ls)2 , displacing the regulatory Cl-inhibitor (C l-IN H) and 
activating C lr, which in turn cleaves C ls  and generates an active serine protease, 
C l. C l then cleaves both C4 and C2. C4 is cleaved to give C4a, a mild 
anaphylatoxin, and C4b. Within C4b there is an internal thioester bond, through 
which C4b binds to hydroxyl and amino groups on the activating surface. C2 binds 
to bound C4b, enabling the C 1 serine protease to cleave C2 into C2a and C2b. C2b 
is released while C2a remains bound to C4b, forming the classical pathway C3 
convertase, C4b2a. This convertase cleaves C3 to give C3a, an anaphylatoxin, and 
C3b. Like C4b, C3b has an internal thioester, and it too binds to the activating cell 
surface. C3b bound in the vicinity o f the C3 convertase forms the classical pathway 
C5 convertase, C4b2a3b.
3
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Figure 1.1
The activation cascades of the complement system.
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(1.2.2) The alternative pathway
The alternative pathway is not reliant on antibody recognition o f antigens, 
but is activated by the binding o f C3b to surfaces devoid o f certain carbohydrates, 
particularly sialic acid, that are common to eukaryotes. Within serum there is a 
constant low-level activation o f C3 (Figure 1.1). This may be due to either cleavage 
by serum proteases or thespofltontous hydrolysis o f the thiolester. Intact C3 with an 
hydrolysed thiolester is known as C3i or C3(H20). In the presence o f factor D 
C3(H20) is able to bind to factor B, giving an unstable fluid-phase C3 convertase, 
C3(H20)Bb. This then cleaves C3 to C3a and C3b. In the absence o f an activating 
surface, C3b is readily hydrolysed. If there is a surface present, however, C3b binds 
non-specifically, and together with factors B and D forms the alternative pathway 
C3 convertase, C3bBb, which is stabilised by the binding o f properdin. More C3 is 
cleaved to C3a and C3b. The C3b molecules bind to the surface around the initial 
site o f activation, thus providing a positive loop for the amplification o f the cascade. 
C3b is also able to bind to molecules o f the C3 convertase, forming the alternative 
pathway C5 convertase, C3bBb3b.
(1.2.3) The mannan-binding lectin pathway
The third known pathway is similar to the classical pathway. Its activation is, 
however, antibody-independent. The equivalent o f the C l complex is formed from 
mannan-binding lectin (MBL) and MBL associated serine proteases 1 and 2 (MASP- 
1 and MASP-2). MBL, like C lq , has six globular lectin domain heads which bind 
carbohydrate. MASP-1 and MASP-2 are highly homologous to C lr  and C l s. The 
complex is activated by the binding o f the lectin domains o f MBL to mannose, 
glucose, fucose, and A-acetyl-D-glucosamine (GlcNAc) residues presented in certain 
patterns on the activating surface (Figure 1.1). In eukaryotes more complex 
glycosylations are present on cell surfaces and the residues which MBL recognises 
are blocked by the addition o f either sialic acid or galactose, giving rise to a method 
o f discrimination between self and pathogenic surfaces. MBL, through its binding to 
patterns o f carbohydrate residues on surfaces is able to recognise some viruses and 
fungi as well as bacteria. Binding o f MBL to pathogens activates MASP-1 and 
MASP-2, which cleave C4 and C2 in the same way as the classical pathway.
5
(1.2.4) Membrane attack complex formation
At the convergence o f the pathways is the activation of C5 by either the 
classical or alternative pathway C5 convertase (Figure 1.1). C5 is cleaved to give 
C5a, a potent anaphylatoxin, and C5b. This gives rise to a conformational change 
within C5b and initiates the formation o f the membrane attack complex (MAC). C5b 
binds to C6 and C7. Following membrane binding o f the C5b67 complex, C8 binds. 
The C8a subunit o f C8 recruits between 1 and 18 molecules o f C9 giving the 
complete MAC. The MAC inserts itself into the membrane it is bound to creating a 
transmembrane channel and leading to lysis o f the cell. (Miiller-Eberhard, 1986)
(1.3) The roles of complement
Complement is important as a link between the innate and the adaptive 
humoral immune systems. Following the initiation o f the adaptive immune response, 
the classical pathway is activated and the complement system then acts as a major 
host-defence mechanism. Complement is also able to amplify and enhance the 
adaptive immune response, by, for example, lowering the threshold o f activation of 
B cells by antigen.
Activation o f complement gives rise to a wide range o f responses, not just 
lysis through the MAC. Immune complexes (Ag:Ab complexes) are tagged with C3b 
and C4b. These complexes are then able to bind to receptors, for example, 
complement receptor type 1 (CR1, CD35), which have binding sites for C3b and 
C4b. In humans CR1 is found on erythrocytes and is the means by which circulating 
immune complexes are cleared from the blood to the liver and spleen for processing 
by macrophages.
The complement system plays a role in the phagocytosis o f antigens. C3b, 
C4b, and iC3b are opsonins, so called because their binding to antigen marks it for 
recognition by cell surface receptors on phagocytic cells. Complement receptor 
types one and three (CR1, CR3) and Fc receptors (FcR) are found on phagocytes. 
CR1 binds C3b and C4b, CR3 binds iC3b, and FcR binds the Fc domain o f IgG. 
Receptor binding o f opsonized antigen leads to the internalization and ingestion o f 
the fragment.
The anaphylatoxins generated by proteolytic cleavage in the enzyme 
cascades mediate inflammation and may also help to regulate the immune response.
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C3a and C5a are known to stimulate contraction o f smooth muscles, induce the 
release o f histamine from mast cells, and to increase vascular permeability. In 
addition, C5a can stimulate lysosomal enzyme release (Gerard & Gerard, 1994). 
Both C5a and C3a promote the chemotaxis o f phagocytes to the site o f infection.
(1.4) The regulation of complement
If left unchecked, the complement system has huge destructive capabilities. 
Without tight regulation, complement activation would be excessive and the 
complement proteins in circulation would be quickly depleted. The system therefore 
has several regulators and inhibitory mechanisms (Figure 1.2). On an overall level, 
active complement proteins have a short half-life, even in the absence o f regulatory 
proteins. Host cells are normally well defended against inappropriate complement 
activation on their surface. CD59 is a GPI-anchored protein found on many host 
cells. It binds to C8 o f the MAC, preventing the recruitment o f C9 subunits and 
impeding lysis. Other complement regulatory proteins found on host cell surfaces 
include CR1, membrane cofactor protein (MCP, CD46), and decay accelerating 
factor (DAF). DAF acts to accelerate the decay o f both the classical and alternative 
pathway C3 and C5 convertases. CR1 and MCP are both cofactors for factor I, and 
CR1 is also a convertase decay acceleration protein. Factor I is a serine protease 
which cleaves both C3b and C4b in the presence o f a cofactor. C3b is cleaved to 
iC3b and C3f by factor I along with the cofactors Factor H (FH), CR1, and MCP. 
C4b is cleaved to C4c and C4d by factor I and the cofactors C4-binding protein 
(C4BP), CR1, and MCP. FH, as well as being a cofactor for factor I, controls the 
activity o f the alternative pathway C3 and C5 convertases by competing with factor 
B for C3b binding.
In the alternative pathway, the protease factor D is a cofactor for factor B 
binding with C3b and acts in a rate-limiting manner. In the classical pathway, C l- 
INH is released from the C l complex upon activation. C l-INH is a serpin (serine 
protease inhibitor), and following its release it is able to bind across the C ls-C lr  
active sites thereby deactivating the C l complex.
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Regulation of the complement system cascades.
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(1.5) Complement in disease
The complement system, when properly regulated, is vital to human life. 
Lack o f complement severely affects host defence functions and homeostasis o f the 
immune system. An increase in complement activation is similarly harmful.
MBL deficiency is one o f the most common human immunodeficiencies, 
leading to an overall increased susceptibility to infectious and autoimmune disease 
(Kilpatrick, 2002; Turner, 2003). The deficiency gives rise to opsonic dysfunction 
and is observed as repeated infections, especially in children, at which age the MBL 
pathway is thought to be most important (Super et ah 1989). The therapeutic 
replacement o f MBL in such cases through infusions o f fresh plasma or purified 
plasma-derived protein was shown to be effective (Soothill & Harvey, 1976; 
Valdimarsson et al, 1998). In the autoimmune disease systemic lupus erythematosus 
(SLE), patients have been shown to have an increased frequency o f either MBL 
mutations or deficiency (Davies et ah 1995; Davies et ah 1997).
The deficiency o f classical pathway components is generally associated with 
immune complex disorders and recurrent infection, as well as with the occurrence o f 
SLE. C3 deficiency gives rise to a decrease in the ability to clear immune complexes 
and recurrent bacterial infections. Deficiencies in the alternative pathway are 
relatively low, presenting the possibility that these may be fatal. The terminal 
pathway o f complement activation is involved in many complement-related disease 
states. Deficiency o f the terminal components, with the exception o f C9, is related to 
repeated Neisserial infections and SLE. Activation o f the terminal pathway also 
plays a large role in ischaemia-reperfusion (I/R) tissue injury, with C5a and the 
MAC mediating the most damage (Riedemann & Ward, 2003). Antibodies to C5 
were found to be effective as therapeutic agents in animal disease models o f 
myocardial ischaemia (Vakeva et ah 1998), and this success lead to the clinical use 
o f anti-C5 antibodies in cardiopulmonary bypass patients (Fitch et ah 1999).
The deficiency o f complement regulatory proteins leads to disturbed 
homeostasis. Low levels o f FH causes uncontrolled C3 activation leading to 
membranoproliferative glomerulonephritis (MPGN) and renal failure (Ault et ah 
1997), as well as an increased susceptibility to meningococcal disease (Nielsen et ah 
1989). Missense mutations in FH, particularly in domains 19 and 20, cause atypical 
haemolytic uremic syndrome (aHUS) (Zipfel et al, 2001). Paroxysmal nocturnal 
haemoglobinuria is caused by mutations in the gene for the GPI tail o f DAF and
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CD59, which means that the proteins cannot be inserted into the cell membrane 
(Nicholson-Weller et al, 1983; Pangbum et al, 1983). The deficiency o f factor I 
leads to increased C3 activation, decreased opsonization and subsequently increased 
bacterial infection (Vyse et al, 1996).
(1.6) Therapeutic uses of complement
Under normal circumstances the regulatory proteins o f the complement 
system are able to control the tissue damaging effects o f the system’s activation, also 
assisting with self-recognition. These proteins are therefore o f great interest when 
searching for therapeutic inhibitors o f complement.
Since the inhibition o f the complement system as a whole is not conducive to 
good health, global inhibitors are undesirable, especially those which affect both 
pathways. Local inhibitors that block the cascades at a late step, in particular those 
capable o f being targeted to a specific tissue, are much preferable as the systemic 
effects are more likely to be negligible. In order to develop effective therapeutic 
reagents it is necessary to understand the aetiology o f the disease to be treated as 
fully as possible.
C 1 -INH is a protease inhibitor which is profoundly deficient in patients with 
angioedema, due to either hereditary genetic mutations or, in the acquired form, to 
either autoantibodies to the protein or an associated disease which gives rise to 
increased Cl-IN H  catabolism. It has been used clinically in the treatment o f both 
(Agostoni et al, 1980; Waytes et al, 1996) for almost 30 years with few adverse 
affects (Zanichelli et al, 2004). More recently it has been used in patients with sepsis 
and myocardial infarction, and has been shown to be particularly effective in 
preventing damage to the brain in ischaemia-reperfusion injury (De Simoni et al, 
2003).
CR1 is a powerful regulator o f complement belonging the regulators of 
complement activity (RCA) protein family. All proteins within this family contain 
60-70 amino acid residue short complement repeat (SCR) domains (also known as 
short consensus repeat and Sushi domains). CR1 is involved in the dissociation of 
both the classical and alternative pathway C3 and C5 convertases as well as acting as 
a cofactor for Factor I for both C3b and C4b, and was therefore seen as an ideal 
target for developing as a complement inhibitor. Several different systems have been
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examined. A soluble CR1 (sC R l) construct was made and shown to retain 
functionality (Weisman et al, 1990). Studies with this protein in a model o f 
ischaemia/reperfusion injury showed that it is capable o f inhibiting complement 
activation in vivo. In this way the amount o f tissue injury is reduced, both through 
decreasing the levels o f anaphylatoxins and reducing the effect o f the deposition o f 
the MAC. Furthermore, sCRl has been shown to be effective in human acute and 
chronic inflammatory conditions, including multiple sclerosis (Piddlesden et al, 
1994), glomerulonephritis (Couser et al, 1985), and asthma (Regal et al, 1993). 
sCRl has a relatively low plasma half-life which does not make it a good drug 
candidate in humans and fusion proteins have been created to circumvent this. A 
construct o f CR1 fused to the albumin-binding domain o f Streptococcal protein G 
(Makrides et al, 1996) demonstrated a half-life in rats o f 297 minutes in comparison 
with that o f 103 minutes for sCR l. CR1 SCRs 8-11 were fused to the Fab domain of 
an immunoglobulin (Kalli et al, 1991) and shown to be active, and moreover, an Ig 
fusion would enable targeting o f the inhibitor to local regions o f complement 
activation (Kalli et al, 1994). Unfortunately both o f these fusion proteins are 
potentially immunogenic, restricting their usefulness as therapeutic molecules.
Fusion proteins have also been constructed from two other RCA proteins, 
DAF and CD59. When complement is activated on a cell surface, C3 cleavage 
fragments are covalently attached to that surface. These long-lived fragments are 
abundant at sites o f complement activation and therefore provide a useful target for 
local inhibition. The first two SCR domains o f complement receptor type 2 (CR2), 
another RCA protein, bind to C3 cleavage fragments, enabling the protein to be used 
as a targeting moiety (Song et al, 2003). In these experiments both DAF and CD59 
were fused to SCRs 1-4 o f CR2. It was shown that the fusion proteins were indeed 
targeted to sites o f complement activation and that they are also more efficient in 
their inhibitory role than their soluble, unfused counterparts (i.e. sDAF). Fusions of 
two complement proteins are likely to have a broad therapeutic benefit and are less 
likely to have an immunogenic capacity than antibody fusions. Despite the negligible 
systemic effects o f these inhibitors, it is possible that the use o f CR2 as the targeting 
agent could interfere with the pathogen defence systems o f which CR2 is a part.
Due to the long half-life o f the Fc domain o f Ig molecules (Capon et al, 
1989), Harris et al expressed fusion proteins o f human DAF with the Fc regions o f 
IgG2 and IgG4 (Harris et al, 2003). They had previously shown that steric constraints
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within fusion molecules formed o f an RCA protein linked to an Fc domain were 
implicated in a loss o f function, although the molecules had a good half-life and 
were biologically active (Harris et al, 2002). The function in these molecules was 
partially restored with the insertion o f spacing domains between the Fc and SCR 
domains, and totally restored with the cleavage o f the Fc fragment. Following these 
observations two constructs were created; DAF SCR l-4:IgG4 Fc, and DAF 
SCR:IgG2 Fc. These two Fc domains both have very short, rigid hinges. An 
enzymatic cleavage site was engineered into the constructs between the hinge and 
the first SCR domain to enable release o f DAF from the fusion protein upon arrival 
in the appropriate tissue. When bound to the Fc domain, the DAF has reduced 
function due to steric hindrance, and so there is only a very low level o f global 
activity. When cleaved the biological function is fully restored.
These results indicate a promising future for the development and use of 
complement proteins in therapeutic roles.
(1.7) Complement receptor type 2
Complement receptor type 2 (CR2; CD21) is a type one membrane 
glycoprotein (Goder & Spiess, 2001) belonging to the RCA family o f proteins. CR2 
is important in providing the molecular link between Ag:Ab:C3 complexes and the 
activation o f B cells.
(1.7.1) CR2 expression
CR2 is found at the RCA gene locus (Rodriguez de Cordoba et al, 1985), 
along with FH, C4BP, CR1, DAF, and MCP. The locus maps to human chromosome 
lq32 (Weis et al, 1987), within which CR2 is encoded by a single gene (Fujisaku et 
al, 1989). Analysis o f the full length cDNA of human CR2 showed regions o f 
internal homology (Weis et al, 1988) which was also noted in the genomic 
organisation (Fujisaku et al, 1989). The CR2 exons were observed to be o f three 
different types, either encoding one single SCR domain (domains 3, 7, 11, 15, 16), 
two whole SCR domains fused together (1 and 2, 5 and 6, 9 and 10, 13 and 14), or a 
part of two different SCR domains (domains 4, 8, and 12). The order o f the exons 
within the gene is a repeated array o f a group o f four SCR domains in the order 
fused, single, split for the first three repeats and then fused, single, single for the last
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group, giving a total o f 16 SCR domains. This arrangement would suggest that the 
gene evolved through the duplication o f a basic four SCR domain unit.
In various cDNA libraries two different forms o f CR2 were seen to be 
present (Weis et al, 1988; Moore et al, 1987), one with 15 SCR domains, the other 
with 16, with the additional domain inserted between SCR 10 and 11 o f the 15 
domain protein. This was shown to be due to alternative splicing of the precursor 
mRNA (Toothaker et al, 1989).
CR2 is primarily expressed by B lymphocytes (Weis et ah 1984), but is also 
found on FDC (Reynes et al, 1985), epithelial cells (Young et ah 1986; Birkenbach 
et al, 1992), astrocytes (Gasque et al, 1996), early thymocytes (Tsoukas & Lambris, 
1988), and a subset o f CD4+ and CD8+ peripheral T lymphocytes (Fischer et al, 
1991; Levy et al, 1992). It has been reported that a soluble form o f CR2 is shed 
spontaneously from B and T cells (Fremeaux-Bacchi et al, 1996). Follicular 
dendritic cells constitutively express the 16 SCR domain isoform of CR2 (Liu et al,
1997). In B cells CR2 is expressed only during the early activated and mature stages 
o f cell development (Figure 1.3). It is not expressed in either pro- or pre- B cells or 
in lymphocytes at the plasma cell stage (Tedder et al, 1984). Once B cells are 
activated to the proliferative stage CR2 is lost from the cell membrane and is no 
longer expressed (Boyd et al, 1985).
The expression of CR2 is regulated in several ways. The Cr2 gene has a 
characteristic TATA box, a CpG-rich motif, and several transcription factor binding 
sites. The promoter was found to be active, even in cells that do not express CR2, 
and this is primarily controlled by an intronic silencer (Makar et ah 1998). 
Chromatin remodelling also plays a role in the regulation o f expression, with DEK, a 
chromatin protein, shown to bind in greater quantities in the active promoter region 
o f Cr2 (Hu et ah 2005).
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A schematic representation of B cell development. The developmental stages at which the proteins CD 19, CR2, 
IgM, and IgD are expressed are shown.
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(1.7.2) CR2 sequence
Complement receptor type 2 (CR2/CD21) is a 145 kDa type I membrane 
glycoprotein consisting o f an 111 kDa polypeptide chain with between eight and 
eleven putative N-linked glycosylation sites (Weis & Fearon, 1985). It consists, as 
mentioned previously, o f 15 or 16 SCR domains, a transmembrane region and a 
short cytoplasmic tail. The cytoplasmic domain is 34 amino acids long and contains 
several potential serine and threonine phosphorylation sites (Moore et al, 1987; 
Feramisco et al, 1980). The sequence o f CR2 is highly conserved across species, 
although SCR 3 appears to be missing in the rat protein, and there may be two 
additional SCR domains in the putative bovine CR2 sequence (Figure 1.4).
The first two SCR domains o f CR2 (those furthest from the membrane 
spanning region) contain binding sites for four known ligands, C3 cleavage 
fragments (C3d, C3dg, and iC3b), the Epstein-Barr virus (EBV) coat glycoprotein 
gp350/220 (Lowell et al, 1989; Carel et al, 1990), the low-affinity IgE receptor, 
CD23 (Aubry et al, 1992), and interferon alpha, IFN a (Delcayre et al, 1991). A 
further binding site for CD23 occurs in the SCR 5-8 domains at the N-linked 
glycosylation sites (Aubry et al, 1994).
(1.7.3) CR2 function
CR2 deficiency is associated with an impaired B cell response to T- 
dependent antigen (Aheam et al, 1996; Molina et al, 1996). On mature B 
lymphocytes CR2 acts as a coreceptor for IgM, the B cell receptor (BCR), greatly 
enhancing the B cell response to antibodies (Thyphronitis et al, 1991; Hebell et al, 
1991; Aheam et al, 1996; Molina et al, 1996) and subsequently augmenting the T 
cell response (Heyman et al, 1990). In this way CR2 acts as an interface between the 
innate and humoral acquired immune responses (Dempsey et al, 1996).
The BCR is formed o f IgM with one molecule o f each o f Iga and Igp. IgM 
cannot mediate signalling alone, but does this through Iga  and Igp. These latter 
proteins each have an immunoreceptor tyrosine-based activation m otif (ITAM) in 
their cytoplasmic domain. On antigen binding to IgM the tyrosine residues in the 
ITAMs are phosphorylated by receptor associated Src-family tyrosine kinases. The
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< —  SCR 1 ------------------------------------------------------------------------------------------------------
Mouse(1) --- ISCDPPPEVKNA-RKPYYSLPIVPGTVLRYTCSP------ SYRLIGEKAIFCISENQ 50
Mouse(2) --- ISCDPPPEVKNA-RKPYYSLPIVPGTVLRYTCSP------ SYRLIGEKAIFCISENQ 50
Rat FSELSCDPPPEVNNT-RRLYYSLPVLPGTVVRYTCLP------ GYRLIGEKAIFCISKDQ 293
Human15 — ISCGSPPPILNG-RISYYSTPIAVGTVIRYSCSG------ TFRLIGEKSLLCITKDK 50
Humanl6  ISCGSPPPILNG-RISYYSTPIAVGTVIRYSCSG------ TFRLIGEKSLLCITKDK 50
Bovine  IPCEPPPAISNGDFQSSNRDYFYYGTVVTYQCHVGQNGKKLFDLLGEKSIYCTSKDN 209
Sheep --- 1FCDPPPSIKNG-RSGYHSGPVALNAWTYSCAS------ AFRLIGERRLFCISKDN 50
Mouse (1) VHATWDKAPPICESVN------------------------------------------- KTISCS 72
Mouse (2) VHATWDKAPPICESVN------------------------------------------- KTISCS 72
Rat VTATWDKATPICEPWN KMSACS 315
Human 15 VDGTWDKPAPKCEYFN KYSSCP 72
Human 16 VDGTWDKPAPKCEYFN KYSSCP 72
Bovine QVGIWNSPPPQCIPVVKCPIPEVENGAMESGFRRSFSLNDSVMFKCKPGFTMKGSNTVWC 269 
Sheep VNGIWDKAPPICEYYN RNSVCS 72
Mouse (1) DP----------------------------------------------------------------- 74
Mouse (2) DP----------------------------------------------------------------- 74
Rat KP-------------------------------------------------   317
Human 15 EP----------------------------------------------------------------- 74
Human 16 EP----------------------------------------------------------------- 74
Bovine QPNSKWNPPLPKCFKGCLPPPHTHHGNYNQLDEEFFAVGQEVSYSCEPGYTLIGTNPIQC 329
Sheep EP----------------------------------------------------------------- 74
*
Mouse(1) -------------------------------------------------------------------
Mouse(2) -------------------------------------------------------------------
Rat :-------------------- -----------------------------------------------
Human15 --------------------------------------------------------------- - --
Human16 -------------------------------------------------------------------
Bovine TSLGTWSHLVPKCEVKSCDDIPNQLLNGRVVAPPNLQLGAEVSFVCDKGYRLNGQSSSQC 389
Sheep ------------------------------------------------------------------
—  SCR 2 --------------------------------------------------------------------------------
Mouse (1) ---------------- IVPGGFMNKGSKAPFRHGDSVTFTCKANFTMKGSKTVWCQANEMWG 120
Mouse (2)  IVPGGFMNKGSKAPFRHGDSVT FTCKANFTMKGSKTVWCQANEMWG 120
Rat------- ---------------- IVPGGIINPGSRPPFKHGDSVTVTCKANFTMKGSKTVWCRANKMWG 363
Humanl5 ----------------IVPGGYKIRGS-TPYRHGDSVTFACKTNFSMNGNKSVWCQANNMWG 119
Human 16--- ---------------- 1VPGGYKIRGS-TPYRHGDSVTFACKTNFSMNGNKSVWCQANNMWG 119
Bovine VSEGMRVFWSNKFPVCERGYRSKTSRPPFRHGDAVTFSCNANFTMKGNKTVWCRANRRWG 44 9
Sheep ---------------- IIPGGYRTKTSRPPFRHGDAVTFSCNANFTMKGNKTVWCQANRKWG 120
• ★ *  * • # * * * • * *  « * • • * * • * • *  * . * * * • * *  * *
------------ >  < —  SCR 3 ------------------------------------------------------------------------------
Mouse(1) PTALPVCESDFPLECPSLPTIHNGHHTGQHVDQFVAGLSVTYSCEPGYLLTGKKTIKCLS 180
Mouse(2) PTALPVCESDFPLECPSLPTIHNGHHTGQHVDQFVAGLSVTYSCEPGYLLTGKKTIKCLS 180
Rat PTPLPVCES------- ■-------------------------------------------------- 372
Human15 PTRLPTCVSVFPLECPALPMIHNGHHTSENVGSIAPGLSVTYSCESGYLLVGEKIINCLS 179
Human16 PTRLPTCVSVFPLECPALPMIHNGHHTSENVGSIAPGLSVTYSCESGYLLVGEKIINCLS 179
Bovine PTPLPTCESDIPLECPSLPTIANGHHTGESVGSFAPGLTVTYSCEPGYLLLGENTIHCLS 509
Sheep PTPLPICESDTPLECPSLPTIANGHHTGESVASFAPGLTVTYSCEPGYLLLGENTIHCLS 180
* * * * * *  • • . . .  •
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 > <—  SCR 4 ---------------------------------------
Mouse(1) SGDWDGVIPTCKEAQCEHPGKFPNGQVKEPLSLQVGTTVYFSCNEGYQLQGQPSSQCVIV 240
Mouse(2) SGDWDGVIPTCKEAQCEHPGKFPNGQVKEPLSLQVGTTVYFSCNEGYQLQGQPSSQCVIV 240
Rat  EAKCERPEKLPNGQVKEPPSLRVGTTVYFSCNEGYELQGQPSSKCVIV 420
HumanlS SGKWSAVPPTCEEARCKSLGRFPNGKVKEPPILRVGVTANFFCDEGYRLQGPPSSRCVIA 239
Human16 SGKWSAVPPTCEEARCKSLGRFPNGKVKEPPILRVGVTANFFCDEGYRLQGPPSSRCVIA 239
Bovine SGDWSAVAPTCKEAECEAPGPFLNGQIKRPTSFGVGATVNFSCNEGYRLQGPLSSQCVIF 569
Sheep SGDWSAVAPTCKEAQCEPPRSFLNGQIKRPTSFGVGATVNFSCNEGYRLQGPLSSRCVIV 240
** * .  • * * . . *  * . ★* * *  * . * ★ *  ** *  * * . * ★ *
------------> <-- SCR 5 --------------------------------------------------------------------------
Mouse(l) EQKAIWTKKPVCKEILCPPPPPVRNGSHTGSFSENVPYGSTVTYTCDPSPEKGVSFTLIG 300
Mouse(2) EQKAIWTKKPVCKEILCPPPPPVRNGSHTGSFSENVPYGSTVTYTCDPSPEKGVSFTLIG 300
Rat EQKAVWTKKPVCKEILCPPPPPVLNGRHSGRFSGNVPYGNNVTYMCDPSPEKGVNFTLIG 480
Humanl5 GQGVAWTKMPVCEEIFCPSPPPILNGRHIGNSLANVSYGSIVTYTCDPDPEEGVNFILIG 299
Humanl6 GQGVAWTKMPVCEEIFCPSPPPILNGRHIGNSLANVSYGSIVTYTCDPDPEEGVNFILIG 299
Bovine GQRTFWTRMPACEEILCPSPPPILNGRHTGTSSVIFRYGSTVSYTCDPGPEKGVNFILVG 629
Sheep EQRTFWTKMPACEEILCPSPPPILNGRHTGTSSVIFRYGRTVSYTCDPGPEKGVNFILVG 300
*  * ★ .  * '  + .  * ★ . * * _ * * * .  *  ★ *  ★ *  *  * ; *  * * * ★ * • * * ★  *  .  *
-------------------------------------------- >  < —  s c r  6 ---------------------------------------
Mouse(1) EKTINCTTGSQKTGIWSGPAPYCVLSTSAVLCLQPKIKRGQILSILKDSYSYNDTVAFSC 360
Mouse(2) EKTINCTTGSQKTGIWSGPAPYCVLSTSAVLCLQPKIKRGQILSILKDSYSYNDTVAFSC 360
Rat EKTIYCTNSSEKTGIWSGPAPYCKLSISEAQCLRPQINRGQILSILKESYSYNDTVAFSC 540
Humanl5 ESTLRCTVDSQKTGTWSGPAPRCELSTSAVQCPHPQILRGRMVSGQKDRYTYNDTVIFAC 359
Human16 ESTLRCTVDSQKTGTWSGPAPRCELSTSAVQCPHPQILRGRMVSGQKDRYTYNDTVIFAC 359
Bovine ERTIRCTTDSQKTGTWSGPAPRCELSVSELLCPPPQIPRGQISSGQRDQYSYNDTWFAC 689
Sheep ERTIRCTTDSQKTGTWSGPAPRCELSVSEVRCPPPQIPRGQISSGQRDQYSYNDTWFAC 360
* * . * * *.**■* ****** * * * * * * . * * * . . * . . *.***** * . *
---------------------------- > <—  SCR 7 ----------------------
Mouse(1) EPGFTLKGNRSIRCNAHGTWEPPVPVCEKGCQAPPKIINGQKEDSYLLNFDPGTSIRYSC 420
Mouse(2) EPGFTLKGNRSIRCNAHGTWEPPVPVCEKGCQAPPKIINGQKEDSYLLNFDPGTSIRYSC 420
Rat EPGFTLKGSGRIRCSAQGTWKPPVPVCEKGCQAPPKIINGQKEDRYFLNFDPGTSIRYSC 600
Human15 MFGFTLKGSKQIRCNAQGTWEPSAPVCEKECQAPPNILNGQKEDRHMVRFDPGTSIKYSC 419
Human16 MFGFTLKGSKQIRCNAQGTWEPSAPVCEKECQAPPNILNGQKEDRHMVRFDPGTSIKYSC 419
Bovine MFGFTMKGSRAVRCNAQGTWEPSVPVCEKDCQAPPKILNGQKEDRHRVRFDPGTSIKYSC 749
Sheep IFGFTMKGSRAVRCNAQGTWEPSVPVCEKDCQAPPKILNGQKEDRHRVRFDPGTSIRYSC 420
* * * . * *  .** * . * * * . *  * * * * *  * * * * * . * . * * * * * *  . . * * * * * * * . * * *
---------------------------- > <-- SCR 8--------------------------------------
Mouse(1) DPGYLLVGEDTIHCTPEGKWTPITPQCTVAECKPVGPHLFKRPQNQFIRTAVNSSCDEGF 480
Mouse(2) DPGYLLVGEDTIHCTPEGKWTPITPQCTVAECKPVGPHLFKRPQNQFIRTAVNSSCDEGF 480
Rat DPGYFLVGEDTIHCTSEGKWTPIPPQCKVAECKPVGPHVFERPQNHFIRPAINSSCDEGF 660
Human15 NPGYVLVGEESIQCTSEGVWTPPVPQCKVAACEATGRQLLTKPQHQFVRPDVNSSCGEGY 479
Humanl6 NPGYVLVGEESIQCTSEGVWTPPVPQCKVAACEATGRQLLTKPQHQFVRPDVNSSCGEGY 47 9
Bovine DLGYELVGEESIHCTPDGVWMPTAPTCKVAECEPVGKQVFKKPKNQFIRPDVNSSCDEGY 809
Sheep DPGYVLVGEESIRCTPDGVWIPTAPICKAAECEPVGKQVFKKPKNQFIRPDVNSSCDEGY 480
. ★* * * * * . . * . * * ' . *  *  *  *  *  *  *. * ... . * . . . * . *  . *  *  *  *  *  *  .
------------------------ > <-- SCR 9--------------------------
Mouse(1) QLSESAYQLCQGTIPWFIEIRLCKEITCPPPPVIHNGTHTWSSSEDVPYGTVVTYMCYPG 540
Mouse(2) QLSESAYQLCQGTIPWFIEIRLCKEITCPPPPVIHNGTHTWSSSEDVPYGTVVTYMCYPG 540
Rat QISESAYQLCQGTIPWFIEIRLCKEITCPPPPIILNGTHTWRSSEDVPYGTVITYMCYPG 720
Humanl5 KLSGSVYQECQGTIPWFMEIRLCKEITCPPPPVIYNGAHTGSSLEDFPYGTTVTYTCNPG 539
Humanl6 KLSGSVYQECQGTIPWFMEIRLCKEITCPPPPVIYNGAHTGSSLEDFPYGTTVTYTCNPG 539
Bovine RLGESVYQQCQGTIPWFMEIRLCKDITCPPPPVIYNGVHTGSSSEDVLYGTTVTYTCNPG 8 69
Sheep RLGESVYQQCRGTFPWFMEIRLCKDITCPPPPAIYNGVHTGSSSEDVLYGTTVTYTCYPG 540
» •  *  *  *  *  * *  * *  *  * *  * * *  . * *  *  * *
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 > <—  SCR 10 --------
Mouse(1) PEEGVKFKLIGEQTIHCTSDSRGRGSWSSPAPLCKLSLPAVQCTDVHVENGVKLTDNKAP 600
Mouse(2) PEEGVKFKLIGEQTIHCTSDSRGRGSWSSPAPLCKLSLPAVQCTDVHVENGVKLTDNKAP 600
Rat SEEGVKFKLIGEQTIHCTSDSRGRGSWSSPAPLCKLSLPAVQCTEVHVENGVKLTDNKAP 780
HumanlS PERGVEFSLIGESTIRCTSNDQERGTWSGPAPLCKLSLLAVQCSHVHIANGYKISGKEAP 599
Humanl6 PERGVEFSLIGESTIRCTSNDQERGTWSGPAPLCKLSLLAVQCSHVHIANGYKISGKEAP 599
Bovine PERGVKYNLIGESTIRCISNDQETGIWSGPAPLCKLSLPAVQCSHVHVANGYKISGKEAP 929
Sheep PERGVKYNLIGESTIRCISNDQGTGIWSGPAPLCKLSLPAVQCSHVRIENGYKISGKEAP 600
★ ie ★ • • ★★★★ ★ ★ • ★ • ★ ★★ ★★★★★★★★★ ★★★★• ★★ * • •
 >
Moused) YFYNDSVMFKCDDGYILSGSSQIRCKANNTWDPEKPLCKK----------------------  640
Mouse (2) YFYNDSVMFKCDDGYILSGSSQIRCKANNTWDPEKPLCKK----------------------  640
Rat YFYNNSVTFKCRDGYILIGSSQIRCKANNTWDPEAPHCKK----------------------  820
Humanl5 YFYNDTVTFKCYSGFTLKGSSQIRCKADNTWDPEIPVCEK----------------------  639
Humanl6 YFYNDTVTFKCYSGFTLKGSSQIRCKADNTWDPEIPVCEKGCQSPPGLHHGRHTGGNTVF 659
Bovine YFYNDSVIFKCDDGFILKGSSQVRCKANNTWDPEIPVCEK----------------------  969
sheep YFYNDSVVFKCDDGFILRGSSQVRCKANNTWDPEIPVCEK----------------------  640
★ * * * . . *  * * *  * .  * * * * * . * * * * . * * * * * *  * * . *
<—  SCR 11 --------
Mouse(l) --------------------------------------------EGCEPMR— VHGLPDDSHIKL 659
Mouse (2) --------------------------------------------EGCEPMR— VHGLPDDSHIKL 659
Rat------- --------------------------------------------EGCEPMRK-LPGISDHSLIKL 840
Human 15 --------------------------------------------ETCQHVRQSLQELPAGSRVEL 660
Humanl6 FVSGMTVDYTCDPGYLLVGNKSIHCMPSGNWSPSAPRCEETCQHVRQSLQELPAGSRVEL 719
Bovine -------------------------------------------EAQCQPLEEDVREPPVDSLWP 991
Sheep----- -------------------------------------------EAQCQPLGEDVQKPPVGSPVVP 662
* ■ * . * ;
------------------------------------ > <—  SCR 12 ------------
Mouse(1) VKRTCQNGYQLTGYTYEKCQNAENGTWFKKIEVCTVILCQPPPKIANGGHTGMMAKHFLY 719
Mouse(2) VKRTCQNGYQLTGYTYEKCQNAENGTWFKKIEVCTVILCQPPPKIANGGHTGMMAKHFLY 719
Rat VNRTCQNGYQLTGYTYEKCQNAENGTWFQKIAVCTVILCPPPPTIANGSHTGMMAEHFLY 900
Humanl5 VNTSCQDGYQLTGHAYQMCQDAENGIWFKKIPLCKVIHCHPPPVIVNGKHTGMMAENFLY 720
Humanl6 VNTSCQDGYQLTGHAYQMCQDAENGIWFKKIPLCKVIHCHPPPVIVNGKHTGMMAENFLY 779
Bovine ANISCQEGYRMMKYAFQKCQDDENRVWFQRIPVCEIIHCQDPPVINNGRYRGVLPGGFPY 1051
Sheep ANTSCQDGYRMKNYIYQKCQDDENRVWFQKIPVCEIINCKDPPRINNGKHRGVLPGGFRY 722
. * * . * * . .  • • .  ** .  ** * * . . *  . * . * * * * * * * . * . .  * *
------------------------------------------ > <-- SCR 13 —
Mouse(1) GNEVSYECDEGFYLLGEKSLQCVNDSKGHGSWSGPPPQCLQSSPLTHCPDPEVKHGYKLN 779
Mouse(2) GNEVSYECDEGFYLLGEKSLQCVNDSKGHGSWSGPPPQCLQSSPLTHCPDPEVKHGYKLN 77 9
Rat GNEVSYECDKGFYLLGEKSLQCK GHGSWSGPPPQCLQSSPLTHCPDPEVKYGYKLN 956
Human15 GNEVSYECDQGFYLLGEKKLQCRSDSKGHGSWSGPSPQCLRSPPVTRCPNPEVKHGYKLN 780
Humanl6 GNEVSYECDQGFYLLGEKKLQCRSDSKGHGSWSGPSPQCLRSPPVTRCPNPEVKHGYKLN 839
Bovine GSEVSYECDQGFDLLGEKSIRCISDSKGLVSWSGRAPQCLKS PPVTHCPNPEVMHGHKLN 1111
Sheep GNEVSYECDQGFDLLGEKSIRCIIDSQGNGSWSGPAPQCIKSRPVTHCPNPEVMHGHKLN 782
*  * * * * * * * . * *  * * * * *  . . *  . *  * * * *  * * * . . *  * . * . ★ * . * * *  . * . * * *
 > <—  SCR 14
Mouse(1) KTHSAFSHNDIVHFVCNQGFIMNGSHLIRCHTNNTWLPGVPTCIRKASLGCQSPSTIPNG 839
Mouse(2) KTHSAFSHNDIVHFVCNQGFIMNGSHLIRCHTNNTWLPGVPTCIRKASLGCQSPSTIPNG 839
Rat KTHSAYSHNDIIHVVCNQGFIMNGSHLIRCHTNNTWLPGVPTCIRTASLGCQSPPTIPNG 1016
Humanl5 KTHSAYSHNDIVYVDCNPGFIMNGSRVIRCHTDNTWVPGVPTCIKKAFIGCPPPPKTPNG 840
Humanl6 KTHSAYSHNDIVYVDCNPGFIMNGSRVIRCHTDNTWVPGVPTCIKKAFIGCPPPPKTPNG 899
Bovine KTYSSYSHNDILHIACNPGFIMNGSHLIRCHTNNKWVPGVPTCIKKAFFGCQRPLTISHG 1171
Sheep KTYSSYSHNDILHIACNPGFVMNGSHLIRCHTNNKWVPGVPTCIKKAFLGCQRPFTISHG 842
* * . * . . * * * * * . .  * *  * * . * * * * . . * * * ★ ★ . *  ★ . ★ * * * * * * .  * . * *  * . *
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 > <------------
Mouse(1) NHTGGSIARFPPGMSVMYSCYQGFLMAGEARLICTHEGTWSQPPPFCKEVNCSFPEDTNG 899
Mouse(2) NHTGGSIARFPPGMSVMYSCYQGFLMAGEARLICTHEGTWSQPPPFCKEVNCSFPEDTNG 8 99
Rat NHTGGTIARFSPGMSVMYSCYQGYLMAGEARLICTHEGTWSHPAPYCKEVNCSFPEDTNG 1076
Human15 NHTGGNIARFSPGMSILYSCDQGYLLVGEALLLCTHEGTWSQPAPHCKEVNCSSPADMDG 900
Humanl6 NHTGGNIARFSPGMSILYSCDQGYLLVGEALLLCTHEGTWSQPAPHCKEVNCSSPADMDG 959
Bovine NHTGGDITRFSPGMSILYSCNQGYLLVGEALLLCTHEGTWNQPAPYCKEVNCSFPEHING 1231
Sheep NHTGGDITRFSPGMSIMYSCNQGYLLVGEALLLCTHEGTWNRPAPYCKEVNCSFPEHLNG 902
* * * * * * . * *  * * ★ * . . * * *  * * . * .  * * *  * . * * * * * * *  . *  * * * * * * * *  ★ . *
—  SCR 1 5 --------------------------------------------------------------------------------->
Mouse(1) IQKGFQPGKTYRFGATVTLECEDGYTLEGSPQSQCQDDSQWNPPLALCKYRRWS 953
Mouse(2) IQKGFQPGKTYRFGATVTLECEDGYTLEGSPQSQCQDDSQWNPPLALCKYRSA- 952
Rat IQKGFQPGKTYRFGTTVTLECEDGYSLEGSPQSQCQDENQWNPPLAICKNRS—  1128
Humanl5 IQKGLEPRKMYQYGAWTLECEDGYMLEGSPQSQCQSDHQWNPPLAVCRSRS—  952
Humanl6 IQKGLEPRKMYQYGAVVTLECEDGYMLEGSPQSQCQSDHQWNPPLAVCRSRS—  1011
Bovine IQNGLEPGRMYQYGAVVTLMCEDGYTLEGSPQSQCQEDHRWNPPLAVCKSPS—  1283
Sheep IQNGLEPGRMYQYGAWTLACEDGYTLEGSPQSQCQEDHRWNPPLAVCKSPS—  954
* * . * . . *  .  * . . * .  * * *  * * * * *  * * * * * * * * * *  . . * * * ★ * * . * .
Figure 1.4
The sequence alignment for CR2 from five different species. Sequences were aligned 
using Clustal W (Higgins et al, 1994). Both the 15 and 16 SCR domain forms of 
human CR2 are shown. Domains one to 15 are labelled. The NCBI accession 
numbers are: Mouse (1) P19070; Mouse (2) NP_031784; Rat XP_213977; Humanl5 
NP 001868; Humanl6 NP_001006659; Bovine XP_613039; and Sheep 
NP 001009724. The bovine and sheep CR2 sequences are predicted from genomic 
databases and have not been verified. There appear to be two extra inserted regions 
within the putative bovine sequence in between SCR 1 and SCR 2, which are 
possibly also SCR domains, although there is one Cys residue missing.
Complete conservation o f a residue across sequences is denoted by The symbols 
and refer to conserved and semi-conserved substitutions respectively.
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subsequent intracellular signalling cascade acts on transcription factors to induce 
gene transcription for the proliferation and differentiation o f the activated B cell. The 
strength o f signalling from the BCR is greatly enhanced by cross-linking with CR2 
(Carter et al, 1988). CR2 binds to C3-coated Ag, which in turn binds to the BCR thus 
linking the two. The short, 34 residue, cytoplasmic tail o f CR2 suggested that any 
signalling through the receptor would probably be mediated by an association with 
other membrane proteins and a detergent sensitive complex between CR2 and CD 19, 
a protein with a 243 amino acid cytoplasmic domain, was found (Matsumoto et a i  
1991). Two other proteins, CD81 (target o f antiproliferative antibody-1, TAPA-1) 
and Leu-13 (Chen et al, 1984), were also found to contribute to the CR2-CD19 
complex (Bradbury et al, 1992) (Figure 1.5).
CD 19 is a 95 kDa transmembrane protein found only on B cells and FDC. It 
has three extracellular domains, two o f which are immunoglobulin-like, a 
transmembrane spanning region, and a large cytoplasmic tail (Zhou et al, 1991). 
There are two kinase insert regions within the cytoplasmic domain, which, upon 
tyrosine phosphorylation, recruit phosphatidylinositol 3-kinase (PI3-K) on behalf of 
the non-receptor protein tyrosine kinases activated by mlgM (Tuveson et al, 1993). 
When coligated to mlgM, CD 19 lowers the activation threshold o f B cells (Carter & 
Fearon, 1992), and subsequently CD 19 deficient mice were found to have a poor 
immune response (Engel et al, 1995). The over-expression o f CD 19 was found to 
change B cell tolerance and give rise to the production o f autoantibodies (Tedder et 
ah 1997; Sato et al, 2000). CD81 is a member o f the tetraspanin protein superfamily. 
On B cells CD81 associates with CD 19. Tetraspanins have many different roles, but 
generally act to stabilise and enhance the function o f their associate protein (Maecker 
et al, 1997). CD81 is co-expressed with CD 19 and functions to chaperone CD 19 to 
the cell membrane (Shoham et al, 2003) and to hold the BCR complex together 
following binding by complement-coated Ag (Pierce, 2002; Cherukuri et aL 2004). 
Studies using a chimaeric CD 19 that is unable to associate with either CR2 or CD81 
showed that CD 19 is the key signal-transducing component of the BCR-CR2/CD19 
complex (Matsumoto et al, 1993).
Several experiments established that the cross-linking o f either CR2 or CD 19 
to the mlgM on B cell surfaces gives rise to a 10- to 1000-fold increase in cellular 
responses in comparison with the ligation o f either the BCR or CR2/CD19 alone.
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MAP kinase cascade 
Transcription factor activation
Figure 1.5
Schematic representation of the BCR co-receptor complex on the cell membrane. 
The C3d-Ag complex crosslinks CR2 and mlgM. Signalling is mediated through 
CD 19 and the Iga/p heterodimer. Not drawn to scale.
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Responses include an increase in intracellular Ca (Carter et al, 1988, Carter et al, 
1991), the activation o f MAP kinases (Tooze et a l  1997), and cell proliferation 
(Carter & Fearon, 1992). The signalling occurs through the tyrosine phosphorylation 
o f three sites within the cytoplasmic domain o f CD 19. One o f the phosphorylated 
sites binds Vav, a guanine nucleotide exchange factor, while the other two interact 
with PI3-K. The signalling pathways initiated by the CD19/CR2 complex are 
slightly different to those associated with the BCR as phospholipase C (PLC) was 
shown to be activated in two different ways (Carter et al, 1991). These pathways act 
synergistically with each other to enhance signalling.
Separate to the CR2/CD19/CD81 complex, CR2 also forms a complex on B 
cells with CR1 (Tuveson et al, 1991). Both CR1 and CR2 bind C3 cleavage 
fragments and have been shown to cooperate in the binding o f C3i (Leslie et al, 
2003). It is possible that the role o f CR1 within this complex is to act with factor I to 
promote the breakdown o f C3i into iC3b and C3dg for CR2 binding and initiation of 
B cell signalling pathways.
A T cell-dependent immune response gives rise to the clonal expansion of 
Ag-specific B cells within the FDC networks o f the secondary lymphoid organs. 
This leads to the formation o f germinal centres, within which B cells undergo intense 
proliferation. Somatic hypermutation and affinity maturation occur, along with 
antibody class switching (from IgM and IgD to IgG isotypes). Immune complexes 
are trapped by FDC within the secondary lymphoid organs (Papamichail et al, 1975) 
and may be retained on the cell surface for long periods o f time (Nossal et al, 1968; 
Tew et a l  1990). Several receptors on FDC, primarily CR1 and CR2 (Yoshida et al, 
1993), are able to bind and retain immune complexes for presentation to circulating 
activated Ag-specific B cells. Following B cell recognition of Ag in the trapped 
immune complexes, CR2 rescues the activated B cell from apoptosis (Fischer et al,
1998) and promotes antibody class switching (Fang et al, 1998). The linking of 
CD 19 and CR2 is required for the formation and function of germinal centres (Engel 
et al, 1995). Along with CR1, CR2 on FDC is responsible for the maintenance of 
long-term memory B cell and plasma cell antibody secretion (Qin et al, 1998; 
Barrington et al, 2001; Wu ^  al, 2001).
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CD23 is a type two transmembrane protein that is a low affinity receptor for 
IgE (Bonnefoy et al, 1987; Goder & Spiess, 2001). There are two forms o f CD23, 
one soluble, the other membrane bound. Soluble CD23 interacts with CR2 at both 
SCR 1-2 and SCR 5-8 (Aubry et al, 1992; Aubry et al, 1994). CD23 has been shown 
to influence B cell growth and proliferation (Cairns & Gordon, 1990) and germinal B 
cell survival (Liu et al, 1991). Soluble CD23 binding to CR2 upregulates interleukin- 
4 induced production o f IgE (Aubry et al, 1992; Henchoz et al, 1994). Structural 
analyses showed that soluble CD23 is able to bind mlgE and CR2 simultaneously 
and lead to suggestions that it is this cross-linking which induces the increase in IgE 
synthesis (Hibbert et al, 2005). The membrane bound form of CD23 binds to IgE to 
downregulate IgE synthesis (Gould et al, 2003).
CR2 is the obligate receptor for the Epstein - Barr virus (EBV) (Fingeroth et 
al, 1984). EBV is a human herpes virus which is carried in a latent state in the B 
cells o f over 90% of humans. In most cases there are no symptoms, but EBV can 
cause infectious mononucleosis (Henle et al, 1968). It is also associated with 
Burkitt’s lymphoma, Hodgkin’s lymphoma, and adult T cell leukaemia (Epstein et 
al, 1964; Weiss et al, 1989; Jones et al, 1988). It is also linked to the occurrence of 
several autoimmune conditions including rheumatoid arthritis, systemic lupus 
erythematosus, and multiple sclerosis (Roudier et al, 1989; James et al, 1997; 
Ascherio & Munch, 2000). EBV binds to CR2 on B cells through its coat 
glycoprotein gp350. The binding site was shown to be within CR2 SCR 1-2 (Lowell 
et al, 1989; Carel et al, 1990). Recombinant soluble SCR 1-2 constructs are able to 
bind C3dg and gp350 as well as inhibiting EBV-induced lymphoproliferation, giving 
a possible route for therapy (Moore et al, 1991).
Human immunodeficiency virus type 1 (HIV-1) binds and activates 
complement but due to various defence mechanisms, such as the acquisition o f the 
regulatory proteins MCP, DAF, and CD59 from the host (Frank et ah 1996), is not 
destroyed. The C3 fragments deposited on HIV-1 bind to CR1 and CR2 on B cells. 
When the B cells pass through the secondary lymphoid organs, the virions may be 
passed to FDCs and subsequently to T cells (Boyer et al, 1991; Moir et ah 2000). 
The FDCs in germinal centres are known to be able to hold the virus for long periods 
o f time (Kacani et al, 2000).
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Chapter Two
SCR domain structure
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(2.1) Protein structure within complement
Complement system proteins can be classified into five functional groups 
based on common structural motifs. These groups are summarised below.
(2.1.1) C lq and the collectins
The proteins in this group include C lq , the serum lectin molecules MBL and 
conglutinin, and the lung surfactant proteins SP-A and SP-D. They each contain 
between 12 and 18 polypeptide chains formed into a collagen-like domain with a 
globular C-terminus. In C lq  these globular heads interact with Ig molecules, 
whereas in the other molecules they bind sugar moieties.
(2.1.2) Serine proteases
The enzymes o f the complement system are all serine proteases (SP) o f either 
the chymotrypsin family or the trypsin subfamily. The proteins in this group include 
Factors D and B, C lr, C ls, MASP-1 and -2 , and C2. Their SP domains contain the 
catalytic triad o f His-Asp-Ser. Additional domains within the serine protease 
proteins most likely serve as substrate binding domains.
(2.1.3) The C3 family
The C3 family includes not only C3, but also C4 and C5, along with the non­
complement protein <X2-macroglobulin. Each o f these proteins is synthesised as a 
single chain, becoming disulphide-bond linked multichain proteins following post- 
translational modification. C3 and C4, but not C5, contain an internal thioester bond 
in the a-chain between the Cys and Glu o f the tetrapeptide Cys-Gly-Glu-Gln. This 
important feature allows activated C3b and C4b to bind covalently to other 
molecules, a major factor in the activation cascades o f the complement system.
(2.1.4) The terminal pathway
The terminal pathway proteins, C6, C7, C8a, C80, and C9, each have four 
distinct domains within their structure; a thrombospondin type 1 repeat, an LDL 
receptor class A repeat, a perforin-like segment, and an EGF-like repeat. The most 
important o f these domains is the perforin-like segment, as this plays a role in the 
generation o f the cylindrical structure o f the MAC that perforates cell membranes. 
The function of the other domains within these proteins is unknown.
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(2.1.5) Regulators of complement activity
The proteins in the RCA family include CR1, CR2, DAF, MCP, FH, and 
C4BP. They contain between two and 30 SCR domains (also known as complement 
control protein (CCP) repeats or Sushi domains). These domains bind to C3 and C4 
cleavage products, such as C3b.
(2.2) SCR domain structure
SCR domains were first found in factor B (Morley & Campbell, 1984) and 
are the most abundant domain type in the complement system. Each compact, 
globular domain consists o f around 60 amino acids formed into a hydrophobic core 
surrounded by two antiparallel (3-strands which run approximately along the long 
axis o f the domain (Figure 2.1). Up to eight P-strands are seen in this structure, and 
the position and length o f the strands varies between domains. There are four 
invariant Cys residues and one Trp residue. The Cys form two disulphide bridges, 
one at either end o f the long axis, stabilising the structure. The bonding o f the Cys 
residues is always in a 1 -> 3, 2 -> 4 pattern. Other conserved residues are 
hydrophobic and are found along with the invariant Trp in the hydrophobic core 
(Figure 2.2). The P-strands are joined by loops and turns, one o f which has a very 
low sequence conservation and is known as the hypervariable loop. This loop is 
found between p2 and p3. The multiple SCR domains are joined by short linkers and 
are frequently N-glycosylated.
SCR domains exist in other non-RCA family complement proteins, including 
C2, C6, C7, C lr, and C l s. They are also found outside o f the complement system, 
for example in the P-subunit o f factor XIII (Ichinose et al, 1986), in haptoglobin 
(Kurosky et aL 1980), and p2 glycoprotein I (p2 GP I) (Lozier et aL 1984). This is 
summarised in Table 2.1.
Within proteins containing several SCR repeats, the domains are usually 
arranged contiguously, as if  beads on a string. Due to this, SCR proteins are typically 
elongated. The average length o f the linkers between SCR domains (counted 
between the last Cys o f one domain and the first Cys o f the next) is four residues, 
with the shortest being three and the longest eight residues. The elongation o f SCR 
proteins and the flexibility that multiple linkers may give to the overall structure 
creates problems for structure determination, especially in multi-SCR
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Hypervariable
Loop
Cys 2 - Cys 4
Invariant Trp
Cys 1 - Cys 3
Figure 2.1
The three dimensional structure of an SCR domain showing six out of the possible eight p-strands. The disulphide 
bonds and the invariant Trp are labelled. The hypervariable loop between P2 and p3 can be seen on the left (taken from
Soares & Barlow, 2005).
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lelv 1 CGIPESI--- -ENGKVEDPEST------ LFGSVIRYTCEEP— ----YYYME-GGG— ---EYHCAGNG— — SWVNEVLGPELPKC 61
igpz 2 CGQPRNL--- -PNGDFRYTTTMG---VNTYKARIQYYCHEP— ----YYKMQTEQG— ---VYTCTAQG— — IWKNEQKGEKIPRC 65
lckl 2 CPYIRDP--- -LNGQAVPANG----- TYEFGYQMHFICNEG— ----YYLI— GEE-- ---ILYCELKGS- VAIWSGKP— -—  PIC 59
(-> 0 1 
1
2 CPSPRDI--- -DNGQ— LDIG-----GVDFGSSITYSCNSG— ----YHLI— GES— ---KSYCELGSTGSMVWNPEA--- —  PIC 58
lgkn 2 CKTPPDP--- -VNGM-VHVIT-----DIQVGSRITYSCTTG— ----HRLI--GHS— ---SAECILSGN- TAHWSTKP--- —  PIC 58
lhfi CSQPPQI--- -EHG-TINSSRSSQE-SYAHGTKLSYTCEGG— ----FRIS--EEN-- ---ETTCYM---- -GKWSSP---- —  PQC 57
lhcc CKSPPEI--- -SHG-VVAHMS---D-SYQYGEEVTYKCFEG— ----FGID— GPA— ---IAKCLG---- -EKWSHP---- —  PSC 54
lg40 3 CQSPPSI--- -SNG-RHNGYE---D-FYTDGSVVTYSCNSG— ----YSLI— GNS— ---GVLCSG---- -GEWSDP---- —  PTC 54
lh03 2 CPAPPQI--- -DNG-11QGER---D-H YG YRQS VT YACNKG— ----FTMI— GEH— ---SIYCTVNNDE -GEWSGPP--- —  PEC 59
igkg 1 CGLPPTI--- -ANGDFISTNR---E-NFHYGSVVTYRCNLGSRGRKVFELV— GEP— ---SIYCTSNDDQVGIWSGPA--- —  PQC 67
lly2 1 CGSPPPI--- -LNG-RISYYS---T-PIAVGTVIRYSCSGT— ----FRLI— GEK— ---SLLCITKDKVDGTWDKPA--- —  PKC 60
lh03 1 CPNPGEI--- -RNG-QIDVPGG-----ILFGATISFSCNTG— ----YKLF— GST— ---SSFCLISGS- SVQWSDPL--- —  PEC 58
lqub 2 CPFAGIL--- -ENG-AVRYTT------ FEYPNTISFSCNTG— ----FYLN— GAD— ---SAKCTEEG— — KWSPEL--- —  PVC 54
lg40 1 CTIPSRP--- -INMKFKNSVETDANANYNIGDTIEYLCLPG— ----YRKQKMGPI— ---YAKCTGTG— ---WTLF---- — NQC 61
lqub 4 CPFPSRP--- -DN-GFVN---YPAKPTLYYKDKATFGCHDG— ----YSLD— GPE— ---EIECTKLGN- ---WSAM---- —  PSC 56
lly2 2 CPEPIVP--- — GGYKIRGST-----PYRHGDSVTFACKTN-- ----FSMN— GNK-- ---SVWCQANN— — MWGPTR--- -LPTC 56
lqub 3 CPPPSIPTFATLRVYKPSAGN-----NSLYRDTAVFECLPQ— ----HAMF--GND-- ---TITCTTHG— — NW--TK--- -LPEC 59
lg40 4 CPHPTIS--- — NGYLSSGFKR----SYSYNDNVDFKCKYG— ----YKLS— GSS— ---SSTCSPGN— — TWK-PE--- -LPKC 56
lojv 2 CEVPTRLNSASLKQPYITQNY------ FPVGTVVEYECRPG— ----YRREPSLSP— ---KLTCLQN--- -LKWSTAV--- — EFC 61
lgkn 1 CQAPDHFLFAKLKT-QTTASD------ FPIGTSLKYECRPE — ----YYGRP-FS--- ----ITCLDN--- -LVWSSPK--- — DVC 57
lqub 1 CPKPDDL--- -PFSTVVPLKT----- FYEPGEEITYSCKPG— ----YVSRG-GMR— ---KFICPLTG-- — LWPINT--- — LKC 57
lgpz 1 CPQPKTL--- -DEFTIIQNLQP----QYQFRDYFIATCKQG— ----YQLIE-GNQVLHSFTAVCQDDG— — TWHRAM--- --PRC 63
lckl 1 CEEPPTF--- -EAMELIGKPKP----YYEIGERVDYKCKKG— ----YFYIPPLAT— ---HTICDRNH— — TWLPVS--- -DDAC 60
lojv 1 CGLPPDVP— -NAQPALEGRT----- SFPEDTVITYKCEES — ----FVKIP-GEKD- ---SVICLKGS— — QWSDIE--- — EFC 59
* * • * * *
Figure 2.2
Sequence alignment of SCR domain sequences with solved structures. The PDB codes are shown on the left, with the proceeding number 
denoting different domains within the same PDB file. The four invariant Cys are highlighted in red, and the Trp is in blue. The number of amino 
acid residues in each domain is shown on the far right. The sequences were aligned using Clustal W (Higgins et al, 1994).
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Protein Number of SCR domains
CR1 Complement / RCA 30
CR2 Complement / RCA 15/ 16
DAF Complement / RCA 4
MCP Complement / RCA 4
VCP Complement / RCA 4
C4BP-a Complement / RCA 8
C4BP-P Complement / RCA 3
Factor H Complement / RCA 20
FHR-1 Complement / RCA 5
FHR-2 Complement / RCA 4
FHR-3 Complement / RCA 4
FHR-4 Complement / RCA 4
FHR-5 Complement / RCA 8
Factor B Complement / RCA 3
C lr Complement / non-RCA 2
C ls Complement / non-RCA 2
C2 Complement / non-RCA 3
C6 Complement / non-RCA 2
Cl Complement / non-RCA 2
MASP-1 Complement / non-RCA 2
MASP-2 Complement / non-RCA 2
Factor XIII-P non-complement 8
|32 GP I non-complement 4
haptoglobin-a non-complement 2
GABA-B Receptor 1 non-complement 2
Thyroid Peroxidase non-complement 1
Interleukin-2 Receptor non-complement 2
Interleukin-15 Receptor non-complement 1
Aggrecan non-complement 1
Brevican non-complement 1
Neurocan non-complement 1
Versican non-complement 1
Transmembrane Receptor 1 non-complement 5
Table 2.1
Short Complement Repeat Containing Proteins.
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proteins such as CR1 and FH. The structure of several SCR domains has been 
investigated using a number of techniques, including X-ray crystallography, nuclear 
magnetic resonance (NMR), electron microscopy (EM), and small angle scattering 
(SAS) (Table 2.2). Atomic level structures are mostly constrained to one or two 
domains, although the longer four and five SCR domain structures of Vaccinia virus 
complement control protein (VCP) (Murthy et al, 2001) and P2GPI (Bouma et al, 1999; 
Schwarzenbacher et al, 1999) respectively have been solved by X-ray crystallography. 
The short, two domain NMR structures, for example those o f CR1 (Smith et al, 2002) 
and FH (Barlow et al, 1993), are of interest with respect to elucidating linker flexibility 
and orientation. NMR studies of CR1 used two overlapping SCR domain pairs (where 
one domain o f each pair is the same (i.e. 15-16 and 16-17)) in order to build a model of 
a three domain segment (Smith et al, 2002). NMR is very sensitive to flexibility within 
the linker regions, and this method gives the possibility o f creating an atomic level 
model for the entire structures of longer SCR proteins such as FH, CR2, and CR1. Due 
to the domain pairs being out of context o f the full structure, it would not, however, 
show how, if at all, non-neighbouring SCR domains influence each other and 
subsequently the structure of the overall protein. On the whole, the pattern emerging 
from the NMR and X-ray crystallography work shows no preferred structural orientation 
for a pair of SCR domains, but both the length of the linker and the structure of the 
exposed surfaces of the SCR domains it joins are likely to have some bearing on this.
Lower resolution structures exist for SCR proteins with more domains, including 
CR2 SCR 1-15 (Moore et al, 1989), FH SCR 1-20 (DiScipio, 1992; Aslam & Perkins, 
2001), and C4BP SCR 1-8 (Dahlback et al, 1983; Perkins et al, 1986). EM, like X-ray 
crystallography, gives a static picture o f the protein and the conditions in which it is 
carried out are harsh for biological molecules. SAS provides information on overall 
structural characteristics which can then be used to create a series of viable models. 
Since SCR domains are reasonably uniform in size and shape, neither o f these 
techniques is able to provide detailed information on the exact orientation of each 
domain within the protein. It is possible though to use these techniques to examine 
larger molecules and therefore overall structural elements can be seen, such as average
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Protein PDB Entry Method
CR1 SCR 16 
SCR 15-16 
SCR 16-17
1PPQ
1GKN
1GKG
NMR
NMR
NMR
CR2 SCR 1-2 1GHQ 1LY2 X-ray crystallography
DAF SCR 1-4 
SCR 2-3
10JV
10K2
1NWV
10JW
10K3
10JY
10K9
10K1
X-ray crystallography 
NMR
SCR 3-4 1H03
1UOT
1H04 1H2P 1H2Q
X-ray crystallography
MCP SCR 1-2 1CKL X-ray crystallography
VCP SCR 1-4 
SCR 2-3
1G40
1E5G
1G44 1RID 1Y8E X-ray crystallography 
NMR
SCR 3-4 IV VC 1VVD 1VVE NMR
C4BP-a SCR 1-2 2A55 NMR
Factor H SCR 15 
SCR 16 
SCR 15-16 
SCR 19-20
1HFI
1HCC
1HFH
2BZM
NMR
NMR
NMR
NMR
C lr SCR 2 
SCR 1-2
1MD7
1GPZ
1MD8 X-ray crystallography 
X-ray crystallography
C ls SCR 2 1ELV X-ray crystallography
MASP-2 SCR 2 
SCR 1-2
1Q3X
1ZJK
X-ray crystallography 
X-ray crystallography
p2 GP I SCR 1-4 1C1Z 1QUB X-ray crystallography
GABA-B Receptor 1 SCR 2 1SS2 1SR2 NMR
Interleukin-2 Receptor SCR 1-2 1Z92 2B51 X-ray crystallography
Interleukin-15 Receptor SCR 1 2ERS NMR
Table 2.2
Solved SCR domain atomic resolution structures and their PDB deposition codes.
31
length and shape, particular domain interactions and evidence of more complex tertiary 
structure.
Domain structures may be modelled using the structure o f a similar domain with 
a known structure as a template. A database of modelled SCR domain structures has 
been created recently (Soares et al, 2005). In this, SCR domains were clustered into nine 
different groups, A to 1, based on sequence similarities. The domains were then 
modelled according to known structural templates specific to each cluster using an 
automated comparative procedure. Out o f the initial nine clusters, three had no template 
for modelling.
(2.3) Complement receptor type 2
To date, the structure of CR2 has been investigated using several different 
techniques. Hydrodynamic and EM studies with a soluble recombinant 16 domain CR2 
construct showed that it is a highly extended, flexible, rod-shaped molecule (Moore et 
al, 1989). Circular dichroism indicated an absence o f a-helices in the secondary 
structure. The EM pictures clearly show the beads-on-a-string arrangement and give an 
average overall length of 38.6 ± 3.5 nm for the molecule (Figure 2.3(a)).
It has been determined that the N-terminal two SCR domains, SCR 1-2, are 
responsible for binding the C3 cleavage fragments C3d, C3dg, and iC3b and the EBV 
coat glycoprotein gp350 (Lowell et al, 1989; Carel et al, 1990). The structure of these 
two SCR domains, their interaction with ligands and with the other domains of CR2 are 
therefore of great interest.
Through experiments with a series of truncated CR2 constructs it was shown that 
whilst SCR 1-2 are required for ligand binding, SCR 3-4 increase the binding affinity, 
and the remaining SCR domains mediate the internalisation of the bound ligand (Carel 
et al, 1990). More recently, studies have been done using surface plasmon resonance 
(SPR) and analytical ultracentrifugation (AUC) (Guthridge et al, 2001a). The results of 
the SPR demonstrated that the binding affinities for the binding of both CR2 SCR 1-2
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Figure 2.3
Structures of CR2 and C3d. (a) Electron Microscopy images of the 16 extracellular 
domains of CR2 (taken from Moore et al. 1989). (b) The crystal structure of C3d 
(taken from Nagar et al, 1998). (c) The crystal structure of CR2 SCR 1-2 in complex 
with C3d (taken from Szakonyi et al, 2001). (d) The crystal structure of unliganded 
CR2 SCR 1-2 (taken from Prota et al, 2002).
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and CR2 SCR 1-15 to immobilized C3dg are comparable, although the association and 
dissociation rates differ with those for SCR 1-15 being slower than those of SCR 1-2. 
This suggests thatScfci-2 is the principal binding site and that the other SCR domains 
somehow affect the ligand binding ability. The use o f SPR also resulted in the discovery 
that the binding of CR2 SCR 1-2 to C3dg is dependent on charged interactions and 
therefore influenced by pH and salt concentration. AUC sedimentation velocity 
experiments and subsequent homology modelling o f the SCR 1-2 domain predicted a 
highly extended solution structure.
The structure of the first two SCR domains (SCR 1 -2) of CR2 has been solved 
by X-ray crystallography, both alone and in complex with C3d, but there remains much 
dispute over its conformation. The first structure to be elucidated was that of C3d 
(Nagar et al, 1998) (Figure 2.3(b)). It was found to be an a-a barrel (CATH number 
1.50.10) of dimensions 3.0 nm x 3.0 nm x 5.0 nm with a concave region at one end of 
the barrel and a convex face at the other. Other proteins known to have an a-a  barrel are 
enzymes such as Endogluconase D and Famesyltransferase. The convex surface 
includes the residues that participate in the covalent attachment of antigen and the 
concave side was proposed to be the area for receptor binding as it contains an extended 
acidic pocket. A peptide segment of C3d located partly on the concave surface had 
previously been suggested for the CR2 binding site (Lambris et a l  1985), but following 
point mutagenesis of the site it was discounted (Diefenbach & Isenman, 1995). Due to 
the presence of several highly conserved residues in the area of the acidic pocket and the 
existence of a positively charged region on CR2, the pocket was proposed to be the CR2 
binding site. In other proteins with an a-a barrel structure, it is the concave side that is 
the site for substrate binding. This theory was tested using alanine scanning mutagenesis 
of all the acidic residues in and around the vicinity of the suggested pocket (Clemenza & 
Isenman, 2000), and this approach identified two clusters of residues on C3d that appear 
to be important for CR2 binding.
The binding of C3 fragments to CR2 SCR 1-2 was shown to be inhibited by the 
mAb OKB7 and FE8, and the epitopes of these mAb have been mapped (Molina et a l  
1995; Prodinger et a l  1998). These experiments did not, however, give conclusive 
results, as the mAb map to different sequences within CR2. The structure of CR2 SCR
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1-2 in complex with C3d was published at 0.20 nm resolution (Szakonyi et al, 2001) and 
showed a V-shaped CR2 molecule binding to one edge of the dome shaped structure of 
C3d through SCR 2, with the binding site opposite the N and C termini (Figure 2.3(c)). 
The antigen binding site was shown to be halfway between the CR2 binding site and the 
terminal ends. A large amount of shape complementarity was seen in the CR2-C3d 
interface, with mostly main chain atoms contributing to the hydrogen bonding in the 
interaction between the two molecules, and it was suggested that this was the reason that 
all previous studies using point mutation had failed to identify the CR2 binding site on 
C3d. It was previously thought that both of the SCR domains were involved in binding 
to C3d and kinetic experiments showed that both are required for binding (Lowell et al, 
1989; Carel et al, 1990; Guthridge et al, 2001 a). The crystal structure, however, showed 
that only residues from SCR 2 made contact and it was proposed that the packing 
between the two SCRs must play a part in stabilising the binding site on SCR 2 in some 
way. Those sites recognised by mAb OKB7 and FE8 were shown to be adjacent to the 
C3d binding site, and the site of C3d binding on CR2 SCR 2 was confirmed using a 
mAb (mAb 171) which recognises the site proposed in the crystal structure (Guthridge 
et al, 2001b).
The structure of CR2 SCR 1-2 has also been solved in the absence o f any ligand 
(Prota et al, 2002) (Figure 2.3(d)). In common with the CR2 SCR 1-2 -  C3d co-crystal 
structure, free CR2 SCR 1-2 was found to be in a V-shaped conformation, though there 
is a difference of 0.2 nm in the distance between the N-terminal of SCR 1 and the C- 
terminal of SCR 2 of the two structures. Extensive side-by-side interactions exist 
between the two SCR domains, although these interactions may be non-specific as a 
result of the large amount of flexibility seen when comparing the free and liganded 
structures. Due to the absence and presence of ligand the packing forces and crystal 
forms were found to differ between the free and complexed CR2 SCR 1-2 structures, 
suggesting that the V-shape seen is natural, although it is suggested that it may be 
induced by deglycosylation and therefore only artifactual. Their analysis shows a 
previously undiscussed glycan, found covalently attached to a residue (SCR 2 N107) 
near the linker region at the interface between the two SCR domains, and they propose
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that a more complex glycan at this site would force CR2 SCR 1-2 to adopt a more 
extended structure, possibly resulting in additional contacts between CR2 and C3d.
Mutation studies of the SCR 2 -  C3d interface seen in the co-crystal structure 
once again confirmed the ligand binding to this site (Hannan et al, 2005). Point 
mutations in the positively charged surface patch on CR2 SCR 1 were also carried out in 
order to investigate the possibility of SCR 1 binding with C3d. It was found that four 
residues in particular affect ligand binding -  R13, R28, K41, and K57 -  supporting the 
idea that both SCR domains are actively involved. Long-range electrostatic interactions 
have been proposed to be the mechanism of interaction for the CR2 -  C3d complex 
(Morikis & Lambris, 2004). Using this theoretical model, any changes to the overall 
charge o f the CR2 molecule would have an effect on the complex, meaning that 
mutating the positive residues in SCR 1 would decrease ligand binding regardless of 
whether or not they are in direct contact with the ligand. This also applies to the acidic 
area within the concave surface of C3d and would explain the discrepancies between the 
point mutation data and the interface seen in the co-crystal structure. There is, however, 
some evidence that the interaction of SCR 1 with C3d involves short range interactions 
(Hannan et ah 2005) and therefore further analysis is required.
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Chapter Three
Protein structure determination methods
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(3.1) Introduction
The structure o f proteins is of interest in order to better understand protein 
function and how proteins interact with each other and their surroundings. Several 
experimental techniques with varying resolutions, strengths, and limitations exist for the 
determination of protein structure.
There are at least six low resolution structural techniques, including 
ultracentrifugation, small angle X-ray and neutron scattering, and electron microscopy. 
Circular dichroism (CD) and Fourier transform infrared (FT-IR) spectroscopy are both 
methods of secondary structure determination, relying on the different characteristics of 
a-helices and p-sheets in order to estimate the overall content of each within a protein. 
The diffraction o f macromolecules in solution leads to shape information. The small 
angle scattering of X-ray and neutrons by protein molecules in solution is discussed in 
Section 3.2. Hydrodynamic studies by analytical ultracentrifugation provide overall 
molecular information. The movement of a molecule in solution whilst under a 
centrifugal force is dependent on its size and shape. A more detailed description of 
ultracentrifugation measurements is given in Section 3.3.
Electron microscopy is similar in principle to light microscopy, using an electron 
beam and series of lenses in order to visualise the shape of protein molecules. In 
general, only low resolution structural details can be seen. The high levels of radiation 
destroy biological samples and a low signal to noise ratio means that the information 
from many macromolecules must be combined and averaged. In a typical solution, 
protein molecules are not ordered but may exist in several conformations or views, 
creating difficulties when averaging images. In transmission electron microscopy (TEM) 
samples must be preserved by chemical fixation with glutaraldehyde and osmium 
tetroxide and so a physiological environment is not possible. Negative staining was 
developed in the 1960s. This technique enables the overall shape of macromolecules to 
be seen, although distortions occur due to flattening of the molecules during drying. In 
Cryo electron microscopy (Cryo EM), solutions of sample are rapidly frozen using 
liquid ethane and cooled whilst in the beam with liquid nitrogen. This stabilises the
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sample and decreases the amount of radiation damage sustained. Using cryo EM it is 
therefore possible to visualise macromolecules in a native, hydrated state.
The two main techniques for the determination of protein structure at high 
resolution are X-ray crystallography and Nuclear Magnetic Resonance, both o f which 
give structural information on an atomic coordinate level.
For X-ray crystallography, well-ordered protein crystals that strongly diffract X- 
rays are required. These crystals may be difficult to grow due to the conformational 
properties of proteins and this is often the rate-limiting factor of X-ray crystallography. 
Crystals are exposed to a monochromatic, collimated X-ray beam. X-rays are scattered 
by the electrons within the protein, and the diffracted waves are recorded by a detector. 
The intensities of the spots on the diffraction pattern depend on the phase of the 
scattered waves, i.e., only those waves that positively interfere with each other produce 
a positive beam and subsequently a diffraction spot. In order to calculate the phase of 
the diffracted beams and thence the position of atoms within the crystal lattice, two 
different methods are used. Multiple isomorphous replacement (MIR) involves the 
replacement of a few atoms within the protein molecule with heavy atoms, e.g. Seleno­
methionine, whose strong scattering alters the observed diffraction pattern of the 
protein. Multiwavelength anomalous diffraction (MAD) relies on the anomalous 
scattering of heavy atoms at different X-ray wavelengths to solve the phase problem. An 
electron density map can then be calculated. Well-ordered crystals give high resolution 
diffraction patterns and hence better electron density maps. Protein atoms are then fitted 
into the map by trial-and-error, and the resulting initial model is computationally refined 
to give a final three-dimensional structure.
NMR experiments use the magnetic properties of certain nuclei in order to 
determine structure. Some nuclei, including 'H, 13C, and 15N, possess a magnetic 
moment, or spin. When a strong magnetic field is applied to a protein solution, the net 
spin aligns in the direction of the field. A second magnetic field is then applied to the 
sample using radio frequency pulses perpendicular to the direction of the first field, 
flipping the spin of the nuclei into the plane of the second field. The individual spins of 
the nuclei precess around this plane at a characteristic frequency, which is dependent on 
the chemical environment of the each nucleus. The magnetisation of the perturbed
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nuclei can be detected as an oscillating current. The detected signal, known as the Free 
Induction Decay (FID), is a function of time, which is converted through a Fourier 
transform into a domain o f the frequencies at which the nuclei are precessing. The 
frequencies are measured against a standard reference signal and are known as chemical 
shifts. Two-dimensional NMR experiments are used for structure determination, with 
different types of experiments yielding different information about the environments of 
nuclei. Correlation Spectroscopy (COSY) experiments identifies hydrogen atoms which 
are connected covalently through one or two other atoms, hence providing signal 
assignments. A nuclear Overhauser effect (NOE) spectrum shows the relationship 
between hydrogens which are spatially close but which may be distant in the primary 
structure. Using the information these signals provide on the distance constraints 
between assigned hydrogen atoms, a set o f models can be created for the three- 
dimensional structure of the protein.
(3.2) Small angle solution scattering
Small angle scattering is a diffraction technique which can be used to investigate 
the low-resolution overall structure of macromolecules in solution (Glatter & Kratky, 
1982; Perkins, 1988).
(3.2.1) X-ray scattering theory
In an X-ray scattering experiment the sample is irradiated with a highly 
collimated beam of monochromatic X-rays. The intensity of scattering I  is measured 
against Q, where Q is a function of the scattering angle 20, and from this the scattering 
curve 7 (0  is obtained (Figure 3.1). Scattering of X-rays by protein molecules is due to 
the interaction of the X-rays with electrons in the sample. When the sample is irradiated 
each electron oscillates, emitting electromagnetic radiation of the same wavelength X in 
all directions, but phase-shifted by n with respect to the incident X-ray beam. This is 
known as coherent scattering.
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Figure 3.1
General features of a solution scattering curve I(Q) measured over a Q range. The 
scattering curve is analysed in two regions, that at low Q giving the Guinier plot from 
which the overall radius of gyration RG and the forward scattering intensity 7(0) values 
are calculated, and that at larger Q from which more structural information is obtained. 
At low Q, the scattering curve is truncated for reason of the beamstop (Adapted from 
Perkins, 1994).
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The intensity of scattering by an electron is proportional to the X-ray scattering length /  
o f the electron, which has a value of 2.81 fm (2.81 x 10'15 m, the classical Thompson 
electron radius). The X-ray scattering length for small angle scattering studies of an 
atom is the atomic number (the number of electrons an atom contains) multiplied by the 
electron scattering length. Accordingly, the hydrogen isotopes, lU and 2H, both have the 
scattering length of an electron of 2.81 fm, while the atoms 12C, 14N, 160 , and 32S, which 
are all relevant to proteins, have /  values of 16.9 fm, 19.7 fm, 22.5 fm, and 45.0 fm 
respectively.
(3.2.1.1) The Debye equation
The Debye equation is used to describe the form of the scattering curve I(Q). 
Interference between scattered waves give rise to diffraction phenomena and 
consequently the spatial arrangement of electrons in the protein determine the scattering 
curve. The X-ray scattering from two points within a protein is shown in Figure 3.2. The 
incident X-ray beam is defined by the unit vector so and is scattered from an origin point 
O in a direction denoted by the unit vector s. Since scattering is elastic, so and s have the 
same amplitude, and for convenience this is set as 2n/X. Q is the scattering vector (s -  
so), and its amplitude is 47tsin0/X (Figure 3.2). When the scattering angle is zero, waves 
scattered from all points in the protein will be in phase and the intensity of scattering is 
the sum of all scatterers. When the scattering angle is non-zero, interference is produced 
by phase differences between scattered waves, and this can be considered using the path 
difference between scattering points. In Figure 3.2, the incident X-ray beam is scattered 
by a second point P , and the path difference between waves scattered by points O and P 
is AO + OB. This path difference corresponds to a phase difference of 2n(AO + OB)IX. 
If the vector between O and P is r, then AO — -rso and OB = rsi and the phase difference 
is r{si -  so), or more simply rQ. The phase difference rQ between each individual 
scatterer in a macromolecule determines its scattering curve I(Q), and this relationship is 
contained within the Debye equation:
(Eq. 3.1)
P  0
Scot tered
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,2 S
Figure 3.2
Schematic representation of X-ray scattering from two points in a protein molecule. 
Diffraction is by two points O and P separated by a distance r within a single particle in 
a solution scattering experiment. A and B correspond to the perpendiculars to the 
incident and scattered beams. The unit vectors so and 5 define the incident and scattered 
radiation, and Q defines the scattering vector (s - sq) (Adapted from Perkins, 1988).
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where F2{Q) is the square of the structure factor F(Q) of the macromolecule, F(Q) is a 
regularisation of the scattering curve I(Q) to the intensity of scattering by one electron at 
zero scattering angle Ie [I(Q) = IeF^iQ)], and the summations are performed over all 
points p  and 0, where fp and f0 are the respective X-ray atomic scattering lengths. The 
Debye equation gives the average of F^iQ) for all possible orientations of the molecule, 
and this would therefore require that scattering is spherically symmetrical about the 
incident beam. It can be seen that the Debye equation is only dependent on the 
magnitude of Q. For this to be true in a scattering experiment, the scattering sample 
would have to consist of a monodisperse solution of identical molecules that occupy all 
orientations equally, and act as independent scattering entities. A limitation o f the Debye 
equation is that it describes particles in vacuo and it therefore needs to be modified in 
order to consider aqueous protein solutions.
(3.2.1.2) The two-phase model of solution scattering
The simplest way to consider an aqueous protein solution is as a two-phase 
system consisting of solute and solvent. The Debye equation is modified to consider the 
contrast Ap between the scattering density of the macromolecule in vacuo pv and the 
scattering density of the solvent ps, where Ap = pv -  ps. The Debye equation can also be 
revised according to the resolution limits of the solution scattering experiment. In an X- 
ray solution scattering experiment, data are typically collected to a maximum usable Q 
value of approximately 2.0 n m 1. The maximum Q value can be used to calculate the 
structural resolution of scattering, i.e., the smallest distance d  measured in the 
experiment. Bragg’s Law (k = 2</sin0) is used for this calculation. A Q value of 2.0 nm '1 
corresponds to a resolution of around 3 nm. At this resolution, a few large volume 
elements dvp o f scattering density p(rp) can be used to replace individual X-ray atomic 
scattering lengths fp in the Debye equation (fp = p(rp)dvp = p(rp)(?rp). Thus the intensity 
of scattering is:
(Eq. 3.2) F 2(Q) = \v\ v ( p ( r p)~ p s) ( p ( r 0)~ p s ) ^  ®  d 3r Pd 3rc
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where the integration is taken over the macromolecular volume V.
(3.2.2) X-ray scattering methods
(3.2.2.1) Sample preparation
X-ray solution scattering experiments were designed according to the two-phase 
model o f solution scattering expressed in Equation 3.2. The sample needs to be a pure, 
monodisperse solution of protein at a high enough concentration for the scattering curve 
to be measured. Due to the tendency of protein samples to aggregate, each sample was 
gel filtrated and reconcentrated as shortly before data collection as possible in order to 
remove non-specific aggregates. The choice of buffer is also important since in an X-ray 
scattering experiment, the closer the buffer electron density is to pure water, the higher 
the sample transmission and therefore the better the counting statistics. Phosphate 
buffered saline (10 mM sodium phosphate, 3 mM potassium phosphate, 136 mM NaCl, 
3 mM KC1 at pH 7.2) or HEPES (10 mM HEPES (pH 7.4), 50 mM NaCl) were used for 
X-ray scattering experiments. In order to ensure that the appropriate corrections were 
made for solvent scattering, the protein sample was dialysed against its buffer, and the 
scattering of the buffer was subtracted from the scattering of the protein solution. 
Ideally, a sample volume of 0.5 ml at a concentration between 2 and 10 mg m l1 was 
used for X-ray experiments. The concentration of a protein solution can be determined 
from its tryptophan content by measuring its absorbance at 280 nm, and using an 
absorption coefficient (1%, 1cm) calculated from its amino acid and carbohydrate 
composition by the corrected Wetlaufer procedure (Perkins, 1986).
(3.2.2.2) Data collection on Instrument ID02 at the ESRF
X-ray scattering experiments were performed at the European Synchrotron 
Radiation Facility (ESRF) at Grenoble, France (Figure 3.3(a)). Synchrotron radiation is 
emitted from electrons that are accelerated while moving at speeds close to the speed of 
light. Several stages are used in the production of synchrotron radiation at the ESRF. 
Electrons are produced by a triode gun and then accelerated to 200 MeV in a linear 
accelerator (LINAC). The electrons are then transferred through transfer line 1 to a full
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Figure 3.3
X-ray solution scattering at the ESRF. (a) Schematic representation of the synchrotron. 
The linear accelerator (LINAC), booster synchrotron and the storage ring are shown.
The small-angle scattering instrument is located on beamline ID02 (adapted from the 
ESRF Web Site http://www.esrf.fr). (b) Schematic representation of the layout of the X- 
ray solution scattering cameras at beamline ID02 (adapted from the ESRF Web Site 
http://www.esrf.fr). The configuration denoted by 'pinhole SAXS' is used in this thesis.
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energy fast cycling booster synchrotron where they are accelerated using a radio­
frequency system to 6.0 GeV. The electrons are then injected through transfer line two 
into the storage ring. In the 844.4 m diameter storage ring, 64 bending magnets are 
employed to force the electrons to follow a pseudo-circular orbit, and the beam is 
focused by 320 quadrupoles. Two different types of insertion devices (undulators and 
wigglers) are used to force the beam onto a sinusoidal trajectory, stimulating additional 
radiation. The intensity and lifetime (the time the electrons can be kept in orbit for 
before the storage ring has to be refilled) of the beam depends on the filling mode. 
Uniform filling mode consists o f 992 bunches equally distributed around the 
circumference o f the storage ring, and this has a beam intensity o f 200 mA and a 
lifetime of 60 hours. Single bunch mode is one very intense single bunch, with a beam 
intensity of 16 mA and a lifetime of 6 hours. Over the lifetime of the beam the intensity 
decreases, at which point the storage ring is refilled. The different filling modes 
correspond to two modes of operation of the LINAC. In uniform filling or multibunch 
mode, the booster synchrotron circumference is filled by a 1 ps electron bunch from the 
LINAC. In single bunch mode, the LINAC delivers a 2 ns electron beam pulse to the 
booster, only filling one radio-frequency bucket. Radio-frequency cavities are required 
in the storage ring to maintain the energy of the electrons as close as possible to 6.0 
GeV, since as the electrons pass through the bending magnets and insertion devices they 
radiate photons. The photons are extracted tangentially to the source and directed down 
the beamlines to the experimental stations (Figure 3.3(b)). Small angle X-ray scattering 
experiments were performed on station ID02 (Narayanan et ah 2001). A cryogenically 
cooled Si-111 double crystal monochromates the beam and displaces it vertically by 30 
mm to reduce the background radiation from the storage ring. The beam is then focused 
by an uncooled Rh-coated double-focusing toroidal mirror. There are two collimation 
slits, one before the monochromator and one after the mirror, and two guard slits, both 
between the mirror and the sample. The slits are set at twice the full-width-half- 
maximum of the focused monochromatic beam, which defines the minimum size of the 
beamstop and also the minimum observable scattering angle.
Samples were placed in a specially designed Perspex cell with 10 to 20 pm thick 
ruby mica windows. The mica windows were held in place with Teflon plugs. The
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sample cell had a 1 mm path length, a surface area of 2 mm (vertical) by 8 mm 
(horizontal) and held a maximum volume of 25 pi. The sample cell was held in the X- 
ray beam by a brass sample holder which was maintained at 15°C using a water bath. 
Prior to data collection, the sample holder was manually aligned in the beam. The 
detection system for SAXS experiments on ID02 consists o f an X-ray image intensifier 
lens (XRII) linked to a Fast-readout Low-noise (FReLoN) CCD camera. The detector is 
mounted on a movable platform, housed in a vacuum within a 12 m long detector tube, 
and sample-to-detector distance can be varied between 1 and 10 m. The distance 
between the detector and the sample was set to 3 m so that intensities were measured to 
a maximum Q value of 2.5 nm '1. A Lupolen sample is used for the calibration of 
detector intensities (Kratky et al, 1966), and a silver salt standard (silver behenate) for 
the calibration of the Q range (Huang et al, 1993). The X-ray wavelength on ID02 is 0.1 
nm.
X-rays produce ffee-radicals that can cause proteins to aggregate quickly. In 
order to monitor this aggregation or damage, the scattering intensity of each sample was 
measured for a set time in 10 equal time frames, and the frames were inspected to check 
for the onset of radiation damage. The protein samples were measured in alternation 
with their respective buffers in order to minimise errors in the buffer subtraction 
calculations as the incident beam decreased in intensity.
(3.2.2.3) ESRF data reduction
ESRF scattering data were reduced to obtain scattering curves I{Q). The raw data 
files were first corrected for detector artefacts. The dark current and readout noise were 
subtracted from the files, which were then corrected for any spatial distortion. Each data 
file was then divided by a flat field image (an image containing the relative sensitivities 
of each pixel). Data were normalised to absolute scattering intensities using Lupolen, a 
calibrated standard scatterer with an absolute scattering intensity in the maximum which 
is independent of photon energy (Kratky et al, 1966).
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(3.2.3) Neutron scattering theory
The principles of coherent neutron scattering are the same as for coherent X-ray 
scattering and consequently neutron coherent scattering is also described by the Debye 
equation (Equation 3.1). There are, however, some significant differences between 
neutron and X-ray scattering. Unlike X-rays which are scattered by electrons, neutrons 
are scattered by the nuclei of atoms. The neutron atomic scattering length b, which is 
equivalent to and replaces the X-ray scattering length / i n  the Debye equation, does not 
show a simple relationship with the atomic number. 2H, 12C, 14N, 160 , and 32S have 
comparable b values (6.671, 6.651, 9.400, 5.804, and 2.847 fm respectively). The lH 
isotope, however, has a large, negative b value of -3.742 fm, implying that there is no 
phase-shift o f the scattered waves relative to the incident wave. The large difference in 
the neutron scattering properties of the two hydrogen isotopes is very important in 
neutron scattering experiments, as this leads to contrast variation methods. In small 
angle X-ray scattering, the effect o f a second type of scattering, incoherent scattering, is 
negligible. In neutron scattering, incoherent scattering exists for nuclei with spin. In 
proteins, this is therefore significant only for lH nuclei, where incoherent scattering is 
very large, and this leads to a background level of uniformly scattered neutrons.
(3.2.3.1) The hydration shell
The neutron scattering properties of atoms necessitates that neutron 
experiments are performed in 100% H2O buffers in order to minimise incoherent 
scattering and obtain scattering curves comparable to those measured in X-ray 
experiments. Even under these conditions, however, small differences are often 
observed between measurements from X-ray and neutron experiments and these are 
attributed to the hydration shell which surrounds protein molecules in solution. The 
hydration shell refers to those solvent water molecules closely associated with the 
protein by way of hydrogen bonding. Only in X-ray scattering experiments is the 
hydration shell visible; it is almost undetectable by neutron scattering. The model of 
scattering by an aqueous protein solution described in Equation 3.2 assumes that the 
solute and solvent are discrete entities, although in reality water molecules are hydrogen 
bonded to the protein surface. A water molecule which is bonded to the surface of a
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protein is electrostricted and therefore has a smaller volume (0.0245 nm3) than a water
molecule in the bulk solvent (0.0299 nm3) (Perkins, 1986). As a result, the X-ray
scattering density o f water molecules hydrogen-bonded to the surface of a protein is
increased relative to that of a water molecule in the bulk solvent, becoming more similar
to the X-ray scattering density o f the protein. X-rays typically detect a hydration shell of
0.3 g H2O for each gram of protein (Perkins, 1986). In neutron experiments the
1hydration shell is not visible due to the rapid exchange of H and H atoms between the 
hydration shell and the bulk solvent, giving rise to little difference in scattering densities 
between the two. This is shown by calculations based on the relative scattering densities 
of the hydration shell in these different scenarios (Perkins, 2001).
(3.2.3.2) Contrast variation
The two-phase model of solution scattering described by Equation 3.2 assumes 
that the macromolecule has a uniform scattering density, although in reality biological 
macromolecules exhibit regions of different scattering density. The four major classes of 
biological macromolecules (protein, carbohydrate, lipid, and nucleic acid) all show 
different distinctive X-ray and neutron scattering densities. When working with complex 
macromolecules (containing more than one class, e.g. glycoproteins) it is possible to 
study the component macromolecules individually by altering the contrast of the 
solution scattering experiment. This can be done by several methods, including the 
addition of sucrose to X-ray scattering buffers, chemical labelling of the solute, and in 
vivo deuteration of non-labile solute hydrogen atoms (Worcester, 1988). This is most 
easily achieved by altering the scattering density of neutron buffers by using different 
ratios of 2H20 to ^ O .  Due to the low amounts of non-protein macromolecules studied 
in this thesis, the work presented here did not involve contrast variation experiments. 
Instead, proteins were studied in the highest solute-solvent neutron contrasts, i.e. 100% 
2H20 , in order to maximise the strength of the scattered radiation.
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(3.2.4) Neutron scattering methods
(3.2.4.1) Sample preparation
Samples for neutron scattering experiments were prepared in the same way as for 
X-ray scattering experiments, except that PBS buffer in 100% 2H20 was used. 
Following gel filtration and reconcentration, each sample was dialysed with stirring
against the 2H20 PBS buffer for a minimum of 36 hours, in which time the buffer was
1 0changed four times to ensure full H- H exchange.
(3.2.4.2) Data collection on Instrument LOQ at ISIS
Neutron scattering experiments were performed on the LOQ instrument at the 
pulsed neutron source at ISIS at the Rutherford Appleton Laboratory (RAL) in Didcot, 
U.K. (Heenan & King, 1993). At ISIS, neutrons are produced by a spallation process 
(Figure 3.4(a)). An ion source produces H' ions, which are initially accelerated to 665 
keV. In the second stage, the H' ions pass though a LINAC where they reach an energy 
of 70 MeV. Protons are then produced by stripping the electrons from the FT ions using 
a very thin aluminium foil. Pulses of protons are then accelerated to 800 MeV in a 52 m 
diameter synchrotron, extracted and sent to the heavy metal target station at a rate of 50 
Hz. The bombardment of the uranium or tantalum heavy metal target with high energy 
protons causes neutrons to be chipped out of the nuclei. Moderators are used to slow the 
neutrons and increase the wavelengths. On LOQ the moderator is liquid hydrogen (25 
K). The layout of LOQ is shown in Figure 3.4(b). A supermirror bender removes 
neutrons with wavelengths of less than 0.2 nm, while a frame overlap mirror removes 
those with wavelengths of greater than 1.2 nm. Every other neutron pulse is cut out by a 
chopper, producing an operational frequency of 25 Hz. This eliminates pulse overlaps 
during the time-of-flight measurements. The phase of the chopper is set so that only 
wavelengths in the range of 0.22 to 1.00 nm are used in scattering experiments. The 
neutron beam is collimated by two apertures and the beam used in solution scattering 
experiments has a diameter of 8 mm. Monochromatisation of the neutron beam is 
achieved by time-of-flight techniques, based on a distance of 15.15 m from the heavy 
metal target to the detector. The time-of-flight techniques are advantageous as they
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enable neutron scattering data to be measured over a Q range of 0.08 to 2.5 nm '1 in one 
experiment, and utilise fully the abundance of shorter wavelength neutrons, which 
contribute most to the scattered curve at large Q where the intensities are lowest.
Samples were placed in 2 mm thick rectangular quartz Hellma cells which were 
held in a motorised rack at a constant temperature of 15°C. Neutron scattering intensities 
were measured using a 3He ORDELA detector which had an active area of 64 * 64 cm 
and was positioned at a fixed distance of 4.3 m from the sample. The sample rack held 
multiple samples, allowing the data collection procedure to be automated. Scattering 
intensities were measured for proteins and their corresponding buffers. The scattering 
from a partially deuterated polystyrene standard was also measured, and this was used to 
normalise the spectral intensities (Wignall & Bates, 1987). Neutron transmissions were 
measured for each protein sample and buffer, and for the polymer standard and an 
empty beam position, and these were also used to normalise the scattering data.
(3.2.4.3) ISIS data reduction
Raw data were collected in 100 time frames o f 64 x 64 cells and reduced using 
the standard ISIS software package COLETTE (Heenan et al, 1989). The MASK file is 
routinely updated by the LOQ instrument scientists and controls essential information 
on the properties of the detector. After ensuring that the beam size, the sample thickness, 
the moderator-to-sample distance, and the sample-to-detector distance had been 
assigned correctly, the raw scattering data were processed. The data were corrected for 
detector efficiency, transmission of the direct beam, and transmission of the sample. 
Absolute scattering intensities were calculated by normalisation of the spectra against a 
“LOQ standard sample” of partially deuterated polystyrene (Wignall & Bates, 1987), 
and protein spectra were corrected by buffer subtraction. The time-of-flight techniques 
were used to bin the scattering intensities into individual diffraction patterns, either for 
linear wavelength steps of 0.02 nm, or for logarithmic wavelength steps of 0.08%, over 
the wavelength range of 0.22 to 1.00 nm. These individual diffraction patterns were 
merged, using 0.04% logarithmic binning increments for Q, to give the full scattering 
curve 7 ( 0  in an approximate Q range of 0.08 to 2.5 nm*1. Logarithmic steps were 
optimal for analyses of the Guinier and wide angle regions o f the scattering curves.
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(3.2.5) Analyses of reduced scattering curves I(Q)
Measurements of the overall structural details of a protein can be determined 
from its X-ray and neutron scattering curves.
(3.2.5.1) Guinier analyses
At low Q values, the Debye equation (Equation 3.1) is reduced to a Gaussian 
curve, and this becomes the Guinier approximation
(Eq. 3.3) In I(Q) = In 1(0) -
where 7(0) is the intensity at zero scattering angle, and Rq is the radius of gyration which 
is defined as the root-mean-square distance of all scattering centres in the 
macromolecule from its centre of gravity. This equation is valid in a Q.Rg range o f up to 
0.7-1.3 depending on the macromolecular shape. Rq and 7(0) are determined from an 
experimental scattering curve by plotting In 7 ( 0  against Q1 to give a straight line of 
slope -R q /3 and intercept In 7(0). Rq is a measure of elongation if the internal 
inhomogeneity is negligible, and a useful application of Rq is the calculation of the 
anisotropy ratio of a macromolecule. The anisotropy ratio is Rq/Ro, where Ro is the Rq of
a sphere of equal volume to the macromolecule (the Rq o f a sphere = -s/(3 / 5)r2 , where
r is the radius of the sphere). For typical globular proteins by X-ray scattering, the 
anisotropy ratio is approximately 1.28 (Perkins, 1988). The intensity at zero scattering 
angle 7(0) is proportional to Mx2. The scattering intensities of neutron data measured on 
LOQ are normalised to a partially deuterated polystyrene standard and consequently 
LOQ 7(0)/c values (c = sample concentration) are used to calculate protein Mx values. 
There is a linear relationship between the Mx determined from composition analyses and 
7(0)/c (Figure 3.5), which was used to calculate the Mx and hence the oligomeric state of 
a newly-measured protein.
Guinier plots were performed using the PERL script program SCTPL7 (J. T. 
Eaton and S. J. Perkins, unpublished software). In practise, the Q range selected for line- 
fitting returned a maximum Q.Rg o f approximately 1.5. Nonspecifically aggregated
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protein samples were identified by a steeply curved Guinier plot at low Q values and 
these data were discarded.
(3.2.5.2) The cross-sectional radius of gyration
If the protein has an elongated structure, Guinier-type analyses of the scattering 
curve at larger Q will give the mean radius o f gyration of the cross-section Rxs and the 
mean cross-sectional intensity at zero scattering angle [I(Q)Q\q+o (Hjelm, 1985):
(Eq. 3.4) In[l(Q)Q]= ln [ ( / ( 0 ® ] ^ „  -
Rxs and [I(Q)Q]q+o are determined from an experimental scattering curve by plotting 
In[I{Q)Q] against Q1 to give a straight line of slope -R Xs2/2 and intercept
ln[(/(00k->o.
For uT-shaped” protein structures such as some immunoglobulins, the cross- 
sectional plot exhibits two linear regions, a steeper innermost one and a flatter outermost 
one (Pilz et al, 1973) and in this type of analysis the two regions are referred to as 7?xs-i 
and Rxs-2 respectively.
Cross-sectional plots were performed using SCTPL7. The Q range selected for 
line-fitting went from a minimum Q value, which was greater than the Q values used in 
the Guinier Rq fits, to a maximum Q.Rxs of 1.5.
(3.2.5.3) Determinations of macromolecular dimensions
Assuming a protein is shaped like an elongated elliptical cylinder, the Rq and 
Rxs analyses can be combined to determine its length L (Glatter & Kratky, 1982):
(Eq. 3.5) £ = V 12(R2G- Rxs)
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Figure 3.5
Plot of the molecular mass Mr against 7(0)/c for proteins measured on LOQ. The 
proteins used for this plot are bovine IgGl and IgG2 (mean Mr is 143400, mean l(0)/c is 
0.181; Mayans et al, 1995), IgE (Mx is 75300, 1(0)/c is 0.093; Beavil et al, 1995), factor 
Vila (MT is 51400, l(0)/c is 0.0525) and factor Vila complexed with tissue factor (MT is 
76150,1(0)/c is 0.0735; Ashton et al, 1995), SAP-5 (Mx is 127070, 7(0)/c is 0.146) and 
SAP-10 (Mx is 254140, 7(0)/c is 0.247; Ashton et al, 1997), and MFE-23 (Mr is 27150, 
7(0)/c is 0.032; Boehm et al, 1996). For each new protein studied on LOQ, the Mr value 
of the scattering sample was determined from the linear regression line. Comparison of 
the resulting value to the value calculated for a monomer from its composition enabled 
the oligomeric state of the sample to be determined.
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Alternatively, L is given by (Perkins et al, 1986):
rx: 1 r(Eq. 3.6) L = f------4—
\KQ)Q\->  „
The consistency of these two calculations of L is a useful control of a correct cross- 
sectional analysis for a rod-like particle. For an assumed elliptical cylinder with length 
7, the two shorter dimensions A and B can be calculated from the unhydrated protein 
volume for neutron analyses, or from the hydrated protein volume for X-ray analyses:
(Eq. 3.7) V = izABL; R«  = A2 + B2)  /  4
(3.2.5.4) The real space distance distribution function
The scattering curve 7(g) represents the macromolecular structure in reciprocal 
space. The experimental 7(g) curve can be converted into real space by a Fourier 
transform over 0 < Q < oo :
(Eq. 3.8) P(r) = j - j ) l ( 0 Q r s m ( Q r ) d Q
where P{r) is the distance distribution function and corresponds to the number of 
distances r between any two volume elements within the macromolecule weighted by 
the product of their respective scattering densities. The maximum P(r) is the most
frequently occurring intermolecular distance. P(r) offers an alternative calculation o f R q:
oo
jP (r)r2dr
(Eq. 3.9) = --------
2 J P(r)dr
o
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P(r) termination errors occur because the experimental I(Q) curve cannot be measured at 
zero angle or at very large Q, and in addition high signal to noise ratios are associated 
with measurements at large Q. The Indirect Transform Procedure (ITP) minimises these 
termination errors by fitting the experimental curve to B-splines, which are then 
transformed. This was performed using the GNOM program (Svergun et ah 1988; 
Semenyuk & Svergun, 1991; Svergun, 1992). Dmax is the maximum macromolecular 
dimension, and therefore correspond to the length L. In GNOM, the P(r) curve was 
calculated from I(Q) for a range of estimated Z)max values, and the P(r) curve was 
selected according to several criteria: (1) P(r) should exhibit positive values; (2) The 
from GNOM should agree with that from the Guinier analyses; (3) P(r) should be zero 
when r is zero; (4) P(r) should be stable and reproducible for different experimental I(Q) 
curves when Dmax is varied over a reasonable range. The length L was determined from 
P(r) when this became zero at large r, however errors in L can be significant as a result 
of the low intensity of P{r) in this region.
(3.3) Analytical ultracentrifugation
Analytical ultracentrifugation (AUC) is a technique which uses the effects of 
centrifugal forces to characterise globular proteins in solution.
An analytical ultracentrifuge consists of an optical system and a rotor (Figure 
3.6). Protein samples are held within cells in the rotor. As the rotor spins, the 
distribution of the protein molecules changes and this is monitored in real time by the 
optics system. Two different types of optical measurements are available, absorbance 
and interference. Light from a high-intensity xenon flash lamp is passed through the 
sample cells held within the rotor. A photomultiplier tube beneath the rotor detects the 
light intensity from the sample sector in relation to that from the reference sector 
containing buffer. When the rotor is spinning, light passes through the reference sector 
first, and then through the sample sector. The photomultiplier detects this light, and the 
difference between these signals can then be translated into an absorbance value. 
Interference data is obtained through a laser beam that is shone through the cells from
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Figure 3.6
A schematic diagram of an analytical ultracentrifuge optic and rotor system (Taken 
from Ralston, 1993).
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above and detected, via a series of mirrors and lenses, by a camera. The emission from 
the sample sector is referenced against that of the buffer sector. If the sample solution 
and the reference solution are the same, there is no refraction. This gives an achromatic 
fringe along the optical axis. When the two solutions are different in composition, the 
achromatic fringe shifts, reflecting the difference in the refractive indices of the 
solutions. Where there has been diffusion and sedimentation of the protein, the fringe 
pattern is displaced. The camera sends the data in digital form to a computer that 
performs a fast Fourier transform, giving an on screen image of the fringe pattern as a 
plot of fringe displacement against radius.
A solute particle in a solvent under a gravitational field is subject to three forces; 
gravitational force, buoyant force, and frictional force. If the solute molecules have a 
mass, m, the gravitational force is equal to mco2r, where co is equal to the angular 
velocity of the rotor in radians s'*and r is the radial distance from the centre of rotation. 
The displacement of the solvent molecules by the movement of the solute creates the 
buoyant force that opposes the gravitational force on the solute. This partly 
counterbalancing buoyant force is equal to -mvpco2r, where v is the partial specific 
volume of the solute, and p is the density o f the solvent. The frictional force is 
dependent on the translational frictional coefficient, f  and the absolute sedimentation 
velocity, u. The net sedimentation of molecules when acted upon by a centrifugal force 
is a combination of these three forces and is described by the Svedberg equation:
(Eq. 3.10) mO - v p ) = _ u _ s s  
N f co r
where N is Avogadro’s number and s is the sedimentation coefficient.
There are two main AUC techniques, Sedimentation Velocity (SV) and 
Sedimentation Equilibrium (SE), and these are discussed below.
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(3.3.1) Sedimentation velocity
In SV experiments, a high centrifugal force is applied to the samples and the 
sedimentation of the protein molecules is analysed. The sedimentation of a protein 
depends on its shape and size and therefore AUC data are complementary to those from 
SAS.
Upon the application of a high angular velocity to a uniform protein sample, 
rapid sedimentation of the protein occurs. This gives rise to the formation of a boundary 
between the sedimenting protein and the solvent. The rate o f movement of the boundary 
is measured allowing the determination of the sedimentation coefficient, s. The 
sedimentation coefficient is directly proportional to the mass of the solute particles, and 
indirectly proportional to the frictional coefficient, f  The units of s are seconds, 
although in ultracentrifugation work they are usually given in Svedbergs, S. One 
Svedberg is equal to 10'13 seconds.
The frictional coefficient is dependent on the size of the particle and is 
proportional to the radius of a spherical particle of the same volume as the particle being 
studied, rs, as shown by Stokes law:
(Eq. 3.11) f  = 6K7]rs
where q is the solvent viscosity. The frictional coefficient increases as the particle 
changes in shape from spherical. The frictional ratio f/fa where fo is the frictional 
coefficient for a sphere of the same volume as the protein, shows the extent of the 
deviation.
Measurement o f the rate of spreading of a boundary gives the diffusion 
coefficient, D, which depends on the effective size of the particles:
RT
(Eq. 3.12) D = —
Nf
where R is the gas constant, and T is the temperature in Kelvin.
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(3.3.2) Sedimentation equilibrium
SE experiments involve much lower centrifugal forces than SV. In SE systems, 
the solute molecules do not completely sediment to the base of the cell. Instead, the 
centrifugal force applied is small enough to allow the diffusion of solute molecules to be 
comparable with and to oppose the sedimentation force. At equilibrium the rate of 
sedimentation equals the rate of diffusion and there is therefore no net movement of 
solute molecules. For simple component systems the following equation applies:
(Eq. 3.13) c(r) = c(a) exp[m(l-vp) to2 ( r - t f ^ R T ]
where c(r) is the concentration at the radial position, r, c(a) is the concentration at the 
meniscus, m is the molecular mass of the solute, v is the partial specific volume of the 
solute, p is the density of the solvent, co is the angular velocity of the rotor in r td ib w la  
is the radial distance from the meniscus, R is the gas constant, and T is the temperature 
in Kelvin. Measurements of the distribution of concentration values in the above 
equation are recorded by the optics system in the analytical ultracentrifuge, and using 
known values of v, p, and co, a value for the molecular weight, m, can be calculated.
(3.4) Biomolecular modelling
(3.4.1) Scattering curve modelling
Experimental scattering data present an important means of validating low 
resolution models of proteins and glycoproteins in solution. Full atomic models are 
converted into calculated X-ray and neutron scattering curves and these modelled curves 
are compared with experimental scattering data. The models that show the best 
agreement to the experimental data are selected. Hydrodynamic analyses can be used to 
further validate solution scattering models. The methodology of X-ray and neutron 
scattering curve modelling has recently been reviewed (Perkins et ah 1998; Svergun & 
Koch, 2003), and an outline of the modelling procedure is shown in Figure 3.7.
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(3.4.1.1) Creating atomic models
If an atomic resolution structure is available for the domains of the protein being 
studied, this is used as the basis for the models created by the automated modelling 
procedures. If there is no atomic resolution structure, the individual domains are 
modelled using the known structures of similar domains as templates. Models are 
created using INSIGHT II molecular graphics software and associated programs 
(Accelrys, San Diego, USA). In order to create an arbitrary series of models that tests 
sufficient space, each section of protein outside the fixed domain structures is 
designated as a linker, and a library of different conformations is generated for each 
linker. In the automated modelling procedure, these linkers and domains are joined 
together at random to generate a series of complete models.
If the protein being studied contains glycosylation sites, an average three- 
dimensional structure is determined for the N- and O-linked oligosaccharide chains 
using carbohydrate structural composition analyses in the literature. These structures are 
modelled by adapting suitable oligosaccharide structures from the PDB and the 
structures are positioned at putative N- and O-linked glycosylation sites on the protein 
and extended away from its surface.
(3.4.1.2) Analysis of protein composition
Prior to solution scattering modelling, essential information was extracted from 
the amino acid and monosaccharide composition of the protein using the FORTRAN 
program SLUV (Perkins, 1986). In this, the volume of an unhydrated protein is 
calculated from standard crystal structure volumes for each of the amino acid and 
monosaccharide residues (Chothia, 1975; Perkins, 1986). For concentration 
measurements, the extinction coefficient (at a wavelength of 280 nm) is calculated from 
the Trp, Tyr, and Cys content of a protein by a correction of the Wetlaufer procedure 
(Perkins, 1986). Electron densities and neutron matchpoints are calculated for the 
individual protein and carbohydrate components of a glycoprotein. Electron densities 
are calculated using the molecular volume, which is derived from a consensus amino 
acid volume data set that is based on the sum of the dry amino acid volumes and the 
electrostricted water shell volume as calculated from the amino acid and carbohydrate
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Figure 3.7
Flow chart showing an overview of the automated modelling procedure.
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composition (Perkins, 1986). Partial specific volumes from this give values close to the 
Cohn & Edsall (1943) densitometric calculation. Matchpoints are calculated using the 
neutron scattering lengths divided by the dry volume of the macromolecule, assuming a 
10% nonexchange of the protein mainchain amide protons with solvent.
(3.4.1.3) Sphere modelling
To calculate a theoretical scattering curve from an atomic model of a protein, the 
protein is first converted into a sphere model consisting of small non-overlapping 
spheres of the same total volume as the original atomic model. To do this, the atomic 
coordinate model is placed within a three dimensional grid of cubes. Every cube that 
contains a user-defined minimum number of atoms has a sphere of equal volume to the 
grid point placed at its centre. The minimum number o f atoms required to assign a 
sphere is tested empirically by trial and error against the length of the cube side, so that 
after the grid transformation the resulting sphere model has a volume close to the 
unhydrated volume calculated for the protein. The unhydrated volume is calculated from 
the actual composition using SLUV (see section 3.4.1.2). The length of the cube side 
that is used to produce an unhydrated sphere model is typically about 0.6 nm, which is 
much less than the normal resolution of a normal scattering curve o f around 3 nm. The 
resolution d  is calculated from 2nIQ (derived from X =2d  sin 0 and Q = 4k sin Q/X) and 
for a scattering curve with a maximum Q of 2.0 nm'1, the maximum structural resolution 
is 3.1 nm. Once a grid size has been determined, it is kept constant for the automated 
curve fit searches.
Neutron scattering experiments do not detect a hydration shell around proteins, 
so unhydrated sphere models can be used for neutron scattering curve calculations 
(Smith et al, 1990; Perkins et al, 1993; Ashton et aU 1997). A hydration shell is, 
however, detected around proteins in X-ray scattering experiments, and therefore the 
calculation of an X-ray scattering curve requires that an unhydrated sphere model is 
modified according to the volume of the hydration shell. The hydrated volume of a 
protein is calculated assuming a hydration of 0.3 g water/g protein and an electrostricted 
volume of 0.0245 nm3 per bound water molecule (Perkins, 1986). Spheres 
corresponding to water molecules are added evenly over the surface of the unhydrated
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sphere model to achieve the desired hydration volume. The hydrated sphere models are 
used for X-ray scattering curve calculations (Ashton et al, 1997).
(3.4.1.4) Debye scattering curve calculation
A sphere model containing spheres of a single scattering density is used to 
calculate an X-ray or neutron scattering curve I(Q), by the following application of 
Debye’s Law adapted to spheres (Glatter & Kratky, 1982; Perkins & Weiss, 1983):
(Eq. 3.14) —  = g ( & ( n '  + 2 n 2Y d A j ^ ^ )1(0) Q ]v
(Eq. 3.15) g(Q) = (3(sin QR - QR cos QR) /  /  Q6 R 6
where g(Q) is the squared form factor for the sphere of radius R, n is the number of 
spheres filling the body, A} is the number of distances r} for the value o f j ,  r) is the 
distances between the spheres, and m is the number of different distances ry The single 
density scattering curve calculation is applicable to proteins, and also to glycoproteins 
with a low carbohydrate content, provided that the comparisons between the model 
scattering curves and the experimental data are consistent for the neutron and X-ray 
curves.
If a glycoprotein has a high carbohydrate content, differences between the 
scattering densities of its protein and carbohydrate moieties that may give rise to 
systematic deviations between the neutron and X-ray curves can be modelled using two- 
density sphere models. For neutrons, the relative scattering densities of the protein and 
carbohydrate spheres in an unhydrated sphere model are weighted by an approximation 
to the ratio of their calculated neutron matchpoints, compared with 100% 2H2 0 . 
Correspondingly for X-rays, the relative scattering densities of the protein and 
carbohydrate spheres in a hydrated sphere model are weighted by an approximation to 
the ratio of their calculated electron densities compared with the electron density of bulk 
water. The different scattering densities of protein and carbohydrate are incorporated in 
two-density scattering curves calculated from (Glatter & Kratky, 1982):
66
(Eq. 3.16) I- ^  = g(Q)[nlp] + r,2P2 + 2 p ] f j a ' 1 + 2 p \  £  A ?  ^  ^
1(0) j=l Qrj j=i Qrj
jel , sin O r ,
+ 2 P iP 2 ^LA\ — K n iP ,+ r\2 p 2)
j=i
where g(Q) is the squared form factor for the sphere of radius R (Equation 3.15); the
• • • 11 22 model is constructed from n\ and «2 spheres o f different densities p\ and pi\ Aj , Aj ,
and Ajl2are the number of distances rj for that increment of j  between the spheres 1 and
1, 2 and 2, and 1 and 2 in that order; the summations X are performed for j  = 1 to m,
where m is the number of different distances ry
Synchrotron X-ray cameras utilise a pin-hole configuration that does not produce 
geometrical distortion of the beam (Figure 3.3), so a calculated X-ray curve does not 
have to be corrected for instrumental effects in order for it to be compared with an 
experimental curve. This is possible because X-ray fluxes are very high. Although 
neutron cameras such as those at ISIS also use pin-hole geometries, their dimensions are 
larger than X-ray cameras and they also use longer wavelengths to maximise the 
available neutron flux (Figure 3.4). For these reasons, it is necessary that instrumental 
corrections are applied to the neutron scattering curves of the models. On LOQ, 
wavelengths in the range from 0.2 to 1.0 nm are used simultaneously (with time-of- 
flight techniques providing the necessary monochromatisation). For LOQ, a Gaussian 
function based on a 10% wavelength spread AAA (full-width-half-maximum) at a X of 
0.6 nm and a beam divergence o f A0 = 0.016 radians was applied to the modelled 
neutron curves (Ashton et al, 1997).
(3.4.2) Evaluation of models
Each model is evaluated using several criteria. The volume of each sphere 
model, indicated by the number o f spheres generated from the coordinates during the 
grid transformation, is used to determine whether an automated modelling procedure has
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produced steric overlap of domains. Significant overlap means that the number of 
spheres is much reduced compared to that predicted from its composition. Each model is 
also evaluated by comparison of its calculated scattering curves to the experimental 
data. Guinier fits are used to calculate Rq and Rxs values from each modelled scattering 
curve over the same Q ranges used for experimental measurements. An R factor is 
calculated for a quantitative comparison of each model scattering curve / ( 0 ca 1 against 
experimental scattering data / ( 0 exp over the whole Q range, where /(0)cai is set as 1000:
(Eq. 3.17) R   ^ 100%
s i m .  i
The use of R factor values is analogous to that used for the refinement of 
crystallographic models, and it has been successfully applied to evaluation purposes for 
solution scattering modelling procedures (Smith et al, 1990; Beavil et al, 1995). From 
past experience of good fits, R should be less than 10%. Using these three criteria, it is 
possible to minimise the number of models that have to be considered from a large 
automated search. Models that do not conform to defined ranges of model volume, Rq 
and RXs are rejected using filters, and the remaining models are sorted in order of 
overall best fit using the R factor to identify the final models.
(3.4.3) Calculation of hydrodynamic properties
The theoretical sedimentation coefficient s°2o,w of each hydrated sphere model 
can also be determined and its comparison with the experimental value offers a further 
criterion for validating solution scattering models. In order to determine the theoretical 
s°20,w for a hydrated sphere model, the frictional coefficient of the model is calculated 
using the modified Oseen tensor procedure of Bloomfield (Garcia de la Torre & 
Bloomfield, 1977a, 1977b; Perkins, 1985). In this procedure, each sphere in a multi­
sphere model is assumed to be a point source of friction. The Ith sphere has an associated 
frictional force which is calculated from its Stokes law frictional coefficient:
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(Eq. 3.18) F,=  6 ^ .  (w, -  v,)(/ = 1, n)
• thwhere r\ is the viscosity of the solvent, rx is the hydrodynamic radius of the i sphere, u\ 
is the velocity of the i^ sphere, v* is the velocity the solvent would have at the same 
point if the sphere was absent, and n is the number of spheres. The frictional coefficient 
of each sphere in a multi-sphere model is modulated by the hydrodynamic interactions 
of other spheres in the model, by what is referred to as a hydrodynamic interaction 
tensor. The hydrodynamic interaction tensor, Tlj for spheres of finite sizes and of 
different hydrodynamic radii o f rx and r} is given by:
(Eq. 3.19) T,j = — :— [I  + l k J k + (r ‘ + r i )  ( L . h J k ) ]
" 8m, R , /  ^  Rl '3  Rl
where I  is the unit vector and 7^ is the vector between spheres / and j .  The 
hydrodynamic interaction tensor and the frictional force terms are related by:
(Eq. 3.20) v , = v : - j r ( F ,
J-l
(excluding terms with i = j )  where v,0 is the unperturbed solvent velocity when the 
spheres are absent. The program GENDIA (Garcia de la Torre & Bloomfield, 1977a, 
1977b; Perkins et aU 1993) is used to implement these equations, in which iterative 
procedures are used to calculate /  for an array of non-overlapping spheres. The 
theoretical sedimentation coefficient can then be calculated from /  using the Svedberg 
equation (Equation 3.10) and compared with the experimental value. Updated software 
from the Garcia de la Torre group includes the HYDRO program which can analyse 
sphere models based on overlapping spheres (Garcia de la Torre et al, 1994). Both 
GENDIA and HYDRO are unable to calculate values where the size of the protein gives 
rise to more than 2000 spheres in the sphere model. In these cases, the HYDROPRO 
program (Garcia de la Torre et al, 2000) can be used to calculate a shell model, and 
hence f  directly from PDB coordinates.
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Chapter Four
Solution structure of the complex between CR2 SCR 1-2 and C3d of human 
complement: an X-ray scattering and sedimentation modelling study
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(4.1) Introduction
The crystal structure of the first two SCR domains (SCR 1 -2) of CR2 has been 
solved, both alone (Prota et al, 2002) and when complexed with C3d (Szakonyi et al, 
2001). Several crystal structures for human and rat C3d are available in monomeric and 
dimeric forms (Szakonyi et al, 2001; Nagar et al, 1998; Zanotti et al, 2000). While the 
C3d structure appears relatively straightforward, the conformation of the SCR domains 
in CR2 SCR 1-2 is controversial. The structure of CR2 SCR 1-2 in its complex with C3d 
(Figure 4.1(a)) showed a closed V-shaped CR2 molecule with side-by-side interactions 
between SCR 1 and SCR 2 and binding to one edge of C3d only through SCR 2 
(Szakonyi et al, 2001). A very similar structure for CR2 SCR 1-2 was found in the 
absence of the C3d ligand (Prota et al, 2002). Due to the absence and presence of C3d, 
the packing interactions in the two CR2 crystal structures are different, suggesting that 
this V-shape occurs naturally. The second crystal structure discussed the presence of the 
single-residue glycan attached to Asnl07 in SCR 2 near the linker region at the interface 
between the two SCR domains. It was suggested that if the crystallised CR2 SCR 1-2 
molecule had not been deglycosylated, a more complex glycan at Asnl07 would force 
CR2 SCR 1-2 to adopt a more extended structure, possibly resulting in additional 
contacts between CR2 and C3d. While the crystal structure showed that only residues 
from SCR 2 made contact with C3d, it was previously thought from domain swap 
mutant studies of human and murine CR2 that both SCR 1 and SCR 2 were required for 
binding to C3d (Carel et al, 1990; Aubry et al, 1994; Martin et al, 1991; Lowell et al, 
1989). Analytical ultracentrifugation (AUC) studies on purified CR2 SCR 1 -2 suggested 
that CR2 SCR 1-2 was not a compact V-shape in solution (Figure 4.1(a)), but instead 
was more elongated in shape (Figure 4.1(b)) (Guthridge et al, 2001a).
The discrepancies between the two crystal structures and solution studies 
prompted a more detailed investigation of the structure of the complex formed between 
CR2 SCR 1-2 and C3d. X-ray scattering is a powerful solution technique that enables 
the domain arrangements of multidomain proteins to be elucidated, and is most effective 
when atomic models of the domains are available for constrained modelling of the 
scattering data (Perkins et al, 1998). Earlier solution structural and electron microscopy
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N101
C3d
(a) Compact V-shape (b) Extended (c) Folded back
Figure 4.1
Schematic diagrams of the CR2 SCR l-2/C3d complex to show three alternative models 
for the complex comprising either (a) a compact V-shaped SCR structure; (b) an 
extended SCR structure; or (c) a folded-back SCR structure. The domains are drawn 
approximately to scale. The two SCR domains are joined by an eight residue linker (8) 
with their N-terminus and C-terminus denoted by N and C respectively. Two potential 
N-linked glycosylation sites at AsnlOl and Asnl07 are shown by Y symbols.
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studies on the full length CR2 protein showed that this is a highly extended, flexible, 
rod-shaped molecule (Moore et al, 1989). Sedimentation velocity experiments and 
homology modelling of CR2 SCR 1-2 suggested that this possessed a highly extended 
solution structure (Perkins et al, 2002). In this chapter, small angle X-ray scattering is 
combined with further ultracentrifugation experiments and computer modelling based 
on the crystal structures of CR2 SCR 1-2 and C3d in order to define more closely the 
solution structure of CR2 SCR 1-2, C3d and their complex. We show that CR2 SCR 1-2 
possesses an open V-shaped structure in solution both when free and when complexed 
with C3d, and that it is likely that both CR2 SCR 1-2 domains make contact with C3d in 
the complex.
(4.2) Results and Discussion
(4.2.1) X-ray scattering data analyses of CR2 SCR 1-2, C3d and their complex
The preparations of the recombinant CR2 SCR 1-2 and C3d proteins from P. 
pastoris and E. coli respectively for scattering and ultracentrifugation studies resulted in 
single bands when analysed by SDS-PAGE and homogenous peaks when analysed by 
size exclusion chromatography. The complex was prepared by mixture of the two 
proteins, and excess protein was removed by size exclusion chromatography as separate 
peaks that were well resolved from the single sharp peak for the complex.
X-ray scattering experiments were performed on CR2 SCR 1-2, C3d and their 
complex (Materials & Methods). In Guinier analyses to determine the overall shape of 
the proteins from the radius of gyration Rq (a measure o f elongation), the fits in Guinier 
plots were linear in an appropriate Q.Rg ran8e UP t0 1-2 for CR2 SCR 1-2, 1.4 for C3d, 
and 1.3 for the complex (Figures 4.2(a), 4.2(b) and 4.2(c)), where Q = An sin 0 / X (20 = 
scattering angle; X = wavelength). Slight radiation damage was observed for all three 
samples, most noticeably for CR2 SCR 1-2. In the final data analysis, only the first of 
the 10 successive time frames obtained during each X-ray data acquisition for each 
sample were used for data processing, in which the effect of damage was minimal.
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Figure 4.2
Guinier analyses of X-ray data for CR2 SCR l -2, C3d, and their complex. The filled 
circles between the arrowed Q.Rg ranges show the data points used to determine the Rq 
values, and the straight lines show the best fits through these points, (a) Rq plots for
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(Figure 4.2 legend continued)
CR2 SCR 1-2 using a Q range o f 0.24 -  0.60 n m 1. The curves correspond to sample 
concentrations of 2.3 mg m l'1, 1.7 mg m l'1, and 1.1 mg m l'1 from top to bottom. The 
Q.Rg values as arrowed are based on an Rq value of 2.0 nm. (b) Rq plots for C3d using a 
Q range of 0.16 -  0.55 nm*1. The curves correspond to sample concentrations o f 1.1 mg 
ml*1, 0.8 mg m l'1, and 0.5 mg m l'1 from top to bottom. The Q.Rg values as arrowed are 
based on Rq values of 2.6 nm, 2.4 nm, and 2.3 nm respectively in reflection o f their 
concentration dependence (Figure 4.4). (c) Rq plots for the CR2 SCR l-2/C3d complex 
using a Q range of 0.24 -  0.55 nm*1. The curves correspond to sample concentrations of
1.0 mg m l'1, 0.8 mg ml*1, and 0.4 mg m l'1 from top to bottom. The Q.Rg values as 
arrowed are based on an Rq value of 2.4 nm.
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The mean final X-ray Rq value of CR2 SCR 1-2 was 2.12 ± 0.05 nm. This 
included measurements in two buffers containing either 50 mM NaCl or 200 mM NaCl 
(Materials & Methods). Figure 4.3(a) showed that no significant difference in Rq values 
occurred with the use of either salt concentration. The anisotropy ratio Rq/Ro (where Ro 
is the Rg value of the sphere with the same volume as the hydrated glycoprotein) was 
calculated from the X-ray Rq value o f CR2 SCR 1-2 to be 1.51.
In previous Guinier analyses of SCR proteins in FH and Crry, it had been 
concluded that the cross-sectional radius of gyration Rxs value may monitor short-range 
and long-range interdomain orientation between adjacent SCR domains. Here, the 
corresponding Rxs analyses for CR2 SCR 1-2 necessarily utilised a larger linear fit 
range between Q values of 0.9 to 1.3 nm '1 for reason of the smaller size of CR2 SCR 1-2 
compared to FH and Crry (Glatter & Kratky, 1982). This Q range resulted in a mean Rxs 
value of 1.0 ± 0.1 nm (data not shown). This Rxs value is reduced when compared to 
that of 1.5 ± 0.1 nm for rCrry with five SCR domains, 1.3 ± 0.1 nm for mCrry-Ig with 
ten SCR domains, and 1.7 ± 0.1 nm for FH with 20 SCR domains (Aslam & Perkins, 
2001; Aslam et al, 2003). This reduced Rxs value suggests that this averaged single 
inter-SCR orientation in CR2 SCR 1-2 is more extended than the averaged orientation 
seen in Crry and FH.
The X-ray analyses for C3d differed from that for CR2 SCR 1-2 in that a 
concentration dependence in the Rq values was observed. The slopes in the Guinier plots 
of Figure 4.2(b) visibly increased with increase in concentration, ranging from a Rq 
value of 1.8 nm at 0.3 mg m l'1 C3d to a Rq value of 3.5 nm at 11.2 mg m l'1 (Figure 
4.3(b)). Within a given data acquisition session, the values of l(0)/c increased with C3d 
concentration when ordinarily it should remain constant. Both observations are 
consistent with C3d dimerisation. After fitting to a sigmoidal function, a dissociation 
constant Kd of approximately 40 pM was estimated from the midpoint of the curve at 
1.3 mg ml'1 C3d in Figure 4.3(b). Further sedimentation equilibrium experiments 
(V.A.A. Birch, H.E. Gilbert and S.J. Perkins, unpublished data) determined the Kd to be 
20 pM.
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Figure 4.3
Concentration dependence of the Rq values for CR2 SCR 1-2, C3d, and their complex. 
The values and their standard deviations at each concentration are derived from the
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(Figure 4.3 legend continued)
Guinier fits, (a) The open circles denote the experiments carried out in 10 mM HEPES 
(pH 7.4), 50 mM NaCl. The filled circles denote those done in PBS (pH 7.4) at a final 
NaCl concentration of 200 mM. From regression analysis, the mean Rq value is 2.12 ± 
0.05 nm at zero concentration, (b) The Rq value for the C3d dimer is 3.49 nm and that 
for the monomer is determined from the intercept of the fitted line as 1.95 nm. (c) The 
mean Rq value of the complex is 2.44 ± 0.1 nm.
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As C3 is found in blood at 1.3 mg m l'1 (Law & Reid, 1995; Morgan & Harris, 1999), 
this implies that C3d is present in the monomeric form unless its concentration increases 
in local areas. The R g / R o ratio for C3d was 1.04, showing that this has a relatively 
compact structure which is almost spherical (when Rq/Ro would be 1 for a sphere), in 
accord with the available C3d crystal structures.
For the complex, no association phenomena were observed, showing that the 
binding of CR2 to C3d had removed the ability o f C3d to self-associate (Figure 4.3(c)). 
The Rq value for the complex was 2.44 ± 0.1 nm. The Rg/Ro ratio for the complex was 
1.15, showing by comparison that both C3d and the complex possessed relatively 
similar degrees of elongation in their structures. In turn, this ratio suggestedthat both the 
SCR 1 and SCR 2 domains my bt positioned close to the surface of C3d, hence making 
the structure of the complex slightly larger. This would be consistent with the schematic 
cartoon of Figure 4.1 (c).
The indirect transformation of the scattering curve I(Q) (measured in reciprocal 
space) into real space gives the distance distribution function P(r) (Figure 4.4). This 
represents the summation of all the distances r between every pair o f atoms within the 
protein. The R q , 1(0) and L values that are calculated from the P(r) curve are based on 
the full scattering curve in the Q range between 0.24 nm '1 to 2.2 nm '1, and gave a 
determination of the maximum length L that is independent of shape assumptions. The 
R g  values calculated from the P(r) curves were in good agreement with the Guinier 
values.
(a) The most frequently occurring distance for CR2 SCR 1-2 is 2.1 nm from the 
maximum M in the P(r) curve, and its length L was determined to be 10 ± 0.5 nm at the 
point when P(r) becomes zero at large r.
(b) The P(r) curve for C3d showed a pronounced concentration dependence. A 
single peak Mi at r = 2.8 nm was observed at 0.54 mg m l'1. As the C3d concentration 
increased to 3.7 mg ml'1, peak Mi shifted to r = 3.3 nm and a second peak Mi appeared 
at r = 7.0 nm. The length of C3d increased from L = 7.0 ± 0.5 nm to 10.5 ± 0.5 nm.
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Figure 4.4
X-ray distance distribution functions P(r) for CR2 SCR 1-2, C3d, and their complex. 
The maximum M  of each P(r) curve shows the most frequently occurring distance 
within each molecule. The maximum dimension is denoted by L. (a) For CR2 SCR 1-2,
(continued ...)
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(Figure 4.4 legend continued)
M  occurs at 2.1 nm and L at 10 nm. (b) For C3d, five different sample concentrations 
are shown at 0.5 mg m l'1 (red), 0.8 mg ml"1 (orange), 1.1 mg ml*1 (green), 2.1 mg m l'1 
(blue), and 3.73 mg ml'1 (pink) from bottom to top. The three dashed lines represent P(r) 
curves whose intensities have been increased by factors o f 8.5 (0.5 mg ml"1), 7.0 (0.8 mg 
m l'1), and 5.5 (1.1 mg ml"1) for reason of clarity. Peak M\ corresponds to monomeric 
C3d and peak Mi correspond to its dimer, (c) For the complex, M occurs at 3.0 nm and L 
at 9 nm.
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These changes can be explained by the formation of a dimer of C3d, in which the 
first peak M\ corresponded to all the distances within a single C3d molecule, and the 
second peak M2 corresponded to all the distance vectors between the two separate 
monomers
(c) The P(r) curve for the complex showed a single maximum at r = 3.0 nm. This 
r value is comparable with peak M\ for free C3d. The length of the complex was 9.0 ± 
0.5 nm (Figure 4.4(c)), which is larger than that of monomeric C3d at 7.0 nm. This is 
compatible with the formation of a complex with both domains of CR2 SCR 1 -2 close to 
the surface of C3d (Figure 4 .1(c)).
(4.2.2) Analytical ultracentrifugation analyses of CR2 SCR 1-2, C3d and their 
complex
Sedimentation velocity experiments provided complementary structural data on CR2 
SCR 1-2, C3d and their complex. Both absorbance and interference data were used at 
low C3d concentrations, and only interference data at high C3d concentrations when the 
absorbance signal became saturated. Time-derivative analysis of pairs of scans showed 
a single broad boundary distribution of s* values for all three proteins (Figure 4.5). 
Closer examination of the boundary distributions showed that, although these were 
single-peaked, the centre of the g(s*) distribution visibly varied with concentration for 
C3d, but not for CR2 SCR 1 -2 or the complex. In agreement with the scattering results, 
this indicated the association of C3d. The existence of a single peak for the C3d samples 
and not two or more in the ultracentrifugation results is consistent with a reversible 
equilibrium between a monomer and dimer on the experimental timescale. For a 
monomer-dimer equilibrium, the peak centres in Figure 4.5(b) are a good approximation 
of the weight-averaged sedimentation coefficient s°2o,w, which was calculated by 
integration (Materials & Methods). This approximation is satisfactory provided that the 
system was at equilibrium before the start of sedimentation (Stafford, 2000). These 
s°20,w values shifted from 3.3 S at 0.8 mg m l'1 C3d to 4.85 S at 11.2 mg m l'1 (Figure 
4.6(b)). Curve fitting of the s°2o,w values in Figure 4.6(b) using a sigmoidal function 
gave a similar outcome to that shown in Figure 4.3(b) for the Rq values. The midpoint at 
concentration of 1.5 mg m l'1 for C3d led to a dissociation constant of 40 pM. However
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Figure 4.5
Sedimentation velocity fits of the g(s*) distributions for CR2 SCR l -2, C3d, and their 
complex, (a) The fit for CR2 SCR 1 -2 was based on interference data from 42,000 rpm
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(Figure 4.5 legend continued)
for a sample concentration of 2.6 mg ml"1 in 10 mM HEPES (pH 7.4), 50 mM NaCl. 
The s°2o,w value was determined to be 1.46 S (arrowed), (b) The four fits were based on 
absorbance data obtained at 32,000 rpm for C3d concentrations at 0.8 mg m l'1 (blue), 
2.8 mg m l'1 (green), and 11.2 mg m l'1 (red) in 10 mM HEPES (pH 7.4), 50 mM NaCl. 
The s°20,w values were determined to be 3.26 S, 4.30 S and 4.85 S as arrowed from left to 
right. The residuals for these data sets are similar to those shown for CR2 SCR 1 -2 and 
the complex, (c) This fit was based on absorbance data obtained at 37,000 rpm for the 
CR2 SCR l-2/C3d complex at 3.3 mg m l'1 in 10 mM HEPES (pH 7.4), 50 mM NaCl, 
from which the s°2o,w value was determined to be 3.52 S (arrowed).
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Concentration dependence of the s 20,w values for CR2 SCR 1-2, C3d, and their 
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the best estimate for the s°2o,w value for monomeric C3d was taken to be 3.17 S as the 
mean of the two lowest s°2o,w values, rather than the value of the intercept at zero 
concentration. The corresponding s°2o,w determination for the dimer gave a s°2o,w value 
of 4.34 S. Both free CR2 SCR 1-2 and its complex with C3d showed no concentration 
dependences (Figure 4.6). The s°2o>w values for CR2 SCR 1-2 and its complex with C3d 
were readily determined from extrapolations to infinite dilution to be 1.40 ± 0.03 S and 
3.45 ± 0.01 S respectively. By analogy with the Rq/Rq anisotropy ratios of 1.51, 1.04 
and 1.15, the frictional coefficient anisotropy ratios fifo were computed for CR2 SCR 1- 
2, C3d and the complex. These were 1.36, 1.00 and 1.21 respectively. It was gratifying 
that the relative magnitudes of the f/fo ratios agreed with those determined from the 
Rq/Rq ratios.
(4.2.3) Modelling of the X-ray scattering curves of CR2 SCR 1-2, C3d and their 
complex
The constrained modelling o f the X-ray scattering data for CR2 SCR 1-2, C3d 
and their complex was based on the crystal structure for the complex. Firstly, the CR2 
residues that were missing from this crystal structure for reason of crystallographic 
disorder or high mobility were replaced, namely the addition of an N-terminal peptide 
(EAE) in a fixed conformation, and a C-terminal peptide (EQKLIS) in random 
conformations to CR2 SCR 1-2 (Guthridge et al, 2001a) (Materials and Methods). The 
SCR 1 and SCR 2 domains are linked by eight residues (EYFNKYSS). In general, the 
inter-SCR linkers are known to adopt many conformations, where only the shortest 
linkers with three or four residues show a restricted range of structures (Aslam et al, 
2003). Hence, for the modelling of CR2 SCR 1-2, a total of 1,000 random orientations 
were used to represent a wide range of possible linker conformations (Materials and 
Methods).
A constrained modelling search was performed to determine the solution 
arrangement of the two SCR domains within CR2. A total of 199 CR2 linkers selected 
from the family of 1,000 conformations were combined with 500 randomly-selected C- 
terminal tails to create 9,950 models (Table 4.1). This procedure randomised the relative
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Filter Models Inter-SCR angle (°)a Spheres Rg (nm) R factor (%) / ( g/sec) s%.w(S )b
(a) CR2 SCR 1-2
Modelling None 9,950 16.1 -  179.0 112-151 1 .63-2 .68 2 .8 -1 2 .4 3 .5 4 -5 .2 8 1 .37-2 .05
Modelling Rg 1,823 2 9 .0 -  179.0 2 .01 -2 .23 3 .4 -9 .7 4 .1 1 -4 .4 0 1 .65-1 .76
Modelling R factor 6 63 .2 -121 .3 135-137 2 .1 0 -2 .1 4 3.5 4 .1 5 -4 .3 2 1 .68-1 .74
Modelling Final model 1 69.1 136 2.10 3.5 4.23 1.71
Experimental 140 2.12 ±0.05 1.40 ±0.03
(b) M onomer and dim er of C3d
Crystal structure 1 374 2.02 ±0.01 11.6 4.26 3.43
Experimental 1.95 c 3.17 c
Dimer model 1 560 3.2 15.3 6.42 4.5
Experimental 3.49 4.34
(c) CR2 SCR l-2/C3d complex
Modelling None 9,950 16.1 -  179.0 282 -351 2 .2 1 -2 .9 2 6 .6 -1 1 .6 3 .97 -7 .53 2 .9 -5 .5
Modelling Rc 602 22.3 -  155.4 2 .3 8 -2 .5 2 8.1 -  10.0 5 .41 -5 .68 3.84 - 4.04
Modelling R factor 6 2 2 .3 -  105.2 337 - 346 2 .41 -2 .43 8.1 -8 .2 5 .4 9 -5 .5 9 3.91 -3.98
Modelling Final model 1 47.7 337 2.41 8.1 5.51 3.96
Experimental 346 2.44 ±0.1 3.45 ±0.01
Table 4.1
Summary of the X-ray modelling fits for the CR2 SCR 1-2, C3d and CR2 SCR l-2/C3d solution structures.
a Other details are reported in Figure 4.8.
bNo filtering was performed using the s%,w values.
cThe Rc value for monomeric C3d was taken from the intercept of the fitted line in Figure 4.3(b), but the corresponding s°2o>w value was taken as 
the mean of the two data points at 0.6 mg ml'1 and 0.8 mg ml'1 in Figure 4.6(b).
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SCR 2
C3d C3d
Figure 4.7
Molecular graphics views of the models created to identify the best-fit models for 
CR2 SCR 1-2 and the CR2 SCR 1-2 / C3d complex, (a) The first 200 unfiltered 
models of the 9950 models created for CR2 SCR 1-2 are shown, superimposed upon 
SCR 2 (thick ribbon) to show that all orientations had been sampled, (b) The six 
filtered best-fit models for CR2 SCR 1-2 superimposed upon SCR 2. The upper view 
shows the arrangements of six SCR 1 domains about SCR 2 viewed down the long 
axis of SCR 2. (c) The first 200 unfiltered models of the 9950 models created for the 
CR2 SCR l-2/C3d complex. The models are superimposed over C3d (red) and CR2 
SCR 2 (thick blue ribbon) to show that all orientations had been sampled, (d) The six 
filtered best-fit models for the CR2 SCR l-2/C3d complex, superimposed upon C3d 
and CR2 SCR 2.
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arrangements o f the two SCR domains. Inspection of the first 200 o f these 9,950 
models showed that they occupied all conformations as desired (Figure 4.7(a)). 
Measurements o f the inter-SCR domain angle between the two long axes o f SCR 1 
and SCR 2 showed that all angles between 16.1° to 179.0° were represented. Note 
that an inter-SCR angle below 16.1° would mean that the SCR 1 and SCR 2 become 
clearly sterically overlapped. After hydration of these models, the Rg values o f these 
9,950 models ranged between 1.63 nm to 2.68 nm. These encompassed the 
experimental Rq value of 2.12 ± 0.05 nm. The use o f the experimental Rg value as a 
filter reduced the number o f valid models to 1,823 (Table 4.1). The normal use of 
steric overlap as a filter (Perkins et al, 1998) was found to be ineffective for reason 
o f the extended nature o f the SCR domains and their connecting peptides, meaning 
that overlaps could go undetected. Accordingly these peptides were manually 
checked to ensure that sterically-overlapping SCR conformations were not present. 
The 1,823 models were then sorted in order o f their goodness-of-fit R factors. Six 
CR2 SCR 1-2 structures were identified that corresponded to the best fit solution 
structures. All six models showed open V-shaped structures with an interdomain 
angle between 63.2° to 121.3° (Table 4.1(a); Figure 4.7(b)). The X-ray R factors for 
the six best models were all 3.5%, and this compared well with other similar 
modelling analyses (Perkins et al, 1998). The corresponding R factors for the two 
available crystal structure models for CR2 SCR 1-2 (Prota et al, 2002; Szakonyi et 
al, 2001) are both higher at 8.8%, showing that the best solution models are 
improved over the crystallographic models. The survey o f all 9,950 models in Figure 
4.8(a) showed that the six best models corresponded to the lowest R factors o f the 
sterically-acceptable models. However the modelling was not able to identify one 
favourable inter-SCR domain angle, but only a range o f these (Figure 4.8(b)). The 
conformational average o f these six structures is depicted in Figure 4.9(a), together 
with the good curve fit between the experimental data and modelled curve. No large 
difference in the outcome of the modelling was observed between the models with 
the added N- and C-terminal peptides and those without.
The modelling of the C3d scattering curve was based on the unmodified 
crystal structure and the experimental scattering curve at 0.54 mg m l'1 when C3d is 
monomeric.
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Figure 4.8
Analysis of the models for (a,b) free CR2 SCR 1 -2 and (c,d) its complex with C3d. 
(a) Comparison of the RG values of all 9950 CR2 SCR 1-2 models with their R factor 
values. The open circles indicate models that exhibit steric overlap between the two 
SCR domains. The 4453 red, yellow and blue circles show models that satisfy the 
steric overlap filters. The remaining 1823 models in yellow satisfy both the overlap 
and Rq filters, with those in blue being the six best fit models with the lowest R 
factors. These six models have a mean R factor of 3.5%. (b) Comparison of the RG 
values of the 9950 CR2 SCR 1-2 models with their inter-SCR domain angles. The 
colouring scheme follows that in (a), (c) Comparison of the RG values of the 9950 
CR2 SCR l-2/C3d complex models with their R factor values. The colouring scheme 
follows that in (a), however 3360 models now satisfy the overlap filters. The 
remaining 602 models in yellow and blue satisfy both the overlap and RG filters, with 
those in blue being the six best fit models with the lowest R factors. These six 
models have a mean R factor of 8.15%. (d) Comparison of the RG values o f the 9950 
CR2 SCR l-2/C3d complex models with their inter-SCR domain angles. The 
colouring scheme follows that in (c).
(c) CR2 SCR 1-2 / C3d complex (d) CR2 SCR 1-2 / C3d complex
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Figure 4.9
X-ray curve fits for the best-fit models for (a) CR2 SCR 1-2, (b) C3d monomer and 
dimer, and (c) the SCR 1-2 / C3d complex. The open circles or triangles (o and A) 
denote the experimental scattering curves, while the continuous lines shows the
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(Figure 4.9 legend continued)
modelled curve. For each curve fit, an a-carbon trace o f the corresponding model is 
shown. For CR2 SCR 1-2 and the complex, the best model from the small selection 
of best-fit models (as shown in Figure 4.7) is used. The modelled scattering curve for 
monomeric C3d was taken from its crystal structure (red line). The modelled curve 
fit for the best-fit C3d dimer is indicated by the blue line, where no a-carbon trace is 
shown for reason of the arbitrary nature o f the dimer structure.
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Despite the high signal-noise ratio at this low concentration, especially at large Q 
values, an excellent curve fit was nonetheless obtained for monomeric C3d (Figure 
4.9(b)). The R factor of this fit was 11.6% which again corresponds to a satisfactory 
modelling outcome. The R factor is higher than would normally be acceptable, but 
this is due to the signal-noise ratio o f the sample, as can been seen in the scattering 
curve in Figure 4.9(b). The modelling o f the C3d dimer was based on the scattering 
curve at 11.2 mg ml’1, at which C3d is dimeric (Figure 4.3(b)). A total o f 921 
symmetric C3d dimers were arbitrarily created from pairs o f C3d structures to 
include all possible connections between two C3d monomers (Materials & 
Methods). After ranking the curve fits by order o f R factors, the most satisfactory 
C3d dimer gave a good curve fit that reproduced an inflexion in the scattering curve 
at around Q o f 1 nm '1 (Figure 4.9(b)). This gave an R factor o f 15.3%. The modelled 
scattering curve from this best-fit dimer gave a predicted P(r) curve with a double 
peak (not shown) that resembled closely the experimental P(r) curve at 3.73 mg ml’1 
in Figure 4.4(b). The prominence o f the two peaks in the P(r) curve for the C3d 
dimer in Figure 4.4(b) and the clear inflexion in the C3d dimer scattering curve at 
around Q o f 1 nm '1 both imply that the C3d dimer is formed from an extended pair 
o f monomers with relatively few contacts between them.
The solution arrangement o f the two SCR domains within CR2 in the 
complex with C3d was determined using the same 9,950 models used to model free 
CR2 SCR 1-2. The view in Figure 4.7(c) o f the first 200 o f these 9,950 models again 
revealed that all orientations of SCR 1 relative to SCR 2 and C3d had been sampled 
in the modelling. The Rq values o f these 9,950 models ranged between 2.21 nm to 
2.92 nm, which encompassed the experimental Rq value of 2.40 ± 0 .1 0  nm for the 
complex. The Rq filter reduced the number o f allowed models to 602 (Table 4.1). 
The absence o f steric overlap in these 602 models was established by manual visual 
checks of the 199 linkers in their complexes with C3d. The 602 models were then 
sorted in order o f their R factors to identify six CR2 SCR 1-2 structures in the 
complex that corresponded to the best fit solution structures. All six models resulted 
in open structures in which SCR 1 was positioned close to the surface o f C3d, 
making it possible that both SCR 1 and SCR 2 bind to C3d (Figure 4.7(d)). Here, the 
interdomain angle ranged between 22.3° to 105.2° (Table 4.1(b)), which is slightly 
larger but similar to that for free CR2 SCR 1-2. The X-ray R factors for the six best
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models were satisfactory at 8.1% to 8.2%. The corresponding R factor for the crystal 
structure o f the complex (Szakonyi et al, 2001) is higher at 9.8%. Despite the 
relatively large size of C3d in the complex, which will dominate the scattering curve 
o f the complex, the solution model again offers an improvement over the 
crystallographic model. The survey o f all 9,950 models in Figure 4.8(c) showed that 
the six best models corresponded to the lowest R factors o f the sterically-acceptable 
models. As for the free CR2 protein, the modelling was not able to identify one 
favourable inter-SCR domain angle (Figure 4.8(d)). The most representative o f these 
six structures is depicted in Figure 4.9(c) together with the good curve fit between 
the experimental data and modelled curve.
(4.2.4) Modelling of the sedimentation coefficients of CR2 SCR 1-2, C3d and 
their complex
For CR2 SCR 1-2, previous calculations o f the s°2o,w values for a very 
extended structure derived from homology modelling predicted that this was 1.36 S, 
which was within error o f the value o f 1.25 ± 0.12 S determined by experiment 
(Guthridge et al, 2001a). In the current study, the experimental value was 
reproducibly redetermined to be 1.40 ± 0.03 S. This value was compared with the 
s°20,w values calculated from the 9,950 hydrated CR2 SCR 1-2 models using the 
GENDIA program (Table 4.1). The predicted s°2o,w values ranged between 1.37 S to 
2.05 S, the lower values being comparable with the experimental value. The six best 
scattering models gave predicted s°2o,w values o f 1.68 S to 1.74 S, and the final 
scattering model gave a predicted value o f 1.71 S. This outcome is higher by 0.31 S 
than the experimental s°2o,w value o f 1.40 ± 0.03 S. This suggested that the CR2 SCR 
1-2 structure may be too small to replicate the experimental s°2o,w value, even though 
this had been hydrated by the standard amount o f 0.3 g / g glycoprotein. The most 
likely reason for the difference is that CR2 SCR 1-2 structures exist in solution that 
are more elongated than those determined by scattering in Figure 4.7(b).
In the case of the C3d monomer, the experimental s°2o,w value was 3.17 S. 
The GENDIA calculation from the hydrated C3d crystal structure gave a value o f 
3.43 S which is in good agreement with this (Table 4.1). The s°20,w value for dimeric 
C3d was 4.34 S. The GENDIA calculation using the best-fit scattering model for the 
C3d dimer gave 4.50 S, also in good agreement (Table 4.1). It was concluded that
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the sedimentation properties of C3d in its monomeric and dimeric forms could be 
well explained.
For the complex, the predicted s°2o,w values calculated for the 9,950 hydrated 
CR2 SCR 1-2 models in association with C3d occurred in a range o f 2.9 S to 5.5 S 
(Table 4.1). The experimental value of 3.45 ±0.01 S was well within this range. The 
six best scattering models gave predicted s°2o,w values o f 3.91 S to 3.98 S, and the 
final scattering model gave a predicted value of 3.96 S. This outcome is higher by 
0.46 S than the experimental s°20,w value o f 3.45 ± 0.01 S, meaning that the structure 
of the complex may be too small to replicate the experimental s°2o,w value. The most 
likely reason for the difference is again that there are sufficient CR2 SCR 1-2 
structures that are more elongated than those determined by scattering in Figure 
4.7(d).
(4.2.5) Point mutation-directed modelling
Point mutations in the area of the positively charged surface patch on CR2 
SCR 1 showed that four residues - R13, R28, K41, and K57 - affect ligand binding 
(Hannan et al, 2005) (Figure 4.10(a,b)). Our modelling work with the CR2 SCR 1- 
2/C3d complex showed that CR2 SCR 2 is folded back onto the surface o f C3d 
(section 4.2.3). A negatively charged channel on C3d contiguous with the SCR 2 
binding site was proposed to be the site at which SCR 1 interacts with the ligand 
(Hannan et al, 2005) (Figure 4.10(a,b)). A series o f manually constructed models 
based on the crystal structure o f the complex (Szakonyi et al, 2001) and the results 
o f the mutational studies was created to test this possible interaction site. The best 
model from this search (Figure 4.10(c,d)) had an R q  of 2.30 nm, which falls outside 
the 5% filter on the experimental value o f 2.44 nm. The R factor was 8.6%, slightly 
higher than those of 8.1 - 8.2% for the best-fit models from the large-scale 
constrained modelling search. Increasing the R q  of the models causes a further 
increase in R factor. The interdomain angle was determined to be 51.0°, and the N- 
to C-terminal distance is 4.1 nm, both o f which are comparable to the values seen in 
the six best-fit models from the constrained search.
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Figure 4.10
Molecular graphics views of the mutation-directed modelling, (a) A ribbon diagram 
representation of the CR2 SCR l-2/C3d complex. The residues forming the 
negatively charged channel on the surface of C3d are shown in red. The residues in 
CR2 SCR 1 identified through mutation studies are shown in blue. Q20, the site of 
antigen attachment on C3d, is shown in yellow, (b) An electrostatic representation of 
the CR2 SCR l-2/C3d complex (modified from Hannan et al, 2005). (c, d) The best- 
fit model of the complex from the mutation-directed modelling, (c) is in the same 
orientation as (a) and (b). (d) is rotated 90° clockwise to show the position o f SCR 1 
in relation to C3d. The key residues in the negatively charged channel are 
highlighted in yellow.
(4.3) Conclusions
This solution study by scattering and ultracentrifugation has added new 
insights to the crystal structures o f the complex formed between CR2 SCR 1-2 and 
C3d, and those for unbound C3d, and unbound CR2 SCR 1-2 (Prota et al, 2002; 
Szakonyi et al, 2001; Nagar et al, 1998). In contrast to the closed V-shaped structure 
in which SCR 1 and 2 made contacts with each other (Figure 4.1(a)), the scattering 
data visualised more open arrangements in solution in which the two SCR domains 
are no longer in contact. The constrained modelling o f this data enabled the SCR 
domain positions to be visualised to a precision o f about 1 nm. As the open V- 
shaped structures correspond to increased separations o f about 2 nm between the tips 
of the SCR 1 and SCR 2 domains, the scattering modelling is readily able to detect 
this conformational difference. While excellent curve fits were obtained by this 
approach, the precise inter-SCR rotational orientation cannot be assessed by this 
procedure. An unexpected dimerisation o f C3d in solution was also revealed from 
these studies, and this could likewise be modelled. While it is not possible to predict 
specific binding sites between SCR 1 and C3d in the complex, or between the C3d 
monomers in the dimer, the solution studies have clarified important properties of 
these two proteins.
The scattering studies of free CR2 SCR 1-2 showed that a family o f open V- 
shaped structures provided the best description o f its solution structure. This most 
probably exists as a conformational equilibrium between different open structures. 
The eight residues in the linker (one o f the longest known in the SCR superfamily) 
are presumed able to permit unrestrained motion between the two SCR domains. The 
crystallisation o f complexed and free CR2 SCR 1-2 as a closed V-shaped structure 
by two independent groups (Prota et al, 2002; Szakonyi et al, 2001), in distinction to 
the open V-shapes seen in solution, shows that this flexibility leads to different 
structures under different conditions. The discrepancy between the observed and 
calculated sedimentation coefficients for CR2 SCR 1-2 suggests that the open V- 
shapes can become even more elongated. This is as expected, as the six individual 
best-fit V-shaped structures did not show reasons why the CR2 SCR 1-2 structure 
should be maintained as a rigid V-shape in solution.
The solution study o f C3d revealed its hitherto unknown dimerisation 
properties. The Kd o f about 40 pM for this equilibrium indicates that C3d will be
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monomeric under physiological conditions in serum, but will form dimers if  present 
in high localised concentrations during inflammatory conditions. Biochemical 
binding studies o f C3d will require concentrations below 1 mg ml’1 to permit study 
of the monomeric form. This monomer-dimer equilibrium was not detected in the 
earlier X-ray and neutron scattering work on serum C3dg and tryptic-cleaved serum 
C3d for reason o f the limited concentration range studied previously (Perkins & Sim, 
1986). The previously reported Rg value o f 2.9 ± 0.2 nm at 4 mg m l'1 is consistent 
with the dimers reported here in Figure 4.3(b), showing that both the recombinant 
and serum-derived proteins behaved similarly. The previously reported length of 
C3dg of 10 nm is in good agreement with the P(r)-determined length o f 10.5 ± 0.5 
nm here in Figure 4.4(b) for dimeric C3d. Truncated rat C3d was crystallised as 
dimers at a concentration of 12 mg m l'1 in phosphate buffer at pH 7 (Zanotti et al, 
2000). However, as these authors note, the dimer interface would be partially 
occluded if the N-terminal residues 960-1008 (rat numbering) were in place. Full 
length C3d, on the other hand, crystallises as a monomer in the asymmetric unit in 
space group P2i2i2i at a concentration o f 10 mg m l'1 in a 12% polyethylene glycol 
solution buffered by 100 mM 2-morpholinoethanesulphonic acid, pH 6.4 (Nagar et 
al, 1998). The failure o f this crystallisation solution to produce dimeric C3d may be 
due to the very different conditions in which the protein was studied.
The solution study of the complex between CR2 SCR 1-2 and C3d showed 
that CR2 SCR 1-2 maintained a similar conformational family of open V-shaped 
structures in this complex as in the unbound protein, SCR 1 and SCR 2 were both 
likely to make contacts with the surface o f C3d, and the dimerisation properties of 
C3d were abolished. The modelling has assumed that SCR 2 is located in the 
position seen in the crystal structure o f the complex. The precise molecular location 
of SCR 1 on the surface o f C3d cannot be identified for reason o f the nature o f the 
scattering modelling technique. Molecular graphics inspections o f the six best-fit 
models for the complex suggested that SCR 1 was mostly located on the perimeter o f 
the dome-shaped C3d structure, rather than within the concave surface o f C3d that 
had previously been predicted as the CR2 SCR 1-2 site, although subsequent 
modelling based on mutational studies (Figure 4.10) (Hannan et a lt 2005) shows that 
it is possible that CR2 SCR 1 interacts with a negative channel at one edge o f the 
convex surface of C3d. It is o f interest that the CR2 SCR 1-2 structure is not required
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to undergo a major conformational change to form the complex with C3d, i.e. its 
unbound conformation corresponds to that found in its C3d complex. There are thus 
no indications o f an induced-fit mechanism for complex formation, and likewise 
there is no evidence for an allosteric mechanism for the functional role o f CR2 in B- 
cell activation.
This study was strengthened by the combination of the scattering results with 
analytical ultracentrifugation and the constrained molecular modelling o f the results. 
Analytical ultracentrifugation is a single parameter method in which the 
sedimentation coefficient provides structural information o f the degree o f structural 
elongation, by analogy with the Rq parameter from the scattering curve at very low 
Q values. While good agreement was obtained with the C3d sedimentation data, less 
good agreements were observed for unbound CR2 SCR 1-2 and its complex with 
C3d. These differences can be explained if  CR2 SCR 1-2 exists in additional 
conformations that are more extended than the open V-shaped structures inferred by 
solution scattering. This comparison reinforces the view that CR2 SCR 1-2 has a 
flexible solution structure. A less likely explanation for the differences is that CR2 
SCR 1-2 is heavily hydrated (Furtado et al, 2004), but there is no reason to expect 
that this might be the case.
The ability of CR2 to interact with its C3d ligand is characterised by a high 
nM affinity (Guthridge et al, 2001a). A single SCR 2 interaction with C3d provided 
a contact surface area o f 14.0 nm or 7.9 nm and this is extensive enough for this to 
drive the association forward (Prota et al, 2002; Szakonyi et al, 2001). The crystal 
structure suggests that there is less need for SCR 1 to participate in this complex 
formation, however the evidence from domain deletion mutants o f CR2 show that 
both SCR 1 and SCR 2 are required and sufficient to bind C3dg and Epstein Barr 
Virus (Carel et al, 1990; Martin et al, 1991; Lowell et al, 1989). It has thus been 
surprising that only SCR 2 was seen to interact with C3d in the crystal structure o f 
the complex. This present solution scattering has resolved many o f these surprises by 
showing that CR2 SCR 1-2 possesses a more open V-shaped structure in solution 
than that seen by crystallography (Figure 4.7(b)), and that this open V-shaped 
structure is largely carried into the complex with C3d (Figure 4.7(d)). Site specific 
mutagenesis of residues in the SCR 1 domain shows that SCR 1 participates in the
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CR2 SCR 1-2 and C3d interaction (Hannan et al, 2004; Hannan et al, 2005), and 
these results are supported by the scattering modelling of the CR2 SCR l-2/C3d 
complex. The model shown in Figure 4.10(c,d) demonstrates that interaction o f the 
positive surface patch on CR2 SCR 1 with the negatively charged region on C3d 
would not occlude the site o f antigen attachment (Figure 4.10(a)).
(4.4) Materials and Methods
(4.4.1) Production and purification of CR2 SCR 1-2 and C3d
CR2 SCR 1-2 was expressed in Pichia pastoris and purified as described by 
Guthridge et al (Guthridge et al, 2001a) by the Holers laboratory, UCHSC, Denver, 
CO, USA. Briefly, the cell supernatant was buffered in 10 mM formate (pH 4.0) and 
passed over a SP-Sepharose column. Bound protein was eluted using 10 mM formate 
(pH 4.0) with a 0.0 to 0.5 M NaCl gradient. The eluted protein was then 
deglycosylated overnight at 37°C with 33,000 units o f EndoH per millilitre. The 
sample was passed over a SP-sepharose column again and eluted as before. The 
eluted protein was then additionally purified using a Superdex-75 column to ensure 
the removal o f small molecular weight contaminants. C3d was expressed in 
Escherichia coli and purified, also as described (Guthridge et al, 2001a) during the 
course o f a working visit to the UCHSC, Denver, CO, USA, and was subsequently 
supplied by Dr. J.P. Hannan. Briefly, the cell supernatant was passed over a DEAE 
column, followed by a MonoQ column, and then a MonoS column. Protein was 
eluted each time using a linear salt gradient up to 1 M NaCl. The absorption 
coefficient at 280 nm (1%, 1 cm path length) was calculated from the sequence to be 
17.6 for CR2 SCR 1-2, 13.1 for C3d, and 14.4 for their complex (Perkins, 1986).
(4.4.2) X-ray data acquisition and analyses
Small-angle X-ray scattering data was collected in three separate sessions on 
the ID02 high brilliance beamline at the European Synchrotron Radiation Facility in 
Grenoble, France (Narayanan et al, 2001). All experiments were done in single­
bunch mode in order to reduce the incident flux on the sample. Ring currents varied 
from 6.5 mA to 18.2 mA and the ring energy was 6.0 GeV. The sample-to-detector 
distance in each session was 3.0 m and the sample temperature was 15°C. The 
experiments were carried out in 1 mm path thickness Perspex cells with 25 pm thick
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mica windows. For each sample, two sets o f ten time frames were taken, with an 
exposure time of 0.1, 1.0, or 2.0 sec per frame. Data reduction included the use o f a 
Lupolen sample for the calibration o f detector intensities, and a silver salt standard 
for the calibration o f the Q range. For CR2 SCR 1-2, 12 sample concentrations 
between 0.6 and 10.2 mg m l'1 were used. For C3d, nine sample concentrations 
between 0.3 and 11.2 mg ml"1 were used. For the CR2 SCR 1-2 complex, eight 
sample concentrations between 0.4 and 4.3 mg m l'1 were used. Samples were in 10 
mM HEPES (pH 7.4), 50 mM NaCl. An additional experiment for free CR2 SCR 1-2 
was carried out in phosphate buffered saline (PBS) (10 mM sodium phosphate, 3 
mM potassium phosphate, 136 mM NaCl, 3 mM KC1 at pH 7.2), which was made up 
to 200 mM NaCl. Sample concentrations o f 0.6, 1.3, 1.9, 2.5, 3.8 and 5.0 mg m l'1 
were used.
For a given solute-solvent contrast, the radius o f gyration R q  is a measure o f 
structural elongation as long as the internal inhomogeneity o f the protein scattering 
densities has no effect. Guinier analyses at low Q  give the R q  and the forward 
scattering at zero angle 7(0) (Glatter & Kratky, 1982):
In I(Q) = In 7(0) -  R o Q 1 /3 
This equation is valid in a Q . R q  range o f up to 1.5. The relative 7(0)/c values 
(where c = sample concentration) for samples measured in the same sample buffer 
gives the relative molecular weights o f the proteins when referenced against a 
suitable standard (Kratky, 1963). The R q  analyses were performed using a PERL 
script program SCTPL7 (J.T. Eaton & S.J. Perkins, unpublished software) on Silicon 
Graphics 0 2  Workstations. The concentration dependence of the R q  values for C3d 
were analysed using the four-parameter sigmoidal fit function in SigmaPlot version
8.0 (SPSS Inc.). Indirect transformation o f the reciprocal space scattering data into 
real space to give the distance distribution function P(r) was implemented using the 
program GNOM (Semenyuk & Svergun, 1991; Svergun, 1992):
P(r) = — 2 )  I(Q) Qr sin(Qr) dQ
2n 0
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P(r) represents the distribution o f distance vectors r between pairs o f atoms within a 
molecule. The calculations are based on the full scattering curve (unlike the Guinier 
analyses which use only low Q values) and provide another calculation o f the Rq and 
7(0) values as well as giving the maximum dimension o f a molecule, L. This was 
done for a variety of Dmax values. The final choice o f Dmax was based on three 
criteria: (i) P(r) should exhibit positive values; (ii) the Rq from GNOM should agree 
with that derived from the Guinier analyses; and (iii) the P(r) curve should be stable 
as Dmax is increased beyond the estimated maximum dimension of the molecule. The 
CR2 SCR 1-2 X-ray I(Q) curve contained 575 data points between Q values o f 0.24 
to 2.2 nm '1 and was fitted with Dmax set as 10 nm. The C3d X-ray 7 ( 0  curves 
contained 440-533 data points in the same Q range and was fitted with Dmax set 
between 7 and 11 nm. The CR2 SCR l-2/C3d complex 7 ( 0  X-ray curve contained 
510 data points in this Q range and was fitted with Dmax set as 9 nm.
(4.4.3) Sedimentation velocity data acquisition and analyses
Analytical ultracentrifugation studies on CR2 SCR 1-2, C3d, and their 
complex were carried out on a Beckman XL-I machine equipped with both 
absorbance and interference optics. The starting sample concentrations were 
monitored using their absorbance at 280 nm. Six concentrations between 0.5 and
10.2 mg ml"1 were used for CR2 SCR 1-2, seven concentrations between 0.8 and
11.2 mg m l'1 were used for C3d, and eight concentrations between 0.3 and 4.4 mg 
m l'1 were used for the complex. Sedimentation velocity data were collected over 12 
h in two-sectored cells with column heights of 12 mm. Several rotor speeds were 
used as follows: for CR2 SCR 1-2 and C3d, 22,000 rpm, 32,000 rpm, and 42,000 
rpm, and for their complex, 22,000 rpm, 27,000 rpm, 32,000 rpm, and 37,000 rpm. 
The optimal rotor speeds were determined to be 42,000 rpm for CR2 SCR 1-2,
32,000 rpm for C3d, and 37,000 rpm for the complex. In order to perform the g(s*) 
analyses, consecutive absorbance and interference scans were collected at 6 min 
intervals. In time derivative analyses, the five pairs o f concentration scans within 
sets o f 10 scans were subtracted from each other and averaged. This ensured that the 
maximum permissible measurable molecular weight calculated from these was over 
16 times the expected value as preferred in order to avoid time broadening effects 
(Stafford, 1992). Individual subtractions were extrapolated to the start time in order 
to give the g(s*) function. The sedimentation coefficient s°2o,w and diffusion
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coefficient were determined from the peak maximum and width respectively, using 
the DCDT+ program (Philo, 2000). The partial specific volume was calculated from 
the sequence to be 0.733 ml/g for CR2 SCR 1-2, 0.746 ml/g for C3d, and 0.741 ml/g 
for their complex (Perkins, 1986). The buffer density was calculated as 1.00030 g 
m l'1 from the program SEDNTERP (Laue et al, 1992).
(4.4.4) Modelling of CR2 SCR 1-2 and its complex with C3d
The CR2 SCR 1-2 and C3d atomic structures used to initiate the modelling 
searches were obtained from their crystal structure (PDB code lghq) (Szakonyi et al, 
2001). Related crystal structures for C3d have PDB codes o f lc3d, lq q f and lq sf 
(Nagar et al, 1998; Zanotti et al, 2000). Free CR2 SCR 1-2 has a PDB code o f lly2 
(Prota et al, 2002).
To model unbound CR2 SCR 1-2, the eight-residue linker sequence between 
the final and starting Cys residues o f SCR 1 and SCR 2 (C)EYFNKYSS(C) was 
generated by amino acid substitution o f ten-residue fragments o f a pre-existing 
library o f 1,000 peptides, each 90 residues in length, followed by 100 cycles of 
energy minimisation to remove any steric clashes generated by the substitutions. 
The random conformations o f the 90 residue peptide had been generated using the 
DISCOVER3 package of INSIGHT98. After an initial round o f 300 energy 
minimisation cycles, the linker was subjected to 1,000 fs of dynamics temperature 
equilibration at 771 K. Following this a 100,000 fs dynamics simulation was carried 
out at 771 K. During this simulation, one linker conformation was saved per 100 fs, 
resulting in 1,000 unique linker conformations in total. Each linker peptide sequence 
included the Cys63 and Cys72 residues of the preceding and following SCR domains 
respectively. Using a Biosym Command Language script within INSIGHT II 
software, a total of 1000 CR2 SCR 1-2 models was created by superimposition of the 
linker Cys residues onto those in the SCR 1 and SCR 2 domains. Duplicate atoms 
were then removed. To complete the creation of the model for the expressed CR2 
SCR 1-2 protein, an N-terminal peptide (residues EAE) was manually added to the 
N-terminus of the SCR 1 model (residues AIS) using the BIOPOLYMER module of 
INSIGHT 98.0. The C-terminal peptide corresponded to only the residues EQKLIS, 
assuming that part of the myc-tag and His-tag in the remaining C-terminal peptide 
(residues EEDLNSAVDHHHHHH) were removed during fermentation (Guthridge
103
et al, 2001a). This sequence was added to the C-terminus of SCR 2 as follows. A 
conformational library of 5,000 C-terminal peptides was generated, starting from a 
p-strand conformation made using BIOPOLYMER. A molecular dynamics 
simulation using DISCOVER3 randomised this starting model. In order to generate a 
wide range of structures, the simulation was performed at a high temperature of 773 
K. First, the peptide structure was subjected to energy minimisation for 300 
iterations. After a temperature equilibration step of 5,000 fs, the simulation was run 
at 773 K for 500,000 fs, capturing models every 100 fs to produce 5,000 o f these. A 
random selection o f 199 linkers from the library of 1,000 was combined with every 
tenth C-terminal peptide tail (500 in all) to create 9,950 models for the CR2 SCR 1-2 
structure.
To model dimeric C3d, dimers o f C3d were created from its crystal structure 
(PDB code lghq) by performing symmetry operations about each o f the 307 cx- 
carbon atoms in C3d. At each one, three putative dimers were formed by 180° 
inversions of the C3d structure along the x-, y- and z-axes using a Biosym Command 
Language script. Scattering curves were calculated for the 921 models, and these 
were ranked using R factors in order to identify the best fit dimer.
For modelling the CR2 SCR l-2/C3d complex, the 9,950 models for the free 
protein were superimposed onto that seen in the crystal structure using the SCR 2 
non-hydrogen atoms, then the crystallographic CR2 SCR 1-2 structure was deleted. 
As controls to evaluate the effect o f the C-terminal tails, models were also made in 
which the N-terminal and C-terminal peptide tails were absent.
A small series o f models o f the CR2 SCR l-2/C3d complex based on the 
results of point mutation studies (Hannan et al, 2005) was created manually by 
rotating bonds within the SCR 1-2 linker region o f the crystal structure using the 
Insight Biopolymer module.
In order to calculate the scattering curves, Debye sphere models were 
created by placing each coordinate model within a three dimensional grid o f cubes, 
where each cube side is of length 0.523 nm for CR2 SCR 1-2 and 0.571 nm for the 
C3d complex. Provided that the number of atoms within a given cube exceeded a
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user-defined cutoff, a sphere of the same volume as the cube (sphere diameter 0.648 
nm for CR2 SCR 1-2 and 0.708 nm for the C3d complex) was placed at the centre o f 
the cube. For the C3d monomer and dimer, the sphere diameters were 0.652 nm and 
0.672 nm respectively. This cutoff was determined by the requirement that the total 
volume of spheres in each model was within 1% of the dry volume o f 20.1 nm and
65.3 nm3 for CR2 SCR 1-2 and the C3d complex respectively, calculated from its 
amino-acid and carbohydrate composition (Perkins, 1986). This resulted in totals of 
140 and 346 dry spheres for CR2 SCR 1-2 and the C3d complex respectively. X-ray 
scattering modelling requires the addition of a hydration shell. A hydration o f 0.3 g 
H2O / g glycoprotein and an electrostricted volume o f 0.0245 nm3 per bound water 
molecule gave hydrated volumes o f 28.4 nm3 and 91.9 nm3 for CR2 SCR 1-2 and the 
C3d complex respectively (Perkins, 1986; Perkins, 2001). This shell was modelled 
using the HYPRO procedure (Ashton et al, 1997), in which excess spheres was 
added to the surface o f the dry sphere model, and these were sequentially removed 
until the desired hydration volume o f 207 and 460 spheres had been reached for CR2 
SCR 1-2 and the C3d complex respectively.
The X-ray scattering curve I(Q) was calculated assuming a uniform 
scattering density for the spheres using the Debye equation as adapted to spheres 
(Perkins & Weiss, 1983; Boehm et al, 1999). The X-ray curves were calculated from 
the hydrated sphere models without corrections for wavelength spread or beam 
divergence as these are considered to be negligible for synchrotron X-ray data. 
Ordinarily the number of spheres N  in the dry and hydrated models after grid 
transformation was used to assess any potential steric overlap between the SCR 
domains and C3d, where models showing less than 95% of the required total were 
discarded (a 5% filter). In practise, this was found to be ineffective for reason of the 
relatively narrow size of the SCR domains. Thus a-carbon views of the 200 models 
were visually checked to ensure the absence o f significant overlap. The modelled 
scattering curves were assessed by calculation o f the Rq values from the modelled 
curve in the same Q ranges used for the experimental Guinier fits, in which a filter 
corresponding to ± 5% of the experimental values was applied. Models that passed 
the Rq filters were then ranked using a goodness-of-fit R factor defined by analogy
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with protein crystallography and based on the experimental curves in the Q range 
extending to 2.0 nm '1 (Smith et al, 1990).
Procedures for hydrodynamic simulations based on sphere models have been 
tested (Smith et al, 1990; Perkins et al, 1993). The GENDIA program was used to 
calculate the s°2o,w values starting from the hydrated CR2 SCR 1-2 and C3d models 
(Garcia de la Torre & Bloomfield, 1977a, 1977b).
(4.4.S) Protein Data Bank accession number
The six best-fit CR2 SCR 1-2 models and the six best fit models for the CR2 
SCR 1-2 complex with C3d has been deposited in the Protein Data Bank as a-carbon 
co-ordinate positions with the accession numbers lw 2r and lw2s respectively.
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Chapter Five
Extended flexible linker structures in the complement chimaeric conjugate 
CR2-Ig by scattering, analytical ultracentrifugation and constrained modelling: 
implications for function and therapy
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(5.1) Introduction
An opportunity to study the SCR 1-2 linker in glycosylated CR2 resulted 
from the creation of a chimaeric CR2 SCR 1-2 antibody (Figures 5.1 and 5.2), in 
which CR2 SCR 1-2 was fused with the Fc fragment o f mouse IgGl and expressed 
in NS/0 nonsecreting myeloma cells (Materials and Methods).
Chimaeric antibodies have industrial importance as therapeutic reagents. 
Several o f these Fc-SCR domain fusion proteins have already been created with a 
view to a possible medical use, including DAF-Ig, CD59-Ig, and (CR2)2-IgGl 
(Harris et al, 2002; Hebell et al 1991). It is hoped that these molecules are the 
beginnings of a new generation o f drugs for complement related disorders with 
negligible systemic effects, and which are capable o f being targeted directly to the 
area of inflammation. Indiscriminate inhibition o f the complement system is not 
desirable as the lack of a complement system severely affects host defence functions 
and the homeostasis o f the immune system as a whole. Severe deficiencies are 
associated with an increased susceptibility to infection and also to endotoxin due to 
impaired immune complex clearance. Local inhibitors are therefore much preferable. 
The chimaeras above have been shown to be functionally active, and (CR2)2-IgGl 
was able to compete with the cellular receptor, suppressing the antibody response 
(Hebell et al, 1991). A CR2-Ig chimaera has utility because the SCR 1-2 domains 
have the potential to block all o f the major ligands described for CR2 including C3b, 
iC3b, C3(H20), C3d, Epstein-Barr virus gp350, CD23 and IFNa (Hebell et al, 1991). 
There is also the possible use o f CR2 chimaeras to target molecules to sites of 
complement activation, which presumes that the bivalent CR2-Ig structure might be 
better than some monomeric chimaeras (Song et al, 2003).
In the crystal structure o f the CR2 SCR l-2/C3d complex, CR2 SCR 1-2 was 
seen to form symmetrical tip-to-tip dimers. The interaction is mainly mediated 
through hydrogen bonds between an aspartic acid residue found at the N-terminal 
end of the long-axis o f SCR 1. The dimerisation o f CR2 SCR 1-2 has not been 
observed in solution and may be an artefact of crystallisation. The proximity o f the 
two CR2 SCR 1-2 arms o f CR2-Ig provides an ideal situation in which to be able to 
investigate this apparent dimerisation.
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As the Fc fragment is relatively rigid in the CR2-Ig chimaera, the application 
o f solution scattering, analytical ultracentrifiigation, and a constrained modelling 
procedure to CR2-Ig provides information on the structure of both the linker 
between SCR 1 and SCR 2 and the linker joining SCR 2 to the Fc fragment. By this, 
it is shown that the solution properties o f glycosylated CR2-Ig correspond to an 
open, V-shaped, flexible conformation o f the CR2 SCR 1-2 domain pair, in 
confirmation o f previous studies (Guthridge et al, 2001a; Gilbert et al, 2005 
(Chapter 4)). In comparison with earlier solution studies o f another chimaeric 
antibody Crry-Ig (Aslam et al, 2003), further insight is obtained into the 
conformational properties o f these structures, in particular an assessment o f the 
possible significance o f the role o f the light chain in determining antibody 
conformations. The immunological implications o f this structure are discussed.
(5.2) Results and discussion
(5.2.1) X-ray scattering data for CR2-Ig
The preparations of CR2-Ig for scattering and ultracentrifugation resulted in a single 
clean band when analysed by SDS-PAGE and a homogenous peak when purified by 
size exclusion chromatography to remove aggregates. X-ray solution scattering 
experiments were performed on CR2-Ig in the concentration range between 4.1 and
12.4 mg m l'1 in PBS (Materials & Methods). Guinier Rq fits were linear in an 
appropriate Q.Rg range up to 1.6 (Figure 5.3(a)), where Q = 4n sin 0 / X (20 = 
scattering angle; X = wavelength). Inspection of the 10 time frames obtained during 
data acquisition showed slight radiation damage effects for CR2-Ig during the 10 
min acquisition through a gradual increase in intensities at the lowest Q values. The 
final analyses circumvented these effects by excluding data points at the lowest Q 
values (Figure 5.3(a)). In confirmation o f this, the 7(0)/c values were constant across 
the concentration range. The mean X-ray Rq value o f CR2-Ig corresponds to 5.39 ± 
0.14 nm (Figure 5.3(a)). The anisotropy ratio is Rg/Ro, where Ro is the Rq o f the 
sphere of volume equal to that o f the hydrated protein. For typical globular proteins, 
Rg/Ro is approximately 1.28 (Perkins, 1988). For CR2-Ig, Rg/Ro was determined as 
2.03, showing that CR2-Ig is highly extended in its solution structure. In comparison 
with CR2 SCR 1-2, the X-ray Rq is 2.12 ± 0.12 nm and its Rg/Ro ratio is 1.51, thus 
CR2-Ig is more elongated than CR2 SCR 1-2. This is as expected from the layout in
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CR2 SCR 1-2
26
Asn108 Asn108rs-si-S-S- Asn102 
i5-S-
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Asn226 FCAsn226
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Figure 5.1
Schematic diagram of CR2-Ig in order to show its domain structure. Each SCR or Ig 
domain is denoted by an ellipse. Presumed N-linked glycosylation sites at Asnl02, 
Asnl08, Asn226 and Asn330 are marked by vj/ symbols. The number o f residues in 
the linkers is shown adjacent to each one. Note that the residue numbering is shifted 
by one compared with that in Figure 4.1.
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Figure 5.2
The amino acid sequence of one chain of CR2-Ig is numbered as shown. The residues shown in red are from human CR2 SCR 1-2 
(SWISSPROT entry P20023 residues 21-153). The N-linked glycosylation sites are shown in bold and underlined. Three Cys residues in the 
hinge region that form disulphide bonds between the two chains of CR2-Ig are also shown in bold and underlined, as is the Factor Xa cleavage 
site in the linker region between the CR2 and Fc moieties.
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Figure 5.3
Guinier Rq and Rxs analyses of X-ray (a, c) and neutron (b, d) solution scattering 
data for CR2-Ig. The Rxs analyses curves in (c) and (d) are arbitrarily displaced on 
the intensity axis for clarity. The filled circles correspond to the data points used to 
obtain Rq or Rxs values and the straight lines correspond to the best fit through these 
points. The Q .R q  and Q.Rxs ranges are arrowed.
(a, b) The R q  analyses for CR2-Ig employed a Q  range of 0.16-0.29 nm '1. The X-ray 
curves correspond to sample concentrations of 8.2 mg m l'1 and 4.1 mg m l'1, while 
the neutron curves correspond to concentrations of 5.4 mg m l'1 and 8.1 mg m l'1.
(c, d) The X-ray and neutron Rxs analyses for CR2-Ig employed a Q range of 0.30- 
0.48 nm '1.
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the schematic cartoon of Figure 5.1, and suggests that the two glycosylated CR2 
SCR 1-2 fragments are independent of each other in solution even though they are in 
proximity to each other. This is relevant as the crystal structure o f deglycosylated 
CR2 SCR 1-2 in complex with C3d had suggested that CR2 SCR 1-2 may dimerise 
as the result o f intermolecular contacts within the crystal lattice (Szakonyi et al, 
2001).
The cross-sectional radius o f gyration Rxs value may monitor short-range and 
long-range interdomain orientation between adjacent SCR domains (Aslam et al, 
2003; Aslam & Perkins, 2001). The mean X-ray Rxs value of CR2-Ig corresponds to
2.18 ± 0.07 nm (Figure 5.3(c)). This is larger when compared to the Rxs  value o f 1.0 
± 0.1 nm for CR2 SCR 1-2. The difference in Rxs value between CR2 SCR 1-2 and 
CR2-Ig is larger when it is compared to that o f 1.5 ± 0.1 nm for rCrry with five SCR 
domains and 1.3 ± 0.1 nm for mCrry-Ig with ten SCR domains (Aslam et al, 2003). 
This difference is attributable to a dominant contribution made by the Fc fragment to 
the scattering curve of CR2-Ig as well as contributions from eight oligosaccharide 
chains (Figure 5.1). It implies that in this instance the Rxs value is not able to 
monitor inter-SCR domain arrangements for reason o f contributions from SCR-Fc 
fragment arrangements, in particular those when the SCR and Fc fragments are close 
to each other.
The indirect transformation o f the scattering data I(Q) in reciprocal space into 
real space gives the distance distribution function P(r), which represents all the 
distance vectors between pairs o f atoms within CR2-Ig. This gives an different 
calculation o f the R q  and 7(0) values that is based on the full scattering curve in the 
Q range between 0.013 nm’1 to 2.2 nm '1, and gives the maximum dimension o f CR2- 
Ig, denoted L. The P(r) curve showed a single peak with a maximum M  at an r of 
value o f 4.42 nm. This is of interest as two P(r) peaks M\ and Mi have been reported 
in the case o f the IgAl and IgA2 antibodies and the Crry-Ig chimera (Aslam et al, 
2003; Boehm et al, 1999; Furtado et al, 2004). This double peak was attributed to 
the relatively rigid hinges and T-shaped structures in the cases of IgAl and IgA2 and 
the existence of two independent Crry antennae in the case of Crry-Ig. A single P(r) 
peak for CR2-Ig can be attributed to either the existence of an appropriate single 
conformation in solution that leads to this, or to a high degree of hinge flexibility
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that results in multiple SCR arrangements in solution and a loss of detail in the P{r) 
curve (Sun et al, 2005). The maximum dimension from the P(r) curve corresponds to 
a L value of 17 nm (Figure 5.4(b)). The Rq values calculated using GNOM were in 
good agreement with the Guinier value calculated by Guinier fits (data not shown). 
In comparison with CR2 SCR 1-2 (Figure 5.4(a)), M is  2.1 nm and L is 10 ± 0.5 nm. 
By this comparison, CR2-Ig is more extended than CR2 SCR 1-2, in agreement with 
the Rg/Ro analysis.
Crystal and NMR structures for 32 single SCR domains show that the average length 
is 3.6 ± 0.2 nm (Aslam et al, 2003). Two SCR domains would be of length 7.2 nm, 
while crystal structures for the Fc fragment are o f length 6.3 nm. If  the solution 
structure of CR2-Ig consists of two SCR arms that are vertical and parallel to each 
other at the top of the Fc fragment, as viewed in Figure 5.1, its length would be 7.2 
nm + 6.3 nm or 13.5 nm. If the two SCR arms were fully extended away from each 
other in a T-shaped structure, and the Fc fragment is disregarded, its maximum 
length would be 14.4 nm. As the observed values of L are greater at 17 nm, this 
suggests that the linkers between SCR 1 and SCR 2 and between SCR 2 and the Fc 
fragment are responsible for generating a structure that is even more extended than 
that deduced from the known sizes of the four SCR domains and one Fc fragment in 
CR2-Ig.
(5.2.2) Neutron scattering data for CR2-Ig
Neutron scattering experiments were performed on native CR2-Ig at 
concentrations between 2.2 to 14.3 mg ml"1, in PBS buffer in 2H20 (PBS: phosphate 
buffered saline; with or without 200 mM KC1, Materials & Methods) using 
Instrument D ll  at the ILL and Instrument LOQ at ISIS. Neutrons were used as a 
control for the absence of radiation damage effects on the scattering curve that were 
encountered with X-rays. The first measurements on CR2-Ig samples at D 11 showed 
that they were aggregated, even in the presence of 200 mM KC1. This was attributed 
to the use of FLO buffers which is a promoter of aggregation of glycoproteins. 
Subsequent measurements on LOQ with CR2-Ig at lower concentrations resulted in 
reduced aggregation, and this resulted in successful Guinier analyses although the 
data at the smallest Q  values could not be used (Figure 5.3(b)). The R q  value was 
determined to be 5.29 ± 0.01 nm, which is in good agreement with the X-ray R q  
analyses of 5.39 ± 0.14 nm, but is 2% less as neutrons observe an unhydrated
114
(a) CR2 SCR 1-2 (X-ray)100
(b) CR2-lg (X-ray)100
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Figure 5.4
X-ray and neutron distance distribution functions P(r) for CR2 SCR 1-2 in 
comparison with those for CR2-Ig. The maximum of the P(r) curve is denoted by M, 
the most frequently occurring distance within the protein, and L denotes its 
maximum dimension.
(a) The X-ray analysis for CR2 SCR 1-2 gave an M  value of 2.1 nm and an L value 
o f 10 nm. (b) The X-ray analysis for CR2-Ig gave an M  value of 4.4 nm and an L 
value of 17 nm. (c) The neutron analysis for CR2-Ig gave an M  value of 4.3 nm and 
an L value of 17 nm.
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macromolecule compared to X-rays which observe the hydrated structure (Perkins, 
2001). The molecular weight of CR2-Ig was calculated from the l(0)/c value of 
0.118 ± 0.008 (referenced to a deuterated polymer) for data obtained between 2.5 mg 
m l'1 and 8.1 mg ml*1 from the relationship MW = 9 x 106 x /(0)/c (Boehm et al, 
1999). A value of 107,000 ± 7,000 Da was determined. This is in good agreement 
with the sequence-derived molecular weight of 106,600 Da based on an assumption 
that eight triantennary complex-type oligosaccharide chains are present in CR2-Ig 
(Figure 5.1). This agreement verified both the Guinier X-ray and neutron analyses. If  
eight biantennary chains were present, the molecular weight would be decreased by 
5,200 Da.
The neutron Guinier Rxs value was determined using the same Q range used 
in the X-ray analyses to be 1.93 ± 0.12 nm (Figure 5.3(d)). This is 9% smaller than 
the X-ray Rxs value of 2.18 ± 0.07 nm. The larger difference between the X-ray and 
neutron Rxs values than that between their R q  values is attributed to the nature o f the 
hydration shell. As a monolayer o f water molecules will be o f approximate thickness 
0.28 nm, and as the R q  and Rxs values are dominated by the overall length o f the 
protein and its cross-sectional dimensions respectively, it can be seen that the 
addition of a 0.28 nm thick hydration shell will have a disproportionate effect on the 
Rxs values.
The neutron P(r) analysis for CR2-Ig is in good agreement with the X-ray 
analyses, and show that both scattering data sets have monitored the solution 
structure of CR2-Ig. The neutron GNOM analysis (Figure 5.4(c)) gave a maximum 
dimension, Z, o f 17 nm and the most frequently occurring distance M  is 4.25 nm, 
both of which are in agreement with the X-ray values.
(5.2.3) Sedimentation equilibrium and velocity data for CR2-Ig
In order to demonstrate that CR2-Ig is monomeric in solution, sedimentation 
equilibrium experiments were performed for CR2-Ig at three concentrations between 
0.3 mg ml*1 and 1.5 mg m l'1 in PBS buffer (Materials & Methods). Absorbance data 
monitored at 280 nm showed that the averaged molecular weight o f CR2-Ig was
106,000 ± 7,000 Da from samples at 0.3 mg ml*1 and 0.5 mg ml*1 measured at three 
rotor speeds of 11,000 rpm; 14,000 rpm; 17,000 rpm (Figure 5.5(a)). Interference
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Figure 5.5
Sedimentation equilibrium analyses for CR2-Ig by analytical ultracentrifugation, (a) The best-fit curve analysis for CR2-Ig at 0.50 mg m l'1 at a 
rotor speed of 14,000 rpm using absorbance optics. This resulted in a MW of 106,000 Da. The residuals of the curve fit
shown in the upper panel are randomly distributed, (b) The corresponding analysis for CR2-Ig based on interference optics at a rotor speed of
14,000 rpm, from which a MW of 101,000 Da was determined.
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data gave an averaged molecular weight o f CR2-Ig o f 101,000 ± 6,000 Da from 
samples at 0.5 mg m l'1 and 1.5 mg m l'1 measured at rotor speeds o f 11,000 rpm and
14,000 rpm (Figure 5.5(b)). Both values agree well with the composition-derived 
value of 106,600 Da, although the presence o f some biantennary chains cannot be 
ruled out from these determinations. The residuals showed random distributions, 
indicating that the CR2-Ig samples were well analysed as a single monodisperse 
species.
The sedimentation coefficient s°2o,w monitors macromolecular elongation and 
provides complementary structural data on CR2-Ig that is independent o f the Rq 
value. Velocity experiments were performed at 35,000 rpm and 42,000 rpm using 
CR2-Ig samples at concentrations between 0.4 mg ml"1 and 2.1 mg ml"1 in PBS 
buffer. Analysis using the g(s*) method to analyse pairs o f scans showed that the 
s°20,w value was 4.42 S from the peak positions in Figure 5.6. The mean absorbance 
s°20,w value was determined to be 4.49 ± 0.11 S from two concentrations at two rotor 
speeds. This was indistinguishable from the mean interference s°2o,w value o f 4.48 ± 
0.15 S from three concentrations at two rotor speeds. The s°2o,w value for CR2 SCR 
1-2 was 1.40 ± 0.03 S (Gilbert et al, 2005). By analogy with the Rg/Ro anisotropy 
ratios of 1.51 and 1.98 for CR2 SCR 1-2 and CR2-Ig, the frictional coefficient 
anisotropy ratios f/fo were computed to be 1.36 and 1.60 respectively. It was 
gratifying that the relative magnitudes o f the f/fo ratios agreed with those determined 
from the Rg/Ro ratios.
(5.2.4) Constrained modelling of the domain arrangement in CR2-Ig
Constrained molecular modelling o f the X-ray and neutron scattering data 
was performed in order to determined structures at medium structural resolutions. 
Crystal structures for CR2 SCR 1-2 and the mouse IgGl Fc fragment were used to 
represent the five globular moieties (Figure 5.1) (Szakonyi et al, 2001; Harris et al, 
1998). Oligosaccharide chains were added to the eight N-linked glycosylation sites 
(Materials and Methods) (Figures 5.1 and 5.2). These were orientated to point away 
from the protein surface in extended conformations. This leaves undefined the two 
pairs of two linkers o f unknown conformation, the first o f which possesses eight 
residues and the second has 26 residues. Full models for CR2-Ig were generated 
starting from the two crystal structures by the creation of libraries of structurally
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Figure 5.6
Sedimentation velocity fit of the g(s*) distribution for CR2-Ig. This is based on 
scans recorded using absorbance optics at a rotor speed of 35,000 rpm for a sample 
concentration of 0.41 mg ml*1 in PBS. From this, the s°2o,w value was determined to 
be 4.4 S (arrowed).
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randomized peptide conformations for each o f the linker peptides (Materials and 
Methods). After the conversion to Debye sphere models and the hydration o f these 
models, the 5,000 or 20,000 dry (neutron) or hydrated (X-ray) models below were 
then submitted to scattering curve calculations. By the use of filters, the results were 
compared with the experimental data to eliminate the poor fit models. By this 
procedure, the CR2 SCR 1-2 domain arrangements were randomized into all 
orientations, including those in which the domains sterically overlapped with each 
other and with the Fc fragment. This random generation o f all possible orientations 
meant that steric overlap clashes between the domains occurred. Accordingly, after 
removal of the poor fit models, models that showed sterically-overlapping SCR 
domains were rejected by visual inspection. Overlaps between a single SCR domain 
and the remaining CR2-Ig structure would not have been reliably detected by 
computer filters based on the number o f spheres in the models (Aslam et al, 2003).
A total o f four modelling strategies were used with the linkers to create full 
structural models for CR2-Ig in order to explore the assumptions used to fit the 
scattering data. This is summarized:
(1) In the first search, 5000 randomised symmetric models for CR2-Ig were 
created, in which each of the SCR 1-SCR 2 and SCR 2-Fc linker pairs are identical, 
and the disulphide bridges in the hinge were not present. A plot o f the R factors (the 
goodness of agreement between calculated and experimental curves) against the X- 
ray and neutron Rq values provided a summary o f this search (Figure 5.7). The R 
factors were relatively high. A 15% filter for the Rq and Rxs values showed that only 
14 models jointly satisfied the X-ray and neutron values, and very few models 
corresponded to Rq values close to 5 nm. The visual comparison o f the best fit 
modelled and the experimental scattering curves showed a pronounced inflexion that 
was located at variable Q positions between 0.4 -  0.6 nm '1 in the modelled curves 
that was not present in the experimental one (Figure 5.8).
(2) The second search generated another 5,000 symmetric models in which 
the three crystallographically-observed disulphide bridges in the hinge were 
connected (Figure 5.2). The R factors were reduced. While the use o f a 10% filter for 
the Rq values and a 15% filter for the Rxs values identified individual best fit X-ray 
models and neutron models, very few o f these jointly fitted both data sets (Figure
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Figure 5.7
A summary of the X-ray and neutron analyses for the 5,000 models from search one. 
(a,b) The open circles denote the models that did not fit the experimental criteria. 
The 14 models that satisfied the 15 % filters on Rq and Rxs for both the X-ray and 
neutron data simultaneously are shown with red filled circles.
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Figure 5.8
X-ray scattering 7(g) curves to show the pronounced inflexion seen in the curve fits 
from the first three modelling searches, (a) The open circles denote the experimental 
X-ray scattering curve, while the continuous line shows the modelled curve. The 
inflexion can clearly be seen at 0.5 nm '1. An a-carbon ribbon trace o f the model is 
shown. The modelled P(r) curve is shown as an inset to the right for comparison 
with Figure 5.4. (b) The continuous line shows the X-ray scattering curve calculated 
from the IgGl Fc fragment (seen in the a-carbon ribbon trace). Comparison o f the Fc 
scattering curve with the experimental and modelled curves in (a) shows the 
contribution of the Fc portion o f the molecule to the overall I(Q) curve. The P(r) 
curve is shown as an inset to the right.
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Figure 5.9
A summary of the X-ray and neutron analyses for the 5,000 models from search two. 
The open circles denote models that did not fit any of the experimental criteria, (a) 
The coloured circles show all of the models that satisfied a 10% filter on the 
experimental X-ray R q  value. The blue circles represent the eight models from that 
set with the lowest X-ray R factors. The green circles show the eight models with the 
lowest neutron R factors. The two yellow circles denote the only models to be satisfy 
both the X-ray and neutron experimental criteria to within 10% of the R q  values, (b) 
The coloured circles show all of the models that satisfied a 10% filter on the 
experimental neutron R q  value. The blue circles represent the eight models from that 
set with the lowest X-ray R factors. The green circles show the eight models with the 
lowest neutron R factors. The two yellow circles denote the only models to be satisfy 
both the X-ray and neutron experimental criteria to within 10% of the R q  values.
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5.9). The visual comparison of the best fit modelled and the experimental scattering 
curves again showed a pronounced inflexion (Figure 5.8). This search failed again to 
identify a range of best fit structures.
(3) The third search relaxed the requirement o f symmetry in the second 
search by the creation of 5,000 asymmetrical CR2-Ig models in which all four 
linkers were different. The R factors were slightly reduced again. However the use of 
a 10% filter for the R q  and Rxs values resulted in the identification o f only four 
models that gave joint good fits to both the X-ray and neutron data, and the R factors 
for these were not the lowest (Figure 5.10) The visual comparison o f the best fit 
modelled and the experimental scattering curves showed a pronounced inflexion 
(Figure 5.8).
(4) The fourth search assumed that the linker between SCR 1 and SCR 2 
corresponded to our previously-determined best-fit conformation o f an open V- 
shaped structure for free CR2 SCR 1-2 (Gilbert et al, 2005), and this conformation 
was held fixed in order to improve the likelihood of obtaining best-fit structures. 
This was the previous best strategy used to fit the mCrry-Ig solution structure 
(Aslam et al, 2003). Two different randomised SCR 2 - Fc linkers were used to 
create 20,000 asymmetric models for CR2-Ig. These were jointly tested against the 
X-ray and neutron data. The X-ray R q  values o f the 20,000 hydrated models ranged 
between 3.02 nm to 5.53 nm. These were similar to or less than the experimental X- 
ray R q  value of 5.39 ± 0.14 nm as required (Table 5.1). Likewise the Rxs values 
ranged between 0.06 nm to 2.69 nm, and these spanned the experimental value of
2.18 ± 0.07 nm. A plot o f the R factors against the X-ray R q  values showed that the 
lowest R factors corresponded to R v a lu e s  close to 5 nm (Figure 5.11(a)). Hence 
Figure 5.11(a) showed that the 20,000 models had explored a sufficient number of 
possible CR2-Ig conformations. The 43 largest R q  values above 4.98 nm gave 
reasonable R factors while remaining within 10% of the experimental value (Table 
5.1). This set comprised only the most extended CR2-Ig models. Figure 5.12 showed 
that no preferred conformation o f CR2 SCR 1-2 relative to the Fc fragment could be 
identified for these. Nine of these 43 models gave good joint fits with low R factors 
(red and green circles in Figure 5.11(a)). Figure 5.13 showed that all nine showed 
relatively extended arrangements o f CR2 SCR 1-2 structures relative to the Fc 
fragment, and yielded R factors in a range o f 7.5% to 8.1% which are in an
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Figure 5.10
A summary of the X-ray and neutron analyses for the 5,000 models from search 
three. (a,b) The open circles denote the models that did not fit the experimental 
criteria. The 4 models that satisfied the 10 % filters on Rg and Rxs for both the X-ray 
and neutron data simultaneously are shown with red filled circles.
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Filter Models Linker length 
a (nm)
Spheres Rg (nm) Rxs (nm) R factor (%) / (  g/sec) s V ( S ) b
Modelling None 20,000 n.a. 1587-2033 3.02 - 5.53 0.06 - 2.69 6 .1 -2 6 .0 n.a. n.a.
>>ccL. Modelling Rg ± 10% 43 1.56-6.20 1900- 1987 4.98 - 5.53 1.72-2 .66 7.5 - 14.6 8.76 - 9.87 4 .4 6 -4 .8 2
X
Modelling R factor 9 2.06 - 6.20 1927 - 1986 4.98 - 5.20 2 .14-2 .45 7 .5 -8 .1 8.89 - 9.39 4 .5 9 -4 .7 7
Modelling Final model 1 3.76 and 4.57 1927 5.20 2.14 7.8 9.39 4.59
Experimental 1742 5.39 ±0.14 2.18 ±0.07 4.49 ±0.11
Modelling None 20,000 n.a. 1089- 1312 2.93 - 5.22 0.05 - 2.42 4 .2 -2 1 .9 n.a. n.a.
eolm
Modelling Rg ± 10% 43 1.56-6.20 1254 - 1296 4.76 - 5.22 1.62-2 .39 4.2 - 6.9 n.a. n.a.
34>z, Modelling R factor 9 2.06 - 6.20 1266 - 1290 4 .76-4 .91 2.02 - 2.23 4 .2 -4 .7 n.a. n.a.
Modelling Final model 1 3.76 and 4.57 1266 4.91 2.02 4.2 n.a. n.a.
Experimental 1314 5.29 ±0.01 1.93 ±0.12
Table 5.1
Summary of the X-ray and neutron modelling fits for the CR2-Ig solution structure based on the premises of a fixed open CR2 SCR 1-2 
structure and two conformationally independent hinge linker regions.
a The two linkers are conformationally different. Each hinge length is defined as the distance between the a-carbon atoms of Cysl27 and Cysl56, i.e. from 
the C-terminal Cys residue of SCR 2 to the N-terminal residue in the first disulphide bridge of the Fc fragment (Figure 5.2). 
b No filtering was performed using the s°2o,w values.
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Figure 5.11
Summary of the X-ray and neutron analyses for 20,000 models for CR2-Ig from 
search four. The 20,000 R factor values were calculated from the CR2-Ig models 
after comparison with the X-ray and neutron scattering curves and are shown in (a) 
and (b) respectively. The open circles denote models that do not satisfy the 
experimental filters. The 43 circles in three colours correspond to CR2-Ig models 
whose Rq values are within 10 % of the experimental values. The one green and 
eight red circles show the nine best-fit models (Figure 5.13) and the arrowed green 
circle is the best-fit model that gave the most satisfactory Rq and R factor values 
(Figure 5.13(a); Table 5.1).
(a) X-ray
Neutron
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Figure 5.12
Summary of the 43 best-fit models for CR2-Ig from the conformational search of 
20,000 models. The 43 models satisfy the filtering criteria of Table 5.1 and are 
shown superimposed upon the Fc fragment. The CR2 SCR 1-2 structures are shown 
as blue a-carbon traces, while the Fc fragment is shown as a red ribbon trace. Two 
orthogonal views of the 43 CR2-Ig models are shown in which the Fc fragment is 
viewed face-on from its side (upper) or from below (lower).
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Figure 5.13
Molecular graphics views of the nine best-fit models o f CR2-Ig to show the degree 
of conformational variability in the position of the two CR2 SCR 1-2 arms. The two 
polypeptide chains are shown in green and blue. Model (a) gave the best fit to both 
the X-ray and neutron data. The goodness-of-fit R factors from the X-ray fits are 
shown next to each model.
acceptable range (Perkins et al, 1998). The best-fit o f these nine models gave an Rq 
value o f 5.20 nm, which is slightly less than the experimental value o f 5.39 ± 0.14 
nm, and gave a satisfactory R factor o f 7.8%. Its Rxs value o f 2.14 nm is within error 
o f the experimental X-ray value of 2.18 ± 0.07 nm.
The neutron analysis o f the 20,000 dry models followed a similar path to that 
of the X-ray analysis (Table 5.1). Again the most extended models best fitted the 
experimental neutron Rq values and R factors (Figure 5.11(b)), in which the Rq 
values are smaller because o f the absence o f the effect o f hydration. The same 43 
best fit models were identified. The final best-fit neutron model gave an Rq value o f 
4.91 nm, which is slightly less than the experimental value o f 5.29 ± 0.01 nm, and 
gave a satisfactory R factor o f 4.2%. Its Rxs value o f 2.02 nm is within error o f the 
experimental neutron value o f 1.93 ±0 .12  nm.
The X-ray and neutron curve fits o f Figures 5.14(a) and 5.14(b) showed good 
visual agreement between the experimental and calculated scattering curves. The 
pronounced inflexion at Q = 0.4 -  0.6 nm ' 1 in the modelled curve that was prominent 
in the first three searches is now much less apparent, as shown in both Figure 5.14(a) 
and 5.14(b). This agreement corroborated the analyses of Table 5.1. From this fit, the 
modelled P(r) curve was calculated (insets to Figures 5.14(a) and 5.14(b)). This 
showed a major and a minor peak at r = 4.3 nm and 8.9 nm (X-ray) and r = 4.4 nm 
and 9.5 nm (neutron) respectively. Comparison with Figures 5.4(b) and 5.4(c) 
showed that, while the length o f 17 nm was satisfactorily reproduced, only a single 
peak at r = 4.42 nm was observed experimentally in both cases. This difference 
suggests that a single static structure o f the type shown in Figure 5.13(a) is not a true 
indication of the solution structure of CR2-Ig. This, along with the contribution o f 
the relatively large, fixed structure o f the IgGl Fc portion of the molecule, would 
result in the inflexion seen in the modelled curves and the double peak seen in the 
P(r) curve (Figure 5.8). The absence o f these features in the experimental curves 
makes it more likely that CR2-Ig adopts a range o f solution structures, and the 
scattering curves correspond to an averaged assemble of many structures, all 
resembling the structures shown in Figure 5.13.
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Figure 5.14
Final X-ray and neutron I(Q) curve fits for the best fit model of CR2-Ig. The open 
circles denote the experimental scattering curves, while the continuous lines show 
the modelled curves. An a-carbon ribbon trace o f the best-fit model used for both fits 
(taken from Figure 5.13(a) but rotated by 180° about a vertical axis) is shown in the 
lower panel, in which the Fc fragment is in red and the two CR2 arms are in blue. 
The modelled P(r) curves are shown as insets to the right for comparison with Figure 
5.4.
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Sedimentation coefficients were calculated for the best CR2-Ig models using 
the HYDRO and HYDROPRO programs (Materials and Methods). HYDROPRO is 
based on the molecular models for CR2-Ig (Figure 5.12), and was found to give a 
better account of the experimental s°2o,w value than HYDRO which is based on the 
hydrated sphere models used for the X-ray modelling. All 43 models gave predicted 
s°2o,w values close to the experimental value o f 4.49 ± 0.11 S (Table 5.1). The best-fit 
scattering CR2-Ig model gave a predicted s°2o,w value o f 4.59 S by HYDROPRO. 
HYDRO returned slightly higher values, giving one o f 4.96 S for the best fit model 
(Figures 5.13(a) and 5.14(b)). It was concluded that the three independent structural 
analyses of X-ray and neutron scattering and sedimentation modelling are mutually 
self-consistent with each other. This validated the structural analyses.
(5.3) Conclusions
The structure determination for CR2-Ig has provided useful insights on the 
solution structures o f proteins o f the SCR superfamily, the most abundant domain 
type in the complement proteins. Both the experimental data and the modelled CR2- 
Ig structure show that the CR2 SCR 1-2 entity possesses an open SCR structure 
which is probably V-shaped, and is fully independent o f the second CR2 SCR 1-2 
entity in the same molecule (Figure 5.15(a)). This results confirms the previous 
ultracentrifugation and scattering analyses o f CR2 SCR 1-2 which was shown to be 
monomeric in solution (Guthridge et al, 2001a; Gilbert et al, 2005), but with the 
important difference in that CR2 SCR 1-2 is now glycosylated. Both crystal 
structures for deglycosylated CR2 SCR 1-2 had suggested that the two SCR domains 
were folded back upon each other, and one structure suggested that CR2 SCR 1-2 
was able to dimerise (Szakonyi et al, 2001; Prota et al, 2002). Our results suggest 
that dimerisation is more likely to result from the intermolecular interactions present 
in the crystallographic unit cell. The modelling results emphasize the high flexibility 
of the CR2-Ig structure. This is partly explained by the eight residues present in the 
inter-SCR linker peptide, which are most commonly three or four residues in length 
(Aslam et al, 2003).
132
(a) CR2-lg (b) Crry-Ig
(c) lgG2a (d) lgG1
Figure 5.15
Comparison of the solution structures of CR2-Ig and Crry-Ig with the crystal 
structures of murine IgG2a and IgGl. The protein main chains are depicted as 
ribbons. The Fc fragments in all four models are shown in dark green. The light 
chains in IgG2a and IgGl are shown in blue. Both IgG2a and IgGl are orientated as 
shown to clarify their relationship with their hinge peptide. The Fc fragment is 
accordingly less visible in (c) and (d). The oligosaccharide chains are shown as red 
spheres.
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The solution structure of CR2-Ig also provides useful insights on antibody- 
type proteins that are formed from two identical fragments connected to a single 
central fragment by two identical hinges. Its most distinctive feature is the length o f 
its hinge peptide. This was modelled as 26 residues (Figure 5.1), but it is 39 residues 
in length if  it is defined in the same way as those found in IgA l, IgA2 and IgD.
Constrained scattering modelling has shown that the monomeric human 
IgAl, IgA2 and IgD antibody classes are flexible T-shaped structures in solution, 
and this corresponds to a single family o f related structures (Boehm et al, 1999; 
Furtado et al, 2004; Sun et al, 2005). The main difference between these three wild- 
type antibodies and CR2-Ig is that no such single family o f related structures could 
be identified for CR2-Ig. Curve fit algorithms based on two-fold symmetry were 
successful for IgAl, IgA2 and IgD, but much less so for CR2-Ig (see Searches 1 and 
2 above). When the assumption o f two-fold symmetry was relaxed, a sufficient 
number of good models resulted and fitted the scattering data (Search 4). A high 
degree of flexibility was indicated by the 43 best-fit CR2-Ig structures o f Figure 
5.12. This is attributable to the 39-residue length o f the hinge. Even though the 
antibody hinge peptide is as long as 64 residues in the case o f human IgD, the IgD 
scattering modelling showed reduced hinge flexibility, most possibly because of the 
O-glycosylation of part of its hinge (Sun et al, 2005). This is likewise thought to be 
the case for the 23 residues o f the O-glycosylated IgAl hinge (Boehm et al, 1999). 
The absence of the equivalent to the two light chains present in IgA l, IgA2 and IgD 
may also contribute to a higher degree o f mobility in CR2-Ig. This is suggested from 
the comparison between Figures 5.15(a,b) and Figures 5.15(c,d). The absence of the 
light chains would favour a greater mobility of the CR2 and Crry fragments about 
the hinge o f CR2-Ig and Crry-Ig.
CR2-Ig is a model system for chimaeric antibodies, and the comparison with 
the Crry-Ig chimaera is instructive (Aslam et al, 2003). In Crry-Ig, each Crry entity 
has five SCR domains. The CR2-Ig linker peptide is 39 residues in length between 
the C-terminal Cysl27 of SCR 2 and the N-terminal Seri 67 of the Fc fragment 
(bolded and underlined)
(CVSVFPLEGSIEGRGGSELADPEVPRDCGCKPCICTVPEVS). For the 
constrained modelling, only the 28-residue linker between Cysl27 to Cysl56
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(bolded and underlined) was conformationally randomised. This is similar in length 
to the 25 residues in the randomised linker peptide o f Crry-Ig 
(CVSRLADPEVPRDCGCKPCICTVPEVS). In this sense, both studies are 
comparable. Neither of these modellings resulted in the identification o f a single 
structural family that was identified for the wild-type antibodies. However CR2-Ig is 
expected to show a greater degree o f hinge flexibility than Crry-Ig. This assumption 
is supported by the views of the constrained modelling (Figure 5.12) as well as the 
single peak seen in the P(r) curve (Figure 5.4). A similar outcome in terms o f 
structural views o f the Crry-Ig chimaera was obtained (Aslam et al, 2003). Crry-Ig 
showed two peaks in the P{r) curve, indicating that its structure is less flexible than 
that of CR2-Ig. This can be explained in terms o f the shorter SCR-SCR linkers 
between the five SCR domains as well as the shorter SCR-Fc linker in Crry-Ig. For 
CR2-Ig, this higher flexibility may imply that the Factor Xa site in the CR2-Ig hinge 
would be less susceptible to enzymatic cleavage because o f its high conformational 
variability and the need to adopt the correct conformation to enable Factor Xa to 
bind. The cleavage of the IgAl hinge by bacterial proteases may benefit from a 
relatively rigid IgAl hinge structure (Boehm et al, 1999). More interestingly Figure 
5.15(a) suggests that the two oligosaccharide chains at A snl02 and A snl08 are 
positioned on SCR 2 in such a way that they could partially mask access to the 
Factor Xa cleavage site. Preliminary experiments with Factor Xa to explore this 
suggest that the glycosylated protein was not readily cleaved, but a bacterial version 
of CR2 is (J.M. Guthridge, J.P. Hannan, and V.M. Holers, unpublished 
observations.) Another implication of this flexibility is to make the binding sites on 
the CR2 SCR 1-2 entity of CR2-Ig more accessible to their ligands than in the case 
o f Crry-Ig. In contrast, there may be good immunological reasons to reduce the 
flexibility o f the hinges in the cases of wild-type antibodies such as IgA l, IgA2 and 
IgD in terms of better control o f the accessibility o f antigens to their Fab fragments. 
These considerations show that the rational design o f hinge flexibility may be an 
achievable goal, and this may bring therapeutic or immunological benefits.
Chimaeric antibodies are important in biotechnology through their ability to 
double the effective concentration o f a protein ligand binding site, and to couple this 
with antibody effector function. The therapeutic utility o f CR2-Ig resides in its 
potential to block C3d-CR2 interactions. Another version of the CR2-Ig molecule
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blocks primary immune responses in vivo (Hebell et al, 1991), while recombinant 
CR2 SCR 1-2 proteins have been shown to be effective in blocking EBV-induced 
lymphoproliferative disease in mice (Moore et al, 1991). In addition to this potential 
o f a CR2-Ig chimaera as an inhibitor/immune modulator for immune responses 
where CR2 is important, there is also the possible use o f CR2 chimaeras to target 
molecules to sites o f complement activation. This was demonstrated by the use o f a 
monovalent CR2 chimera in which CR2 was conjugated with decay acceleration 
factor (Song et al, 2003). The utility o f a CR2-Ig chimera is that a bivalent molecule 
is created, and the conjugation o f CR2-Ig to other antibodies may provide better 
opportunities to target other molecules in a similar way. The rational design o f these 
therapeutic antibody-based molecules is much facilitated by solution structural 
studies o f the type described here and elsewhere that enable these structures to be 
visualized (Aslam et al, 2003).
(5.4) Materials and methods
(5.4.1) Expression and purification of the CR2-Ig chimaera
The human CR2 SCR 1-2 domains (corresponding to residues 21-153 in the 
SWISSPROT entry P20023) were cloned by Dr. J.M. Guthridge and Prof. V.M. 
Holers into a vector that contains a very strong CMV promoter and a CD5 signal 
peptide followed by a Notl cloning site (Quigg et al, 1998). The CR2 SCR domains 
and linker (residues 2-136 in Figure 5.2) were produced in frame with the hinge and 
the CH2 and CH3 domains o f mouse IgGl immunoglobulin (residues 137-376 in 
Figure 5.2). Amino acid 1 in Figure 5.2 is derived from the vector signal peptide. 
The chimaeric protein contained an engineered Factor Xa protease cleavage site at 
Argl40-Glyl41 to enable the removal o f the mouse IgGl Fc domains if  desired. 
This vector was transfected into NS/0 nonsecreting myeloma cells, and transfectants 
expressing recombinant protein were selected for using the antibiotic G418 and 
screened for secretion levels by a standard anti-mouse IgGl ELISA. Typical 
production levels o f CR2-Ig were between 60 and 70 mg/litre. Functional CR2-Ig 
was purified by Dr. J.M. Guthridge by ligand affinity chromatography on a human 
C3-sepharose resin (Basta & Hammer, 1991; Micklem et al, 1984). Binding was 
achieved under low ionic strength (50 mM NaCl) conditions, and elution o f the 
specifically bound CR2-Ig chimaera was achieved by increasing the salt
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concentration to 0.5 M NaCl. An additional purification step by gel filtration was 
performed on a Superdex-200 HiLoad column to remove any non-specific 
aggregates.
Immediately prior to scattering data acquisition, residual non-specific 
aggregates were removed by size exclusion chromatography on a Superdex 200 
HiLoad 16/60 column (Amersham Pharmacia Biotech) by Dr. M. Aslam. The 
protein fractions were pooled and concentrated under N 2 pressure using an YM10 
membrane in a pressure cell (Amicon). The CR2-Ig concentration was determined 
using an absorption coefficient o f 11.9 (1%, 280 nm, 1 cm path length), which was 
calculated from its composition by assuming the presence o f eight triantennary 
complex-type oligosaccharides (Figures 5.1 and 5.2) (Perkins, 1986). The X-ray 
scattering curves and analytical ultracentrifugation data were measured in PBS 
(phosphate buffered saline, Sigma D-5652: 137 mM NaCl, 2.7 mM KC1, 8.1 mM 
Na2HPC>4 , 1.5 mM KH2PO4 , 0.5 mM EDTA, pH 7.5) to which were added 0.02% 
NaN 3, and 0.1% Pefabloc SC (Pentapharm Ltd), or sometimes PBS which also 
included 0.5mM MgCL. Alternatively 0.5 mM EDTA, 0.05% NaN 3 and 0.1 mM 
Pefabloc were added to the buffer. The neutron scattering experiments were 
measured in PBS dissolved in 99.9% H2O. For these experiments, the protein was 
dialysed into PBS in 99.9% 2H2 0  at 6 °C for 48 h with three changes o f dialysate. For 
one session on the instrument D l l  at the ILL, the protein were dialysed into PBS 
containing 200 mM KC1 and adjusted to pH 6.7 with DC1. All CR2-Ig samples were 
routinely analysed by SDS-PAGE before and after scattering and ultracentrifugation 
experiments to confirm their integrity.
(5.4.2) X-ray data from Station 2.1 at the Synchrotron Radiation Source
X-ray scattering data acquisition was performed by Dr. M. Aslam and Prof. 
S.J. Perkins in two independent sessions at the Synchrotron Radiation Source at 
Daresbury, Warrington, UK at the solution scattering camera on Station 2.1 equipped 
with a 500-channel quadrant detector (Towns-Andrews et al, 1989; Worgan et al, 
1990). The apparatus is described elsewhere (Aslam, 2003). Experiments were 
performed with beam currents in a range between 176-231 mA and a ring energy o f
2.0 GeV. The final data analyses were performed with a sample-to-detector distance 
o f 3.51 m, which yielded a Q range from 0.01 nm*1 to 2.2 nm*1. The Q range was 
calibrated using fresh, wet, slightly stretched rat tail collagen, based on a diffraction
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spacing o f 67.0 nm. CR2-Ig concentrations between 4.1 and 12.4 mg ml"1 were 
measured at 15°C in Perspex cells o f sample volume 20 pi, contained within mica 
windows o f thickness between 10 to 15 pm. Acquisition times were 10 min using 10 
time frames o f 1 min which were checked for the absence o f time-dependent 
radiation damage effects. Buffers and samples were measured in alternation to 
minimise background subtraction errors. Runs were normalised using an ion 
chamber monitor positioned immediately after the sample. Data reduction was 
performed using the standard Daresbury software package OTOKO (Boulin et al, 
1986). The buffer and sample runs were corrected by dividing by a detector response 
measured for at least 8  h using a uniform 55Fe radioactive source. Reduced curves 
were calculated by subtraction o f the buffer runs from those o f the samples.
(5.4.3) Neutron data from Instrument D l l  at ILL and Instrument LOQ at ISIS
One neutron scattering experiment was performed by Dr. M. Aslam and 
Prof. S.J. Perkins on Instrument D l l  at the high-flux reactor at the Institut Laue- 
Langevin (ILL) in Grenoble, France (Lindner et ah 1992). D l l  is described 
elsewhere (Aslam, 2003). CR2-Ig was measured at 4.9 mg ml"1 in PBS and at 2.2-4.4 
mg ml"1 in PBS supplemented with 200 mM KC1, all in rectangular quartz Hellma 
cells of path thickness 2 mm at 15°C, typically with acquisition times o f 5-20 min. 
Sample-detector/collimation distances o f 2.0 m/5.5 m and 10.0 m/10.5 m, a 
wavelength X o f 1.00 nm (AXfk o f 10%) and a rectangular beam aperture o f 7 x 10 
mm were used as these configurations avoided any need for detector deadtime 
corrections. The combined Q range was 0.05 to 1.12 nm"1. Data reduction was based 
on standard ILL software packages using the DETEC, RNILS, SPOLLY, RGUIM 
and RPLOT routines (Ghosh, 1989).
Neutron scattering data were obtained by Dr. M. Aslam and Prof. S.J. Perkins 
in three different beam sessions on the LOQ instrument at the pulsed neutron source 
ISIS at the Rutherford Appleton Laboratory, Didcot, U.K (Heenan & King, 1993). 
The pulsed neutron beam was derived from proton beam currents o f 190 pA. 
Monochromatisation was achieved using time-of-flight techniques. A 3He ORDELA 
wire detector recorded intensities at a fixed sample-to-detector distance o f 4.3 m. 
The samples and buffers were measured in 2 mm-thick rectangular quartz Hellma
138
cells positioned in a thermostatted rack at 15°C. Data acquisitions were for 80 - 320 
x 106 monitor counts in runs lasting 1 - 4 h for CR2-Ig concentrations between 2.5 to 
14.3 mg ml*1. Spectral intensities were normalised relative to the scattering from a 
partially deuterated polystyrene standard (Wignall & Bates, 1987). Transmissions 
were measured for all samples and backgrounds. Reduction o f the raw data collected 
in 100 time frames o f 64 x 64 cells utilised the standard ISIS software package 
COLETTE (Heenan et al, 1989). Scattered intensities were binned into individual 
diffraction patterns based on the wavelength range from 0 . 2 2  nm to 1 . 0 0  nm, and 
were corrected for a linear wavelength-dependence of the transmission 
measurements. The patterns were merged to give the scattering curve I(Q) in a Q 
range o f 0.05 - 2.2 nm’1. The Q range was based on 0.04% logarithmic increments, 
which was optimal both for Guinier analyses at low Q and better signal-noise ratios 
at large Q.
(5.4.4) Analysis of reduced X-ray and neutron data
For this PhD thesis, the data was analysed as in Chapter 4.4.2. The CR2-Ig 
X-ray 7 ( 0  curve contained 453 data points between Q values o f 0.16 to 2.2 nm ' 1 and 
was fitted with Dmax set as 17 nm. The neutron 7 ( 0  curves contained 70 data points 
in the same Q range and was fitted with Dmax set as 17 nm.
(5.4.5) Analytical ultracentrifugation data acquisition and analysis
Analytical ultracentrifugation was performed by Dr. M. Aslam and Prof. S.J. 
Perkins on a Beckman XL-I instrument in which the protein concentration 
distribution within the cell was monitored using its absorbance at 280 nm and its 
refractive index measured by interferometry. Sedimentation equilibrium experiments 
were performed for CR2-Ig at three concentrations between 0.3 mg ml' 1 and 1.5 mg 
ml' 1 in PBS. Data were acquired over 45 h using six-sector cells with column heights 
o f 2 mm at rotor speeds o f 11,000 rpm, 14,000 rpm., 17,000 rpm., and 20,000 rpm. 
until equilibrium had been reached at each speed as shown by the perfect overlay o f 
runs measured at 5 h intervals. The molecular weight (MW) was analysed on the 
basis of a single species using Beckman software provided as an add-on to Origin
Version 4.1 (Microcal Inc.), for which the partial specific volume v for CR2-Ig was 
calculated to be 0.716 ml/g from its sequence (Perkins, 1986):
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cr = cro exp [(cq2/2RT) MW (1- vp) (r2 - r02)]
where cr is the concentration at radius r, cr0 is the concentration o f the monomer at 
the reference radius r0, co is the angular velocity, R is the gas constant, T is the 
temperature in Kelvin, and p is the solvent density.
Sedimentation velocity data were acquired over 16 h at rotor speeds o f
35,000 rpm and 42,000 rpm in two-sector cells with solution column heights o f 12 
mm. The CR2-Ig concentration was 0.4 mg ml*1 to 2.1 mg ml*1. For the g(.s*) 
analyses, successive absorbance and interference scans were recorded at 8  min 
intervals, the shortest interval possible under standard measurement conditions. In 
time-derivative analyses, the subtraction o f pairs o f concentration scans vs. radius in 
the cell eliminates systematic errors from baseline distortions in the cell windows 
and permits the averaging o f many pairs o f subtractions. The extrapolation of 
individual subtractions to the start time gives the g(s*) function, which was 
computed using the DCDT+ program (Philo, 2000), from which the sedimentation 
and diffusion coefficients were determined from the peak position and width 
respectively (Figure 5.6). The fits were determined in conditions when the maximum 
permissible measurable molecular weight was over 16 times the expected value, 
meaning that time broadening effects were negligible.
(5.4.6) Modelling and conformational searches for CR2-Ig
For this PhD thesis, the two CR2 SCR domains were taken from the crystal 
structure o f CR2 SCR 1-2 in complex with C3d (PDB code lghq ) (Szakonyi et ah 
2001). The Fc fragment and its hinge starting from Cysl56 (Figure 5.2) was 
modelled using the crystal structure o f murine IgGl (PDB code ligy) (Harris et ah 
1998). Four missing residues SPGK were appended to the two C-termini o f the Fc 
fragment in extended p-strand conformations. A total o f 28 (14 x 2) residue changes 
were made to the Ch2 and Ch3 domains in the Fc crystal structure in order that this 
corresponded to the CR2 -Ig sequence (Aslam et ah 2003). Most notably, the residue 
changes introduced a second pair o f glycosylation sites in the Ch3 domains at 
Asn330 that are not present in the mouse IgGl crystal structure (Figures 5.1 and
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5.2). Triantennary complex-type carbohydrate structures
(MansGlcNAcsGalsNeuNAcs; Mr 2,900) were added to each o f the four N-linked 
glycosylation sites at Asn226 and Asn330 in an extended conformation from the 
protein surface, based on the oligosaccharide structure in the crystal structure o f the 
Fc fragment o f murine IgGl (PDB code ligy) (Harris et al, 1998) (Figures 5.1 and
5.2).
In order to perform four different types o f randomized model generation for 
CR2-Ig, a strategy based on generating randomised linker conformations was 
developed in which SCR 1 and SCR 2 was connected by an eight-residue linker, and 
SCR 2 and the Fc fragment were connected by a 26-residue linker, each generated by 
molecular dynamics simulations (Aslam & Perkins, 2001; Boehm et al, 1999). The 
sequence for the CR2 SCR 1-2 linker (C63)EYFNKYSS(C72) included the last Cys 
residue o f SCR 1 and the first Cys residue o f SCR 2 (Figure 5.2). Cys63 and Cys72 
were used for superimpositions o f this linker with the same residues in SCR 1 and 
SCR 2. The 26-residue linker sequence between CR2 SCR 2 and the Fc fragment 
(C 127)VS VFPLEGSIEGRGGSELADPEVPRDCG(C 156) extended from the last 
Cys residue o f SCR 2 (Cys 127) to the third residue o f the Fc hinge (Cys 156) which 
was visible in the Fc crystal structure. This procedure retained a linker length similar 
to that o f the 28-residue linker used for the modelling o f Crry-Ig, but the CR2-Ig 
modelling did not include the C-terminal sequence o f the hinge KPCICTVPEVS that 
is visible in the IgGl Fc crystal structure (cf: Figure 5.2). Consequently these two 
anchor points at the N-terminus o f the Fc fragment represent a static point of 
asymmetry in all the modelling described below. Conformational libraries o f 5,000 
structures for each o f the two linkers were generated using the BIOPOLYMER and 
DISCOVER3 modules within INSIGHT II software (Accelrys, San Diego). The 
libraries were used to assemble CR2-Ig models in four different ways:
(1) For the first search for good fit CR2-Ig models, the Fc hinge region was 
not constrained by disulphide bridges at any o f Cys 156, Cys 159 or Cysl61 as seen in 
the mouse IgGl Fc crystal structure (Figure 5.2). One SCR 1-2 linker and one SCR 2 
- Fc linker were chosen at random from each of the two linker libraries, duplicated 
and superimposed onto the SCR 1, SCR 2 pairs and the SCR 2 - Fc fragment. This 
created 5000 randomised symmetric models for CR2-Ig in which each o f the SCR 1- 
SCR 2 and SCR 2 -F c linker pairs are identical.
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(2) The second search utilised a further 5,000 symmetrical model that were 
created in the same way as in the first search. This time, the Cys 156, Cys 159 or 
Cysl61 residues in the Fc hinge were connected by disulphide bridges as constraints 
(Aslam et al, 2003).
(3) The third search employed 5,000 asymmetrical models that were created 
by randomly selecting two different linkers from each o f the SCR 1 - SCR 2 and SCR 
2 - Fc linker libraries, i.e. all four linkers were different. The Fc hinge region was 
connected by three disulphide bridges as in the second search.
(4) The fourth search assumed that the linker between SCR 1 and SCR 2 
corresponded to the best-fit conformation for free CR2 SCR 1-2 that was identified 
in our previous study (Gilbert et al, 2005). Only the SCR 2 - Fc linker was modelled 
in this search. For each of 20,000 asymmetric models, two different linkers were 
chosen at random from the library.
(5.4.7) Debye scattering curve and sedimentation modelling of CR2-Ig
In order to calculate the scattering curves, Debye sphere models were 
created by placing each full coordinate model for CR2-Ig within a three dimensional 
grid o f cubes, where each cube side is o f length 0.459 nm. This length is much less 
than the nominal resolution o f the scattering curves. Provided that the number o f 
atoms within a given cube exceeded a user-defined cutoff, a sphere o f the same 
volume as the cube (sphere diameter 0.570 nm) was placed at the centre o f the cube. 
This cutoff was determined by the requirement that the total volume o f spheres in 
each model was within 1% of the dry volume o f 127.1 nm3 for CR2-Ig (1314 dry 
spheres), calculated from its amino-acid and carbohydrate composition (Perkins, 
1986). The dry sphere models were used to calculate the neutron scattering curves. 
X-ray scattering and sedimentation modelling requires the addition of a hydration 
shell. A hydration of 0.3 g H2O / g glycoprotein and an electrostricted volume of 
0.0245 nm3 per bound water molecule (Perkins, 2001; Perkins, 1986) gave a total 
hydrated volume of 168.5 nm3. This shell was modelled using the HYPRO 
procedure (Ashton et ah 1997) in which excess spheres were uniformly added to the 
surface o f the dry sphere model, and these were sequentially removed until the 
desired hydration volume of 1742 spheres had been reached.
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The X-ray and neutron scattering curve I(Q) was calculated assuming a 
uniform scattering density for the spheres using the Debye equation as adapted to 
spheres (Perkins & Weiss, 1983). The X-ray curves were calculated from the 
hydrated sphere models without corrections for wavelength spread or beam 
divergence as these are considered to be negligible for synchrotron X-ray data. A 
full-width-half-height wavelength spread o f 10% for X o f 0.6 nm and a beam 
divergence o f 0.016 radians were used to correct the calculated curve for the LOQ 
neutron data fits (Ashton et al, 1997). The modelled scattering curves were assessed 
by calculation o f the Rq and Rxs values from the same Q ranges used for the 
experimental Guinier fits, in which filters corresponding to ± 10% o f the 
experimental values were applied. Models that passed these filters were then ranked 
using a goodness-of-fit R factor defined by analogy with protein crystallography and 
based on the experimental curves in the Q range extending to 2.0 nm ' 1 (denoted as 
R2 .0) (Beavil et al, 1995).
Procedures for hydrodynamic simulations based on sphere models and the 
use o f the GENDIA and HYDRO programs were previously applied to the study o f 
CR2 SCR 1-2 and its complex with C3d (Gilbert et al, 2005). Here, version 5a o f the 
HYDRO program was used to calculate the s°2o,w values directly from the 43 
hydrated sphere models from the X-ray scattering best-fit models, as none o f these 
CR2-Ig models exceeded the HYDRO program limit of 2000 spheres (Garcia de la 
Torre et al, 1994). Version 5a o f the HYDROPRO program was used to calculate the 
s°20,w values directly from the 43 best-fit molecular models for CR2-Ig, together with 
the recommended value of 0.31 nm for the atomic element radius for all atoms as an 
empirical approximation of the hydration shell (Garcia de la Torre et al, 2000).
(5.4.8) Protein Data Bank accession numbers
The best-fit C a  coordinate model for CR2-Ig (Figure 5.14) has been 
deposited in the Protein Data Bank with the accession code 2aty.
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Chapter Six
A flexible 15 SCR extracellular domain structure of human complement 
receptor type 2 promotes its multiple ligand interactions
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(6.1) Introduction
This chapter describes the solution structure determination o f intact CR2. 
CR2 is formed o f 15 or 16 SCR domains depending on alternative splicing (Figure 
6.1) (Toothaker et al, 1989; Fujisaku et ah 1989), a transmembrane region and a 
short cytoplasmic tail. It is possible from sequence and genomic analyses that the 15 
CR2 SCR domains exist as four long homologous repeats (Figure 6.1) (Weis et ah 
1988; Fujisaku et ah 1989; Molina et ah 1990), although the sequence identities are 
not as marked as the long homologous repeats found in complement receptor type 1 
(CR1, CD35) (Klickstein et al, 1987).
Six inter-SCR linkers in CR2 are seven or eight residues in length, in contrast 
to the median length o f three to four residues seen in many other SCR containing 
proteins (Aslam et ah 2003; Murthy et al, 2001; Schwarzenbacher et ah 1999). 
Crystal structures for four-SCR or five-SCR domain proteins such as Vaccinia coat 
protein and P2-glycoprotein I show generally linear structures with minor bends 
(Murthy et al, 2001; Schwarzenbacher et al, 1999). Accordingly the effect o f the 
longer linkers on the overall structure of CR2 is o f great interest. Hydrodynamic data 
and electron microscopy on recombinant CR2 SCR 1-16 showed extended 
conformations, but with a variable inter-SCR orientation (Moore et ah 1989). The 
comparison o f the interaction o f CR2 SCR 1-2 and SCR 1-15 for its C3dg ligand has 
been studied by surface plasmon resonance studies to show that these are dependent 
on the number o f SCR domains, however the molecular basis for this is unknown 
(Guthridge et al, 2001a; Asokan et al, 2006).
The clarification of how CR2 SCR 1-15 interacts with membrane-bound IgM 
and C3 fragments requires a molecular structure for the intact protein. Molecular 
structures have been determined for other SCR proteins such as the 20 SCR domains 
in Factor H (FH) (Aslam & Perkins, 2001) and the five SCR domains in rodent Crry 
(Aslam et al, 2003). FH was found to possess a folded-back solution structure, while 
Crry was an extended rod-like structure. In this chapter, the application o f solution 
scattering, ultracentrifugation and constrained modelling to CR2 shows that, unlike 
FH, CR2 is flexible and on average is semi-extended in solution. We
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Figure 6.1
A schematic diagram of CR2 showing the 15 SCR domains. The position of the 
sixteenth domain in the alternatively spliced form of CR2 is indicated by the dashed 
ellipse labelled 1 Oa. The long homologous repeats (LHR) are indicated in bracketed 
ranges, in which SCR 15 does not fit the pattern. The binding sites for four sets of 
ligands are shown by horizontal arrows. The number of residues in each of the 14 
inter-SCR linkers is shown between each pair o f domains. The 11 predicted N-linked 
glycosylation sites are marked by \j/ symbols. Underneath, the 15 SCR sequences of 
CR2 are aligned. Each SCR sequence is numbered at its start and end, counting from 
residue 1 at the start of the signal peptide (not included) (SWISSPROT entry 
P20023). The sequence from residue 972 onwards is not included. Conserved Cys 
and Trp residues are highlighted in red, and the linker sequences are highlighted in 
green. The N-linked glycosylation sites are underlined. See Figure 1.4 for a 
comparison with other mammalian CR2 sequences.
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how that such a structure is apparently able to fold back, and this would facilitate 
ligand interactions occurring across SCR domains that are separated in the CR2 
sequence. The comparison o f the dimensions o f CR2 SCR 1-15 with other SCR 
proteins and the proteins known to be co-located with CR2 on cell surfaces enables 
us to rationalize the way in which CR2 interacts with its ligands, in particular with 
antigen-C3d complexes that are bound to the B cell receptor.
(6.2) Results and Discussion
(6.2.1) X-ray scattering data for CR2 SCR 1-15
The preparations o f CR2 SCR 1-15 for scattering and ultracentrifugation 
were subjected to size-exclusion chromatography before use. Initial work indicated a 
tendency for sample aggregation and degradation, and this was attributable to the 
large size o f the protein and the long lengths o f six CR2 linker peptides which may 
make this protein susceptible to cleavage. The homogenous peak obtained from size 
exclusion chromatography was used for final data collection and showed a single 
clean band when analysed by SDS-PAGE. X-ray scattering experiments were carried 
out on CR2 SCR 1-15 between 0.5 and 2.5 mg ml' 1 in PBS. Other experiments were 
performed in 10 mM HEPES buffer, however the lower concentrations o f these 
samples did not result in satisfactory signal-noise ratios (Materials and Methods).
Guinier radius o f gyration Rq fits were linear in an appropriate Q.Rg range up 
to 1.6, where Q = 4n sin 0 / X (20 = scattering angle; X = wavelength). As minor X- 
ray induced radiation damage effects were visible during the ten time frames o f data 
acquisition, only the first time frame was used for Guinier analyses, in which this 
effect was negligible. The mean X-ray Rq value o f CR2 SCR 1-15 is 11.5 ± 0.9 nm 
(Figure 6 .2 (a)). The anisotropy ratio is Rg/Ro, where Ro is the Rq o f  the sphere of 
volume equal to that of the hydrated protein. For typical globular proteins, Rg/Ro is 
approximately 1.28 (Perkins, 1988). For CR2 SCR 1-15, Rg/Ro was determined as 
4.1 to show that this is highly elongated.
The cross-sectional radius o f gyration Rxs value monitors the shorter axes o f 
an elongated macromolecule. In the case o f SCR-containing proteins, this parameter 
is a monitor o f the averaged short-range and long-range orientation between adjacent
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Figure 6.2
Guinier analyses o f the X-ray and neutron scattering data for CR2 SCR 1-15. The X- 
ray R q  and Rxs analyses in (a) and (c) are both arbitrarily displaced in the intensity 
axes for clarity. The neutron Rq and Rxs analyses are shown in (b) and (d). The filled 
circles correspond to the data points used to obtain Rq or Rxs values and the straight 
lines correspond to the best fit through these points. The Q .R q  and Q.Rxs ranges are 
arrowed. (a,b) The X-ray and neutron R q  analyses for CR2 SCR 1-15 employed a Q 
range of 0.09-0.14 nm*1. The X-ray curves correspond to sample concentrations of 
1.8 and 1.4 mg ml*1, while the neutron curve corresponds to a concentration of 1.5 
mg ml*1. (c,d) The X-ray and neutron Rxs analyses for CR2 SCR 1-15 employed a Q 
range of 0.30 - 0.70 nm*1.
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SCR domains (Aslam & Perkins, 2001). Unlike the X-ray scattering curve for Factor
H, in which two linear regions o f fit were observed, only one fit range was seen for 
CR2 SCR 1-15. From this, the mean X-ray Rxs value o f CR2 SCR 1-15 was 
determined as 1.8 ± 0.1 nm (Figure 6.2(c)). This R v a l u e  is comparable to the 
second Rxs value o f 1.7 ± 0.1 nm for FH (20 SCR domains), and the Rxs values of
I.5 ± 0.1 nm for rat Crry (five SCR domains), and 1.3 ± 0.1 nm for mouse Crry-Ig (2 
x 5 SCR domains) (Aslam & Perkins, 2001; Aslam et al, 2003). The absence o f the 
first Rxs value corresponding to that for FH indicates that the overall arrangement of 
15 SCR domains in CR2 SCR 1-15 is significantly different from that for FH. The 
good agreement with the Rxs values for FH and the Crry proteins indicates that the 
averaged SCR orientation between pairs o f SCR domains is similar in all three 
proteins.
The indirect transformation o f the scattering data I(Q) in reciprocal space into 
real space gives the distance distribution function P(r). This represents all the 
distance vectors between pairs o f atoms within CR2 SCR 1-15 in real space. The 
P(r) function gives an independent calculation o f the Rq and 7(0) values that is based 
on the full scattering curve in the Q range between 0.08 nm ' 1 to 2.07 nm '1, and gives 
the maximum dimension of CR2 SCR 1-15, denoted L. The P(r) curve calculations 
were not straightforward to achieve, this being attributed to its highly extended 
solution structure. Calculations based on the best four I(Q) curves showed a 
maximum M\ at an r value o f 6  nm. That shown in Figure 6.3 has an M\ value at 6.1 
nm and an L value of 38 nm. There were indications o f a second peak Mi at 22 nm. 
The presence o f Mi suggests a long-range structure in CR2 which might arise 
through folding back o f the 15 SCR domains. The R q  value of 11.6 nm calculated 
from this P(r) curve was in good agreement with that calculated from the Guinier 
fits. In addition, the L value of 38 nm is in good agreement with the length o f 38 nm 
estimated for CR2 SCR 1-16 by electron microscopy (Moore et al, 1989).
The averaged length o f a single SCR domain is 3.6 (± 0.2) nm (Aslam et al, 
2003). If CR2 SCR 1-15 were to be fully extended in solution, the 15 domains would 
result in a length o f at least 54 nm if the linker lengths are not included. This 
difference shows that the averaged solution structure for CR2 SCR 1-15 is not fully 
extended. One way o f achieving this notional 30% reduction in length to 38 nm in
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Figure 6.3
X-ray distance distribution function P(r) for CR2 SCR 1-15. The maximum o f the 
P(r) curve is denoted by Mu the most frequently occurring distance within the 
protein, and L denotes its maximum dimension. The M\ value is 6.1 nm and the L 
value is 38 nm. A second feature Mi at r = 22 nm is discussed in the text.
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CR2 SCR 1-15 is to postulate that the 19 individual pairs of SCR domains within 
CR2 have a V-shaped structure with an inter-SCR angle o f 90°. This arrangement 
results in a length of 38 nm. While such a V-shaped arrangement is unlikely (see the 
third modelling search below), this inter-SCR angle o f 90° is close to the mean o f the 
range of 63° to 121° determined in previous best-fit CR2 SCR 1-2 modelling (Gilbert 
et al, 2005). It is also noteworthy that the observed L value for FH is 40 nm, to be 
compared with a maximum possible length o f 73 nm for a fully extended FH model. 
This means that FH demonstrates a notional length reduction of 45%, indicating that 
the solution structure o f FH is comparatively more compact than that of CR2 SCR 1 - 
15.
(6.2.2) Neutron scattering data for CR2 SCR 1-15
Neutron scattering was successfully performed on CR2 SCR 1-15 at 1.5 mg 
ml*1 in PBS buffer in 2H2 0  (Materials & Methods). In general, CR2 SCR 1-15 was 
found to aggregate in H2O. This aggregation is most likely to be the consequence o f 
its 13% glycosylation content, which will be less effectively hydrated in H2O 
buffers in which hydrogen bonding between the glycoprotein and the solvent is 
weaker. From this neutron measurement, the Rq value was determined to be 11.5 ± 
0.5 nm, which is in agreement with the X-ray value o f 11.5 ± 0.9 nm. The Guinier 
Rxs value was determined to be 1.8 ± 0.1 nm using the same Q range in the X-ray 
analyses, which is also consistent with the X-ray value. The neutron P(r) analysis 
gave an M  value o f 6.5 nm and a maximum dimension L o f 38 nm (not shown), both 
o f which agree with the X-ray analyses. As neutron scattering is unaffected by 
radiation damage, the neutron data shows that the X-ray analyses are not 
significantly affected by radiation damage effects.
(6.2.3) Sedimentation equilibrium and velocity data for CR2 SCR 1-15
In order to confirm the monomeric state of CR2 SCR 1-15 and its molecular 
weight, sedimentation equilibrium experiments were carried out at four 
concentrations between 0.5 and 1.8 mg ml*1 in PBS buffer and five rotor speeds 
(Materials and Methods). Even though trace amounts o f aggregates were detectable 
by the appearance o f the residuals, the absorbance and interference data gave an 
average molecular weight of 135,000 ± 13,000 Da (Figure 6.4). Glycoproteins
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Figure 6.4
Sedimentation equilibrium analyses for CR2 SCR 1-15. The residuals of the fits are 
shown in the upper panels of each graph. (a,b) Best-fit curves for CR2 SCR 1-15 at a 
rotor speed of 14,000 rpm using absorbance optics. The concentrations are 1.0 and 
1.4 mg ml*1 respectively. The fits assumed a single species and gave molecular 
masses of 127,000 and 133,000 Da respectively. (c,d) Best-fit curves for CR2 SCR 
1-15 at a rotor speed of 17,000 rpm using interference optics at concentrations of 1.8 
and 1.4 mg m l'1 respectively. The fits gave molecular masses of 139,000 and 
136,000 Da respectively.
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expressed by baculovirus are assumed to contain only high mannose-type 
oligosaccharides (Jarvis & Finn, 1995; Chamberlain et al, 1998). The CR2 SCR 1-15 
sequence between Ile21 and Arg971 resulted in a calculated molecular weight o f
104,000 Da (Figure 6.1), and together with the assumption o f 11 high-mannose 
oligosaccharide chains (Man7GlcNAc2) a calculated molecular weight o f 121,000 
Da. As the experimental and calculated values are in reasonable agreement, all 11 
potential N-linked glycosylation sites were inferred to be occupied by 
oligosaccharide chains. Our value o f 135,000 ± 13,000 Da is in good agreement with 
that of 134,000 Da found for the high mannose precursor form of CR2 (Weis & 
Fearon, 1985). If 11 complex-type oligosaccharide chains 
(NeuNAc4Gal4Man3GlcNAc6) were to be present, the predicted molecular weight 
would be 143,000 Da, in good agreement with the value that is commonly assumed 
for CR2 SCR 1-15 (Weis & Fearon, 1985).
The sedimentation coefficient s°2o,w monitors macromolecular elongation and 
provides complementary structural data on CR2 SCR 1-15 that is an independent 
parameter comparable with the Rg value. Velocity experiments were performed at 
five speeds between 15,000 rpm and 35,000 rpm using samples at concentrations 
between 0.5 and 1.8 mg m l'1 in PBS buffer. Analysis using the g(.s*) method to 
analyse pairs o f scans gave a mean s°2o,w value o f 4.24 ± 0.1 S (Figure 6.5). This is in 
good agreement with the value o f 4.5 S previously determined for rCR2 SCR 1-16 
(Moore et al, 1989). The frictional coefficient anisotropy ratio f/fo was calculated to 
be 1.96, while this is typically 1.2 -  1.3 for globular proteins. This again shows that 
CR2 SCR 1-15 possesses a relatively elongated solution structure.
(6.2.4) Modelling of the SCR domains of CR2
In order to progress to a full model o f CR2 SCR 1-15 by constrained 
scattering modelling, molecular structures for the 15 SCR domains are required. The 
structures of CR2 SCR 1-2 were taken from the crystal structure o f its complex with 
C3d (Szakonyi et al, 2001). Structures for SCR 3-7 and SCR 9-15 were taken from 
the CCP module model database (Materials and Methods) (Soares et al, 2005). 
Unlike the approach in which sequence searches against all the SCR domains of 
known structures identified the closest match for each domain, which was then used
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Figure 6.5
Sedimentation velocity fits of the g(s*) distributions for CR2 SCR 1-15. (a,b) The 
fits were based on interference data at rotor speeds of 25,000 rpm and 35,000 rpm 
respectively at a concentration of 1.8 mg m l'1. The s°2o,w values (arrowed) were 
determined to be 4.41 S and 4.46 S. (c,d) The fits were based on absorbance data for 
a sample concentration of 1.4 mg m l'1 at rotor speeds of 25,000 rpm and 35,000 rpm 
respectively. The s°2o,w values (arrowed) were determined to be 4.15 S and 4.25 S.
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as a structural template for modelling (Aslam & Perkins, 2001; Saunders et al, 
2006), the SCR domains were first clustered into nine different families A to I before 
these were modelled against known structural templates specific to each cluster. For 
CR2, the 15 SCR domains were classified into three clusters A, C and F. The cluster 
types were arranged as four imperfect tetrad repeats to follow the pattern AFAC, 
AFAX, AF*C and AFAF, with the SCR 8  domain being unassigned, and the inserted 
SCR domain 10a being similar to cluster A and asterisked (Figure 6.1) (Soares et al, 
2005). This agrees with the identification o f four long homologous repeats from the 
CR2 sequence (Weis et al, 1988; Moore et al, 1987). These models were used for the 
modelling o f SCR 3-7 and SCR 9-15. SCR 8  had not been modelled by this 
approach, and this was created from a cluster C model based on SCR 11, in 
agreement with the highest sequence identity being found between SCR 5-8 and 
SCR 9-11 (Moore et al, 1987; Weis et al, 1988) and our sequence analyses using 
Clustal W (Materials and Methods).
(6.2.5) Constrained modelling of the domain arrangement in CR2 SCR 1-15
Constrained molecular modelling o f the X-ray and neutron scattering data 
resulted in best-fit CR2 structures. The constraints were the 15 individual SCR 
domain models and the modelled linkers between these. The linkers vary in length 
between three and eight residues (Figure 6.1). Unlike the majority o f interdomain 
linkers in the SCR superfamily, six o f these 14 linkers in CR2 are long at seven or 
eight residues (Figure 6.1).
Three modelling searches were performed to identify best-fit CR2 structures. 
Initially, it was assumed that the linkers could adopt any conformation. The first 
modelling search created 5,000 randomised models in which the 14 SCR linkers 
were free from structural constraints. The R q  values o f the 5,000 models ranged 
between 2.5 nm to 8.9 nm, all o f which were much less than the experimental value 
of 11.5 ± 0.9 nm. None of these models were extended enough to satisfy the 
experimental R q  value, and consequently the R2.0 factor (where the Q  range used to 
determine the R factor is 2.0 nm '1) values o f 14% to 44% were relatively high 
(Figure 6 .6 ).
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Figure 6 . 6
Summary of the X-ray analyses of 5,000 models from the first modelling search for 
CR2 SCR 1-15. (a,b) Neither the X-ray (a) nor the neutron (b) Rq values returned by 
the models satisfy the experimental value of 11.5 nm, and the R2.0 factor values are 
relatively high.
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The second modelling search was improved by fixing the length o f each 
linker peptide to be constrained within 0.25 nm of its maximum length between its 
N-terminus and C-terminus. The linkers were free to reorientate themselves. This 
strategy followed that o f the successful Randomised-1, Randomised-2 and 
Randomised-3 searches used to model the solution structure for FH (Aslam & 
Perkins, 2001). Figure 6.7 confirmed that the 5,000 models corresponded to the 
required wide range of different CR2 conformations in all orientations. The 5,000 Rq 
values ranged between 4.8 nm and 11.9 nm, o f which 306 structures fitted the X-ray 
Rg value o f 11.5 nm to within 5% (Table 6.1). Many models also satisfied the 
experimental Rxs value o f 1.8 nm. It was however not possible to match 
simultaneously both the experimental Rq and Rxs values (Figure 6 .8 (a)). Models 
with an acceptable Rg value showed an Rxs  value that was too low, and vice versa. 
To illustrate this, three CR2 models are identified in blue, green and red across 
Figure 6 .8 . The R2.0 factor values monitor the goodness o f fit across the full 
scattering curve. The model with the lowest R2.0 factor best fitted the Rxs  data (blue). 
This best R2.0 factor model corresponded to an value o f around 9 nm, which is 
lower than the experimental Rg value o f 11.5 nm. The models with the best-fit Rq 
values gave high R2.0 values (red). If the Q range used to determine the R factor is 
reduced to 0.8 nm ' 1 (denoted Ro.s), the minimum of the R factor values is noticeably 
shifted to the right to around 10 nm (Figure 6 .8 (c)). By sorting the models based on 
the Ro.8 factor, from this the best-fit model (green) now gave an improved Rq value 
o f 9.8 nm and a similar Rxs value of 1.7 nm. The Ro.8 factor was good at 5.9 % 
whilst the R2.0 factor was 9.7 % (Table 6.1). The Q dependence of the R factors is 
attributed to the inability to model the full scattering curve as a single CR2 
conformation. From this, it was concluded that CR2 is more flexible than expected. 
Its structure is best described as a family o f varying SCR structural arrangements in 
equilibrium with each other, the average o f which has been observed by scattering.
The three models of Figure 6 . 8  and Table 6.1 accounted for the curve fits to 
the experimental X-ray data in Figure 6.9. The red model o f Figure 6.9(a) best fitted 
the experimental Rq value (red in Figure 6 .8 ). Its structure is relatively extended with 
a maximum length of 48 nm deduced from the P(r) curve shown as an inset. Neither 
the I(Q) nor the P(r) fits are good, where the Ro.8 and R2.0 values are 12.8% and 
19.4% respectively (Table 6.1). The blue model of Figure 6.9(b) corresponds to the
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Figure 6.7
The superimposition of 100 CR2 SCR 1-15 models taken from the 5,000 random 
models generated in the second modelling search. The 100 models were 
superimposed on SCR 8.
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Filtering /  Sotting Models Spheres Rq (nm) R\$  (nm) g (%) R2 0  (%) s %  k-(S) a
None 5,000 1854-2102 4 .8 -1 1 .9  0 .0 3 -3 .2  5 .8 -2 4 .0  9 .1 -2 4 .9  n/a
95% < R o <  105% 306 1966-2090 10.9- 11.9 0 .4 - 1.5 7 .5 - 14.7 13.3-21.1 n/a
Modelling Final model b 1 2023 11.5 1.1 12.8 19.4 3.38
Final model b 1 2036 9.1 1.9 6.5 9.1 4  0 3
Final m o d e l” 1 2032 9.8 1.7 5.9 9.7 3.83
Experimental 2189 11.5 ± 0 .9  1.8 ±0.1 4.24 ±0.10
Table 6.1
Experimental and modelled data from the secor 
a No filtering was performed using the s02o,iv values.
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Figure 6 . 8
Summary of the X-ray analyses of 5,000 models from the second modelling search 
for CR2 SCR 1-15. (a) The comparison of the with the R\s  values. (b,c) The R 
factor values show the goodness of agreement between the model and the 
experimental scattering curve. R2.0 corresponds to the R factor calculated in the Q 
range out to 2.0 nm '1, whilst Ro.g corresponds to the Q range out to 0.8 nm '1 and is 
weighted in favour of the low Q values used for the Guinier R q  and R x s fits. Each 
model is denoted by a circle. The red circle corresponds to an elongated model
(continued...)
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(Figure 6 . 8  legend continued)
which best fits the experimental R q , denoted by the vertical dashed line. The blue 
circle shows a folded back model which best fits the experimental Rxs (horizontal 
dashed blue line). The green circle (arrowed in (c)) denotes the overall best fit model 
which gave good agreement with both the R q  and Rxs values.
161
0.0 0.4 0.8 1.2 1.6
Q (nm '1)
Figure 6.9
Final X-ray curve fits for three CR2 SCR 1-15 models. The open circles denote the 
experimental scattering curves, while the continuous coloured lines show the 
modelled curves (colour coded as in Figure 6.8). An a-carbon ribbon trace of the 
model used in each fit is shown. The modelled P{r) curves are shown as insets to the 
right, with the experimental curve in black and the modelled curve in colour, (a) An 
elongated model which best fits the experimental R q . (b) A folded back model which 
best fits the experimental Rxs- (c) The overall best fit model from the 5,000 initial 
models, which gave good agreement with both the Rg and Rxs values.
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best overall R factor. Its maximum dimension is 30 nm, which is less than that 
deduced from the experimental P(r) curve, while a good fit is shown to the Rxs 
region in the I(Q) curve with a Ro.s value o f 6.5%. The Rg value is low at 9.1 nm for 
reason of the folding back o f its SCR domains. The green model o f Figure 6.9(c) 
gave the best Ro.g value o f 5.9%, while the R2.0 value is higher than that for the blue 
model for reason of the Q dependence o f the R factors seen in Figure 6 .8 (b) and 
6 .8 (c). The Rq value is better at 9.8 nm, while the Rxs value agrees well with 
experiment (Table 6.1). Its P(r) curve showed the best correspondence with the 
experimental curve o f Figure 6.3. The maximum dimension o f 35 nm is slightly 
shorter than the experimental one o f 38 nm, while the modelled P(r) curve showed 
good agreement with both the M\ and M2 peaks. The three curve comparisons 
support the conclusion that CR2 has a flexible solution structure. It is likely that this 
solution structure corresponds to an average o f several, o f which the most typical is 
the green one, while the red and blue ones in Figure 6.9 represent two extremes.
If half o f the six longest linkers in CR2 are bent by 90° at any given moment, 
simple geometry shows that the length o f the resulting SCR structure would be 
reduced from the maximum possible o f 54 nm to the required length o f about 30-40 
nm. Accordingly, as a control, a third modelling search tested another structural 
variant in which the six longest linkers in CR2 SCR 1-15 were held fixed in the V- 
shape structure determined for the best-fit model o f free CR2 SCR 1-2 (Gilbert et al, 
2005). The remaining eight linkers were selected at random from the linker libraries 
created for the second modelling search. As for the first modelling search, none of 
these models fulfilled the experimental Rq requirements (Figure 6.10). The Rq values 
of the 5,000 models ranged between 3.6 nm to 10.2 nm, all o f which were much less 
than the experimental value o f 11.5 ± 0.9 nm. This outcome suggested that the six 
longest linkers in CR2 exhibit a range o f variable conformations.
As an independent check o f the scattering modelling, the sedimentation 
coefficients s°20,wof the three models in Figure 6.9 were calculated from their atomic 
coordinates. The red, blue and green models gave s°2o.w values o f 3.38 S, 4.03 S and 
3.83 S in that order, to be compared with the experimental value o f 4.24 ± 0.1 S 
(Table 6.1). The green model which gave the best scattering modelling fit is in good 
accord with this experimental value, given that the agreement should be within 0.3 S
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Figure 6.10
Summary of the X-ray analyses o f 5,000 models from the third modelling search for 
CR2 SCR 1-15. (a,b) Neither the X-ray (a) nor the neutron (b) Rq values returned by 
the models satisfy the experimental value of 11.5 nm, and the R2.0 factor values are 
relatively high.
(a) Search 3: X-ray
(b) Search 3: Neutron
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(Perkins, 2001). The more compact arrangement o f SCR domains shown by the blue 
model gave a better agreement. The more extended agreement shown by the red 
model differed by 0.86 S. The calculations showed that the averaged CR2 SCR 1-15 
structure is partially folded back, in agreement with the scattering modelling.
(6.3) Conclusions
We have determined the first structure for intact CR2 SCR 1-15 in solution to 
provide new insight into the way in which CR2 interacts with C3d-coated antigens 
on the BCR to enhance the antibody response to antigen. CR2 SCR 1-15 is shown by 
both scattering and ultracentrifugation to be flexible and extended but with evidence 
o f folded back regions. Its length is 38 nm. This is consistent with earlier electron 
microscopy images o f CR2 with 16 SCR domains whose length was determined as 
38.6 ± 3.5 nm (Moore et al, 1989). The CR2 SCR arrangements shown in Figure 6.9 
are consistent with these electron microscopy images, even though the latter were 
obtained in conditions that are harsh compared with those in solution. The degree o f 
folding back o f the SCR domains is less in CR2 SCR 1-15 than was observed in our 
scattering study o f FH (Aslam & Perkins, 2001), which has 20 SCR domains. The 
most likely functional reason for this difference from FH is that CR2 possesses 
ligand binding sites only on SCR 1-2 and SCR 5-8 (Figure 6.1), while FH has 
multiple binding sites for C3 fragments and polyanionic oligosaccharides throughout 
its structure which may need to be brought into proximity for full functionality. It is 
noteworthy that the constrained modelling of the CR2 data yielded good scattering 
curve fits over a wider Q range (up to Q = 2.0 nm '1) than those observed for FH for 
which good curve fits extended only up to Q = 0.3 nm '1. CR2 models that best fitted 
the Guinier Rq region o f the curve at the lowest Q values displayed a degree of 
partial folding back within their structure (Figure 6.9(a)). Other CR2 models which 
fitted the entire scattering curve showed more folding back (Figure 6.9(b)). The best 
fit showed a compromised degree o f folded back SCR domains (Figure 6.9(c)), in 
which SCR 1-2 is folded back towards SCR 4-6, with a further slight turn around 
SCR 11-13, although constrained modelling is unable to distinguish which part o f 
CR2 SCR 1-15 is folded back. Such a structure was able to account for the two peaks 
in the P(r) curve at 6.1 and 22 nm. A Poisson-Boltzmann electrostatic map suggested 
that SCR 1-2 have predominantly basic surfaces, while SCR 5 has a partly-acidic
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surface mediated by Asp304, Asp306, Glu308 and Glu309, and this may provide an 
attractive force for some folding back. The appearance o f the model in Figure 6.11 is 
suggestive o f a “fish-hook”, however we stress that other partially folded-back 
structures that fit the scattering data are possible, and that the solution structure is 
significantly flexible as discussed below. Interconversions between these models 
would account for the inability to fit simultaneously both the Rq and Rxs values in 
any given CR2 model.
This partially folded-back structure o f CR2 SCR 1-15 is unique within the 
SCR superfamily. Solution studies so far have shown that proteins with five SCR 
domains (rat Crry, mouse Crry-Ig, and p2-glycoprotein I) display no tendency to 
form significantly folded back SCR structures (Aslam et al, 2003; Hammel et al, 
2002). The inter-SCR linker lengths are four and five residues in rat and mouse Crry 
and three and four residues in p2-glycoprotein I. These proteins adopt conformations 
which are extended but can exhibit slightly bent SCR orientations. In comparison 
with the 20 SCR domains in FH, five o f its 19 linkers are long ones with six, seven 
or eight residues each, and FH is the most folded back SCR protein in this group. 
CR2 contains proportionately the longest set o f linker lengths. There are six long 
linkers of lengths seven or eight residues (Figure 6.1). The previous modelling of 
CR2 SCR 1-2 gave six best fit models with inter-domain angles of 63° to 121° (see 
Table 1 Gilbert et al, 2005). The inter-SCR domain angle between SCR 1-2 in CR2 
in the crystal structures o f the protein alone and in its complex with C3d are 37° and 
40° respectively, and these are folded back arrangements with SCR 1 and SCR 2 in 
contact with each other (Prota et al, 2002; Szakonyi et al, 2001). This difference is a 
measure o f how much the orientation can vary between two SCR domains if  they are 
joined by an eight-residue linker. This is the most likely reason for why CR2 has 
appeared as the most flexible o f these five SCR proteins.
It is possible that the observed partial folding back in CR2 is the consequence 
o f weak interactions between the SCR domains in distant parts o f the molecule. Such 
interdomain interactions could be protein-protein or protein-carbohydrate in their 
nature, and would be facilitated by the longer than average linkers in CR2. This is a 
less likely scenario. These interactions would need to be weak and transient in order
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CD23
Ovalbumin
Figure 6.11
Views of the overall best-fit model for CR2 SCR 1-15 in comparison with its 
ligands, namely C3d, the C-type lectin domain of CD23 and IFNa. Ovalbumin is a 
model antigen when conjugated with 4-hydroxy-3-nitrophenyl (NP), and its crystal 
structure is shown for comparison. The SCR domains are numbered from 1 to 15 in 
the CR2 model (red; green in Figure 6.9). The ligands (blue) are based on crystal and 
NMR structures with the following PDB codes lghq, lt8d and lrh2, and that for 
ovalbumin has the PDB code lova. The IgM-S monomer model from solution 
scattering and the IgE-Fc fragment from X-ray crystallography (PDB code llsO) are 
shown face-on for comparison (green), in which the Fab and Fc fragments and the 
Cs2 and Cp2 domains are labelled. The scale bar corresponds to the average length 
of one SCR domain.
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to account for the observed extended CR2 structures, and they are unlikely to occur. 
If these proposed interactions were stronger, this would result in a better-defined 
scattering curve, and a reduced discrepancy between the Rq and Rxs regions during 
the modelling. They are likely to lead to the formation o f CR2 dimers in solution. No 
evidence o f CR2 oligomer formation was seen in either the scattering or 
ultracentrifugation work here or previously (Gilbert et al, 2005; Guthridge et al, 
2 0 0 1 a).
The flexibility exhibited by CR2 SCR 1-15 accounts for experimental 
observations showing that SCR domains in CR2 other than SCR 1-2 play a role in 
ligand binding and suggests possible mechanisms o f action for CR2 (Guthridge et al, 
2001a). Biacore association studies have previously shown that the dissociation 
constant Kd for the C3d-CR2 SCR 1-15 equilibrium is 27.5 nM and 27.1 nM. 
(Moore et al, 1989; Guthridge et al, 2001a) While the Kd value was unchanged, the 
kinetic on- and off-rates were reduced for C3d binding to CR2 SCR 1-15 compared 
to CR2 SCR 1-2 and this suggested that SCR 3-15 perturbed the binding o f C3d to 
SCR 1-2 (Guthridge et al, 2001a). In distinction to this, more recent affinity studies 
with each o f C3d, gp350 and IFNa binding to CR2 SCR 1-2, SCR 1-4 and SCR 1-15 
(Asokan et al, 2006) showed that the Kd value increased as the number o f SCR 
domains increased from two to 15. Despite the difference between the two studies, 
the second study also showed that the SCR 3-15 domains are partially able to 
obstruct the ligand binding site on SCR 1-2. The ligand sizes o f C3d and IFNa 
(Szakonyi et al, 2001; Radhakrishnan et al, 1996) are compared with intact CR2 in 
Figure 6.11. Ovalbumin is shown as an illustration o f a representative antigen, as its 
conjugate with 4-hydroxy-3-nitrophenyl (NP) is used in CR2 immunisation studies. 
These differential binding effects are readily explained in terms of the flexibility of 
full length CR2 identified in the present study. The SCR 1-2 domains may move 
sufficiently close to SCR 3-15 to result in the partial obstruction of its SCR 1-2 
ligand binding site. The C3d and IFNa ligands are large enough for mobility 
between the SCR domains to interfere with their binding to CR2 (Figure 6.11). In the 
alternative explanation that SCR 1-2 may interact weakly with one or two other (as 
yet unidentified) SCR domains in CR2, with Kd values in the mM or pM ranges, this 
would mean that these three CR2 ligands would compete with these other SCR
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domains for binding to SCR 1-2. This would also account for the reduced ligand 
affinity of CR2 SCR 1-15 compared to CR2 SCR 1-2. In contrast, CD23 showed a 
marked increase in binding affinity with an increase in the number o f SCR domains 
in CR2 (Asokan et al, 2006). CD23 is known to bind to both SCR 1-2 and SCR 5-8 
(Aubry et al, 1994). The flexibility found in our CR2 SCR 1-15 solution structure 
would enable CD23 to simultaneously form contacts with both SCR 1-2 and SCR 5- 
8  and favour a folded-back CR2 structure. The location o f CD23 in such a complex 
with CR2 may cause the N-terminal tip of CR2 to move into proximity to 
membrane-bound IgE molecules on the B cell surface, as suggested by Figure 6.11 
(Hibbert et al, 2005). CD23 can mediate a functional coligation o f the BCR with 
CR2 to result in a 10- to 100-fold reduction in the threshold concentration o f anti- 
IgM antibodies required to induce proliferation o f human tonsil B cells (Reljic et al, 
1997).
The solution structure o f CR2 SCR 1-15 can now be reviewed in the context 
o f its involvement with the BCR as a coreceptor that links innate and adaptive 
immunity (Fearon & Carroll, 2000; Tolnay & Tsokos, 1998) (Chapter 1). Up until 
now, cartoons of the CR2, CD 19, CD81 and BCR proteins have not accurately 
explained how an extensively long 15-domain membrane-bound protein such as CR2 
is able to interact with ligands near the cell surface. Such cartoons are often not 
drawn to scale. It is important to note that the individual lengths of each o f the Ig 
domains in CD 19 and BCR are similar to that o f SCR domains (Perkins et al, 2002), 
yet the maximum extent o f these domains from a membrane surface is low compared 
to what is possible with the 15 domains in CR2 (Figure 6.11). The importance o f the 
flexibility between the SCR domains in our CR2 solution structure is that this 
enables CR2 to reorientate itself in order to bind effectively to C3d on the surface of 
the antigen irrespective of the size or shape o f the antigen, whether this be small as 
in the case of ovalbumin-NP complexes, or large as in the case of entire bacterial 
surfaces. The six longest linkers in CR2 appear to act as conformationally variable 
joints which are distributed throughout the length o f CR2. The immunological 
importance of these linkers is shown by their unchanged lengths in murine and 
bovine CR2 (Molina et al, 1990; Hein et al, 1998), consistent with their functional 
significance across different species. BLAST sequence searches and CLUSTALW 
alignments suggest that predicted sequences for bovine and rat CR2 (NCBI
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accession codes XP_613039 and XP_213977) also possess identical linker lengths, 
although SCR 3 is missing in rat CR2. It can be deduced that CR2 is well designed 
for the optimal binding and anchoring o f antigen-C3d complexes to the BCR 
receptor, enabling CD 19 molecules to be clustered with the Iga  and IgP polypeptides 
bound to the BCR and trigger the subsequent signalling events (Fearon & Carroll, 
2000).
(6.4) Materials and Methods.
(6.4.1) Expression and purification of CR2 SCR 1-15.
Human CR2 SCR 1-15 was expressed in Sf9 insect cells by Dr. R. Asokan 
and Prof. V.M. Holers as a soluble recombinant protein in the baculovirus expression 
system as described previously (Guthridge et al, 2001a). Briefly, the cDNA coding 
for the first 15 SCR domains with the native human Kozac consensus sequence and 
signal peptide was cloned into the pVL1393 baculoviral expression vector 
(Pharmingen, San Diego, CA). A stop codon was introduced prior to the 
transmembrane domain to create a soluble secreted form o f the receptor. After 
infection o f the insect cells with the recombinant baculovirus spinner cultures were 
grown for 5 days at 27°C. The supernatants were removed, filtered, and 
concentrated. The concentrate was dialysed overnight at 4°C against a one-third 
dilution o f phosphate-buffered saline (PBS) (137 mM NaCl, 2.7 mM KC1, 8.1 mM 
Na2HPC>4 , 1.5 mM K H 2 P O 4 ,  0.5 mM EDTA, pH 7.5). The dialysed supernatant was 
passed through an HB-5 monoclonal antibody (Tedder et al, 1984) affinity column 
followed by a Protein G-Sepharose column in order to remove any trace 
contamination o f HB-5.
Immediately prior to scattering data acquisition, residual non-specific 
aggregates were removed by size exclusion chromatography on a Superdex 200 
HiLoad 16/60 column (Amersham Pharmacia Biotech). The CR2 SCR 1-15 
concentration was determined using an absorption coefficient o f 12.7 (1%, 280 nm, 1 
cm path length), which was calculated from its composition (Ile21 to Arg971) by 
assuming the presence of eleven high mannose type oligosaccharides GlcNAc2Man7 
(Figure 6.1) (Perkins, 1986). The X-ray scattering curves and analytical
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ultracentrifugation data were measured in PBS. Further X-ray scattering experiments 
were carried out in 10 mM HEPES (pH 7.4), 50 mM NaCl, although these data were 
not used in the final analyses due to noise. The neutron scattering experiments were 
measured in PBS dissolved in 99.9% 2H2 0 . For these experiments, the protein was 
dialysed into PBS in 99.9% 2H2 0  at 6 °C for 48 h with three changes o f dialysate. All 
CR2 SCR 1-15 samples were routinely analysed by SDS-PAGE before and after 
scattering and ultracentrifugation experiments to confirm their integrity.
(6.4.2) X-ray data from Instrument ID02 at the ESRF
X-ray scattering data were collected in three independent sessions on the 
ID02 high brilliance beamline at the European Synchrotron Radiation Facility in 
Grenoble, France, operating at a ring energy o f 6.03 GeV (Narayanan et al, 2001). 
To reduce the incident flux on the sample, experiments were performed in four- 
bunch and single-bunch modes with beam currents in a range between 12.1 and 41.2 
mA, instead of the 992 bunches used in normal multibunch mode (beam current ~ 
200 mA). The final data analyses were performed with a sample-to-detector distance 
o f 3.0 m, which yielded a Q range from 0.07 nm ' 1 to 2.1 nm '1. Twelve CR2 SCR 1- 
15 concentrations between 0.5 and 2.5 mg ml' 1 in PBS and four more between 0.10 
and 0.33 mg ml' 1 in HEPES were measured at 15°C in Perspex cells o f sample 
volume 2 0  pi, contained within mica windows o f thickness between 1 0  to 15 pm. 
For each sample two sets o f ten time frames were taken, with an exposure time o f 
either 0.2 sec, 0.5 sec, or 1.0 sec per frame. Buffers and samples were measured in 
alternation to minimise background subtraction errors. Data reduction included the 
use of a Lupolen sample for the calibration of detector intensities, and a silver 
behenate salt standard (C2 iH4 3COOAg) with a d-spacing o f 5.84 nm for the 
calibration o f the Q range (Huang et al, 1993).
(6.4.3) Neutron data from Instrument LOQ at ISIS
Neutron scattering data were obtained in one beam session on the LOQ 
instrument at the pulsed neutron source ISIS at the Rutherford Appleton Laboratory, 
Didcot, U.K. (Heenan & King, 1993). The pulsed neutron beam was derived from a 
proton beam of current 170 pA. Monochromatisation was achieved using time-of- 
flight techniques. A 3He ORDELA wire detector recorded intensities at a fixed 
sample-to-detector distance o f 4.3 m. Samples and buffers were measured in 2 mm-
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thick rectangular Hellma cells positioned in a thermostatted rack at 15°C. Data 
acquisitions were for 80 - 160 x 106 monitor counts in runs lasting 3 h for CR2 SCR 
1-15 at a concentration of 1.5 mg m l'1. Spectral intensities were normalised relative 
to the scattering from a partially deuterated polystyrene standard (Wignall & Bates, 
1987). Transmissions were measured for all samples and backgrounds. Reduction of 
the raw data collected in 100 time frames o f 64 x 64 cells utilised the standard ISIS 
software package COLETTE (Heenan et al, 1989) Scattered intensities were binned 
into individual diffraction patterns based on the wavelength range from 0 . 2 2  nm to
1 . 0 0  nm, and were corrected for a linear wavelength-dependence o f the transmission 
measurements. The patterns were merged to give the scattering curve I(Q) in a Q 
range o f 0.06 - 2.7 nm '1. The Q range was based on 0.04% logarithmic increments, 
which was optimal both for Guinier analyses at low Q and better signal-noise ratios 
at large Q.
(6.4.4) Analysis of reduced X-ray and neutron data
The data was analysed using Guinier plots and P(r) analysis as described in 
Chapter 4.4.2. The CR2 SCR 1-15 X-ray I(Q) curve contained 569 data points 
between Q values of 0.08 to 2.07 nm ' 1 and was fitted with Dmax set as 38 nm.
(6.4.5) Analytical ultracentrifugation data acquisition and analysis
Analytical ultracentrifugation was performed on a Beckman XL-I instrument 
equipped with an An50Ti rotor in which the protein concentration distribution within 
the cell was monitored using its absorbance monitored at 280 nm and its refractive 
index measured by interferometry. Sedimentation equilibrium experiments were 
performed for CR2 SCR 1-15 at four concentrations between 0.5 and 1.8 mg ml' 1 in 
PBS. Data were acquired over 45 h using six-sector cells with column heights of 2 
mm at rotor speeds o f 11,000 rpm, 14,000 rpm, 17,000 rpm, 20,000 rpm and 25,000 
rpm until equilibrium had been reached at each speed as shown by the perfect 
overlay of runs measured at 5 h intervals. The molecular weight (MW) was analysed 
on the basis of a single species using Beckman software provided as an add-on to 
Origin Version 4.1 (Microcal Inc.), for which the partial specific volume v for CR2 
SCR 1-15 was calculated to be 0.729 ml/g from its sequence (Perkins, 1986).
172
Sedimentation velocity data were acquired over 16 h at rotor speeds o f
15.000 rpm, 20,000 rpm, 25,000 rpm, 30,000 rpm and 35,000 rpm in two-sector cells 
with solution column heights o f 12 mm. The experiments were performed at four 
concentrations between 0.46 and 1.84 mg ml' 1 in PBS. For the g(s*) analyses, 
successive absorbance and interference scans were recorded at 8  min intervals, the 
shortest interval possible under standard measurement conditions. In time-derivative 
analyses, the subtraction of pairs of concentration scans vs. radius in the cell 
eliminates systematic errors from baseline distortions in the cell windows and 
permits the averaging o f many pairs o f subtractions. The extrapolation o f individual 
subtractions to the start time gives the g(s*) function, which was computed using the 
DCDT+ program (Philo, 2000), from which the sedimentation coefficient s°2o,w was 
determined from the peak position (Figure 6.5). The fits were determined in 
conditions when the maximum permissible measurable molecular weight was over 
16 times the expected value, meaning that time broadening effects were negligible.
(6.4.6) Modelling and conformational searches for CR2 SCR 1-15
Models for the 15 SCR domains o f CR2 were obtained as follows. SCR 1 and 
SCR 2 were taken from the crystal structure o f CR2 SCR 1-2 in its complex with 
C3d (PDB code lghq) (Szakonyi et al, 2001). The SCR 3 to SCR 7 and the SCR 9 to 
SCR 15 domains were taken from the CCP module model database (Soares et al, 
2005) (http://www.bru.ed.ac.uk/~dinesh/ccp-db.html). Each SCR domain in CR2 
was assigned to either cluster A, C or F of nine clusters lettered A to I, then the 
structures in each cluster were modelled based on known SCR structures when 
available using MODELLER (Sali & Blundell, 1993). A model for SCR 8  was not 
available by this approach for reason o f its low sequence similarity. The use of 
BLAST and Clustal W (vl.82) based on SCR domains with known structures and 
the other CR2 SCR domains showed that CR2 SCR 8  had the highest sequence 
similarity with CR2 SCR 11 (Figure 6.12). The model for CR2 SCR 11 was 
therefore used as a template, and the SCR 8  model was constructed using Insight II
98.0 (Accelrys, San Diego, CA) software on Silicon Graphics workstations. Energy 
refinements were performed using the DISCOVER module, and the structure was 
verified using PROCHECK (Laskowski et al, 1993). As CR2 was expressed with a 
baculovirus system in Sf9 insect cells, models for high mannose type 
(Man7GlcNAc2) oligosaccharides were incorporated at each of the 11 N-linked
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SCR1
V2_1
cW_2
g40_2
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SCR5
SCR9
SC R  12
SCR14
SCR7
It03_2
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SCR3
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SCR4
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SCR15
SCR8
SCR11
SCR2
Iy2_2
SCR13
SCR6
SCR10
g40_4
qub_1
ckl_1
ojv_2
Figure 6.12
A cladogram to show the common ancestry of SCR domains with known structures 
based on sequence similarities. The 15 SCR domains in CR2 are denoted by SCR1 to 
SCR 15. The known structures are indicted by their PDB codes in lower case. The 
number following the underscore shows the domain of the known structure in cases 
where there are more than one domain in the PDB file. CR2 SCR domains 8 and 11 
are shown in the red box.
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glycosylation sites on SCR 1 to SCR 15 (Figure 6.1). These were modelled in 
conformations that extended away from the protein surface.
Two different libraries of linker structures were created. In both, the linker sequences 
contained the last Cys residue o f the previous SCR domain and the first Cys residue 
o f the subsequent SCR domain in order to allow superimposition o f the linkers onto 
the domains. In the first library, sets o f 5,000 unconstrained structures were created 
for each o f the 14 linkers within CR2 SCR 1-15 using molecular dynamics 
simulations (Boehm et al, 1999; Aslam & Perkins 2001). In the second library, each 
linker was constrained to within 0.25 nm o f its possible maximum length in order to 
create 14 sets o f 500 extended structures in all orientations.
Three modelling searches were performed. In the first one, 5,000 full CR2 
models were created that were completely free o f inter-SCR constraints. Linkers for 
each SCR-SCR connection were selected at random from each o f the 14 sets o f the 
first library and superimposed onto the appropriate pair o f SCR domains using their 
terminal Cys residues. In the second search, a further 5000 models were created in 
which the linkers were obtained from the second library. In the third search, only the 
linkers with six residues or fewer were varied. These shorter linkers were taken from 
the second linker library. For the six remaining longer linkers o f lengths seven or 
eight residues (Figure 6.1), the linker that was found in the best-fit solution structure 
for free CR2 SCR 1-2 (Chapter 4; Gilbert et al, 2005) was used as a template.
(6.4.7) Debye scattering curve and sedimentation modelling of CR2 SCR 1-15
In order to calculate the X-ray scattering curves, Debye sphere models were 
created by placing each full coordinate model for CR2 SCR 1-15 within a three 
dimensional grid of cubes, where each cube side is of length 0.496 nm. This length 
is much less than the nominal resolution o f the scattering curves. Provided that the 
number of atoms within a given cube exceeded a user-defined cutoff, a sphere of the 
same volume as the cube (sphere diameter 0.615 nm) was placed at the centre o f the 
cube. This cutoff was determined by the requirement that the total volume o f spheres 
in each model was within 1% of the dry volume of 151.4 nm3 for CR2 SCR 1-15 
(1223 dry spheres), calculated from its amino-acid and carbohydrate composition 
(Perkins, 1986). X-ray scattering and sedimentation modelling requires the addition
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of a hydration shell. A hydration o f 0.3 g H2O / g glycoprotein and an electrostricted 
volume o f 0.0245 nm3 per bound water molecule (Perkins, 1986; Perkins, 2001) 
gave a total hydrated volume o f 200.8 nm3. This shell was modelled using the 
HYPRO procedure (Ashton et al, 1997) in which excess spheres were uniformly 
added to the surface of the dry sphere model, and these were sequentially removed 
until the desired hydration volume o f 1581 spheres had been reached.
The X-ray scattering curve I(Q) was calculated assuming a uniform scattering 
density for the spheres using the Debye equation as adapted to spheres (Perkins & 
Weiss, 1983). The X-ray curves were calculated from the hydrated sphere models 
without corrections for wavelength spread or beam divergence as these are 
considered to be negligible for synchrotron X-ray data. The modelled scattering 
curves were assessed by calculation o f the Rq and Rxs values from the same Q 
ranges used for the experimental Guinier fits, in which filters corresponding to ± 5% 
of the experimental values were applied. Models that passed these filters were then 
ranked using a goodness-of-fit R factor defined by analogy with protein 
crystallography and based on the experimental curves in the Q range extending to 0.8 
nm ' 1 and 2 . 0  nm ' 1 (denoted as Ro.g and R2.0 respectively) (Beavil et al, 1995).
Version 5a of the HYDROPRO program was used to calculate the s°2o,w 
values directly from the best-fit molecular models o f CR2 SCR 1-15 without 
recourse to sphere models. The recommended value o f 0.31 nm was used for the 
atomic element radius for all atoms as an empirical approximation o f the hydration 
shell (Garcia de la Torre et al, 2000).
(6.4.8) Protein Data Bank accession numbers
The best-fit a-carbon coordinate models for CR2 SCR 1-15 (Figure 6.9) have 
been deposited in the Protein Data Bank with the accession code 2GSX.
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Chapter Seven
Conclusions
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The three projects presented in this thesis have served to further define the 
structure o f CR2 and has provided additional insight into the nature o f SCR domains 
in solution. Between them, the projects investigated the functionally active SCR 1-2 
domains o f CR2 and placed these in the context o f the full CR2 SCR 1-15 structure.
The first two domains o f CR2 were shown to exist as a family o f open V- 
shape structures in solution, both with and without glycosylations. The same result 
was obtained with either SCR 1-2 on their own or in the chimaeric form (Chapters 4 
and 5). The range of possible structures consistent with the experimental data 
suggests that the long, eight residue amino acid linker between the SCR 1 and SCR 2 
domains is highly flexible. In contrast, the crystal structure showed that both SCR 
domains made side-by-side contacts with each other. The dimerisation o f CR2 SCR 
1-2 seen in the CR2 SCR l-2/C3d crystal structure (Szakonyi et al, 2001) was never 
observed, even when two molecules o f CR2 SCR 1-2 were potentially brought close 
together spatially in the CR2-Ig chimaera. These results indicate the importance o f 
not relying solely on the domain arrangements seen by X-ray crystallography.
Within the CR2 SCR l-2/C3d complex, both SCR domains were seen to 
occupy positions close to the surface o f C3d, in distinction to the crystal structure. 
Our modelling work resulted in a set o f models where SCR 1 was positioned on the 
edge of the concave side o f C3d. A series o f models based on the mutation studies 
(Hannan et al, 2005) in which SCR 1 was modelled in the vicinity o f a negatively 
charged channel on the convex side o f C3d also gave good fits with our experimental 
data from X-ray scattering. These results support a model in which both SCR 
domains are bound to C3d, both through the main-chain interactions o f SCR 2 and 
through a charge-dependent association with SCR 1. The results from surface 
plasmon resonance experiments showed that both the Kon and X0fr rates for the K& o f 
the CR2 SCR l-2/C3d complex are sensitive to both ionic strength and pH 
(Guthridge et al, 2001a; Hannan et al, 2005). These findings, along with the 
modelling and mutagenesis work, would imply that any electrostatic associations 
between CR2 SCR 1-2 and C3d are short-range in nature, and not long-range as 
previously suggested (Morikis & Lambris, 2004).
The CR2-Ig chimaera (Chapter 5) provides further information on chimaeric 
antibodies, allowing for more rational design o f potential therapeutic agents. In 
contrast to other Ig structures studied in solution (Boehm et al, 1999; Furtado et al,
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2004; Sun et al, 2005), the Fc-SCR 2 linker region in CR2-Ig is particularly flexible, 
showing the probable stabilising contribution o f the immunoglobulin light chain and 
hinge glycosylations to the overall structure o f antibodies in a conventional light- 
heavy chain arrangement. If CR2-Ig were to be developed for therapeutic use as a 
competitive inhibitor of the complement system, several points would need to be 
considered. The structure o f the hinge region in Ig isotypes is thought to play a role 
in the modulation of Ab function (Jefferis & Lund, 1997; Rudd & Dwek, 1998), and 
it has been suggested that differential glycosylation in the Ig hinge region may give 
rise to subpopulations o f each isotype with subtly different functions (Field et al, 
1989). Hinge glycosylation is also known to protect the Ig from proteolytic cleavage 
(Jefferis & Lund, 1997; Rudd & Dwek, 1998) and to increase the half-life o f the 
molecule in vivo. The chimaeric CR2-Ig molecule, with its long, flexible, 
unglycosylated hinge, may be susceptible to cleavage by molecules other than Factor 
Xa for which there is a cleavage site in the Fc-CR2 SCR 2 linker. It is unclear 
whether the flexibility o f the linkers would be beneficial or detrimental to the ability 
o f CR2 SCR 1-2 to bind to its ligands and therefore function well as an inhibitor. 
The flexibility may also occlude the Factor Xa cleavage site. Further experiments to 
determine the biochemical properties o f this molecule are required. In order for the 
CR2 SCR 1-2 to be useful as a therapeutic inhibitor it would need to be directed to 
the site of complement activation and only to be active in that location. The long 
linker is not likely to enable this level of precision. It is probable that a more stable 
structure with less conformational flexibility would enable the CR2 domains to be 
inactive until needed. This stability could be induced by using a shorter Fc-CR2 
linker, possibly engineered to include additional glycosylation sites and thus 
mimicking the hinge of natural Ig.
The 15 SCR domain construct o f CR2 was shown to be highly flexible 
(Chapter 6 ). The six, longer than average inter-SCR domain linkers are likely to 
mediate this flexibility, enabling CR2 to exist as a range of relatively extended 
conformations in solution, as seen by EM (Moore et al, 1989). This inherent 
flexibility would potentially facilitate the interaction o f CR2 with its ligands and the 
BCR, mlgM.
CR2 SCR 1-15 shows a greater degree o f flexibility than any other SCR 
protein studied in solution to date. rCrry, mCrry-Ig, and P2GPI, all o f which have 
five SCR domains and short linkers, show relatively elongated structures with little
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or no tendency to fold back upon themselves (Aslam et a l , 2003; Hammel et al, 
2002). FH, with 20 SCR domains and a variety o f linker lengths, has a much more 
folded-back conformation (Aslam & Perkins, 2001) in solution. Each o f the other 
SCR domain proteins has, on average, much shorter linkers than CR2 SCR 1-15. The 
long linkers in CR2 are conserved across species (Figure 1.4), implying that they are 
both structurally and functionally important. It is known that residues found in SCR 
domains around the linker regions, along with the residues in the linkers themselves, 
contribute to the linker conformation. It is therefore difficult to predict whether or 
not the length of the linker alone determines the flexibility o f the junction. To date, 
the eight residue linker between CR2 SCR 1-2 is the only one o f that length to be 
determined at high resolution, and therefore other examples o f long inter-SCR 
linkers are needed in order for comparisons to be drawn. It is interesting to note that 
the interdomain angle o f over half o f the solved SCR domain pairs is in the range of 
120° to 150° (Soares & Barlow, 2005), whereas the scattering best-fit structures for 
CR2 SCR 1-2 in solution show an interdomain angle o f between 63° and 121°. The 
interdomain angles seen in the crystal structures o f CR2 SCR 1-2 (Szakonyi et al, 
2001; Prota et al, 2002) are 37° and 40° respectively, the smallest angles seen in any 
solved SCR domain structure so far. These values suggest that the longer the linker 
the more flexible it is, although these extreme angles are thought to be artefacts of 
crystallisation.
Given the wide range o f conformations seen for such seemingly similar 
structures, it is likely that flexibility is important for the SCR superfamily as a 
whole. Additional investigations utilising both atomic resolution and solution data to 
complement each other will be important in order to further understand the 
contributions of structure to function in these proteins.
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